Diabetes (clinical) DSS Metadata Online Registry (METeOR)

Female
Description

Female

Pregnancy—current status
Description

Female—pregnancy indicator (current), code N Identifying and definitional attributes Short name: Pregnancy—current status METeOR identifier: 302817 Registration status: Health, Standard 21/09/2005 Definition: Whether the female person is currently pregnant, as represented by a code. Data Element Concept: Female—pregnancy indicator Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N Maximum character length: 1 Permissible values: Value Meaning 1 Yes 2 No Supplementary values: 9 Not stated/inadequately described Collection and usage attributes Guide for use: CODE 9 Not stated/inadequately described This code is not for use in primary data collections. Data set specification specific attributes Diabetes (clinical) DSS DSS specific information: Pregnancy in women with pre-existing diabetes is a potentially serious problem for both the mother and fetus. Good metabolic control and appropriate medical and obstetric management will improve maternal and fetal outcomes. The diagnosis or discovery of diabetes in pregnancy (gestational diabetes), identifies an at risk pregnancy from the fetal perspective, and identifies the mother as at risk for the development of type 2 diabetes later in life. Following Principles of Care and Guidelines for the Clinical Management of Diabetes Mellitus diabetes management during pregnancy includes: · routine medical review every 2-3 weeks during the first 30 weeks and then every 1-2 weeks until delivery · monitor HbA1c every 4-6 weeks or more frequently if indicated to ensure optimal metabolic control during pregnancy · advise patients to monitor blood glucose frequently and urinary ketones · initial assessment and on going monitoring for signs or progression of diabetes complications · regular routine obstetric review based on the usual indicators. Management targets · Blood glucose levels: Fasting Post-prandial · HbA1c levels within normal range for pregnancy. (The reference range for HbA1c will be lower during pregnancy). · The absence of any serious or sustained ketonuria. Normal indices for fetal and maternal welfare. Oral hypoglycaemic agents are contra-indicated during pregnancy and therefore women with pre-existing diabetes who are treated with oral agents should ideally be converted to insulin prior to conception. What to do if unsatisfactory metabolic control: · explore reasons for unsatisfactory control such as diet, intercurrent illness, appropriateness of medication, concurrent medication, stress, and exercise, and review management, · review and adjust treatment, · consider referral to diabetes educator, dietician, endocrinologist or physician experienced in diabetes care, or diabetes centre. Data element attributes Collection and usage attributes Guide for use: CODE 1 Yes: Record if the female individual currently pregnant. CODE 2 No: Record if the female individual not currently pregnant. Collection methods: Ask the individual if she is currently pregnant. Source and reference attributes Submitting organisation: National diabetes data working group Origin: National Diabetes Outcomes Quality Review Initiative (NDOQRIN) data dictionary Relational attributes Related metadata references: Supersedes Female—current pregnancy status, code N Health, Superseded 21/09/2005 Implementation in Data Set Specifications: Diabetes (clinical) DSS Health, Standard 21/09/2005

Data type

integer

Health service event
Description

Health service event

Fasting status
Description

Health service event—fasting indicator, code N Identifying and definitional attributes Short name: Fasting status METeOR identifier: 302941 Registration status: Health, Standard 21/09/2005 Definition: Whether the patient was fasting at the time of an examination, test, investigation or procedure, as represented by a code. Data Element Concept: Health service event—fasting indicator Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N Maximum character length: 1 Permissible values: Value Meaning 1 Yes 2 No Supplementary values: 9 Not stated/inadequately described Collection and usage attributes Guide for use: CODE 9 Not stated/inadequately described This code is not for use in primary data collections. Data element attributes Collection and usage attributes Guide for use: CODE 1 Yes: Record if the patient is fasting at the time of an examination, test, investigation or procedure. CODE 2 No: Record if the patient is not fasting at the time of an examination, test, investigation or procedure. Comments: In settings where the monitoring of a person's health is ongoing and where management can change over time (such as general practice), the service contact date should be recorded. Source and reference attributes Submitting organisation: National Diabetes Data Working Group Cardiovascular Data Working Group Relational attributes Related metadata references: Supersedes Health service event—fasting status, code N Health, Superseded 21/09/2005 Is used in the formation of Person—low-density lipoprotein cholesterol level (calculated), total millimoles per litre N[N].N Health, Superseded 01/10/2008 Is used in the formation of Person—low-density lipoprotein cholesterol level (calculated), total millimoles per litre N[N].N Health, Standard 01/10/2008 Implementation in Data Set Specifications: Cardiovascular disease (clinical) DSS Health, Standard 01/09/2012 Diabetes (clinical) DSS Health, Standard 21/09/2005

Data type

integer

Laboratory standard
Description

Laboratory standard

Microalbumin level—upper limit of normal range (albumin/creatinine ratio)
Description

Laboratory standard—upper limit of normal range for microalbumin, albumin/creatinine ratio N[NN].N Obligation: Conditional Identifying and definitional attributes Short name: Microalbumin level—upper limit of normal range (albumin/creatinine ratio) Synonymous names: Albumin/creatinine ratio METeOR identifier: 270344 Registration status: Health, Standard 01/03/2005 Definition: The laboratory standard for the value of microalbumin measured as an albumin/creatinine ratio that is the upper boundary of the normal reference range. Data Element Concept: Laboratory standard—upper limit of normal range for microalbumin Value domain attributes Representational attributes Representation class: Ratio Data type: Number Format: N[NN].N Maximum character length: 4 Supplementary values: Value Meaning 999.9 Not stated/inadequately described Unit of measure: Milligram per millimole (mg/mmol) Unit of measure precision: 1 Data set specification specific attributes Diabetes (clinical) DSS DSS specific information: Microalbuminuria is a strong predictor of macrovascular disease and diabetic nephropathy. Incipient diabetic nephropathy can be detected by urine testing for microalbumin. Incipient diabetic nephropathy is suspected when microalbuminuria is detected in 2 of 3 samples collected over a 6-month period in patients in whom other causes of an increased urinary albumin excretion have been excluded. Diagnosis of microalbuminuria is established if 2 of the 3 measurements are abnormal. A small amount of protein (albumin) in the urine (microalbuminuria) is an early sign of kidney damage. If microalbuminuria is present: · review diabetes control and improve if necessary · consider treatment with Angiotensin-converting enzyme (ACE) inhibitor · consider referral to a physician experienced in the care of diabetic renal disease If macroalbuminuria is present: · quantify albuminuria by measuring 24-hour urinary protein. · refer to a physician experienced in the care of diabetic renal disease. Data element attributes Collection and usage attributes Guide for use: Record the upper limit of the microalbumin normal reference range for the laboratory. Collection methods: Microalbumin is not detected by reagent strips for urinary proteins, and requires immunoassay. Measurement of microalbumin levels should be carried out by laboratories, or practices, which have been accredited to perform these tests by the National Association of Testing Authority. As urinary albumin varies with posture and exercise it is important to collect the urine under very standard conditions; short-term (2 hours) during rest, overnight (approximately 8 hours) or an early morning sample. For screening purposes an early morning urine specimen is adequate and if the albumin/creatinine ratio is found to be greater than 3.5mg/mmol then a timed overnight sample should be obtained for estimation of the albumin excretion rate. Source and reference attributes Submitting organisation: National Diabetes Data Working Group Origin: National Diabetes Outcomes Quality Review Initiative (NDOQRIN) data dictionary. Relational attributes Related metadata references: Supersedes Microalbumin - units, version 1, DE, NHDD, NHIMG, Superseded 01/03/2005.pdf (16.3 KB) Supersedes Microalbumin - upper limit of normal range, version 1, DE, NHDD, NHIMG, Superseded 01/03/2005.pdf (15.8 KB) See also Person—microalbumin level (measured), albumin/creatinine ratio N[NN].N Health, Standard 01/03/2005 Implementation in Data Set Specifications: Diabetes (clinical) DSS Health, Standard 21/09/2005

Data type

float

Measurement units
  • mg/mmol
mg/mmol
Microalbumin level—upper limit of normal range (micrograms per minute)
Description

Laboratory standard—upper limit of normal range for microalbumin, total micrograms per minute N[NN].N Obligation: Conditional Identifying and definitional attributes Short name: Microalbumin level—upper limit of normal range (micrograms per minute) METeOR identifier: 270341 Registration status: Health, Standard 01/03/2005 Definition: The laboratory standard for the value of microalbumin measured in micrograms per minute (µg/min), that is the upper boundary of the normal reference range. Data Element Concept: Laboratory standard—upper limit of normal range for microalbumin Value domain attributes Representational attributes Representation class: Total Data type: Number Format: N[NN].N Maximum character length: 4 Supplementary values: Value Meaning 999.9 Not stated/inadequately described Unit of measure: Microgram per minute (µg/min) Unit of measure precision: 1 Data set specification specific attributes Diabetes (clinical) DSS DSS specific information: Microalbuminuria is a strong predictor of macrovascular disease and diabetic nephropathy. Incipient diabetic nephropathy can be detected by urine testing for microalbumin. Incipient diabetic nephropathy is suspected when microalbuminuria is detected in 2 of 3 samples collected over a 6-month period in patients in whom other causes of an increased urinary albumin excretion have been excluded. Diagnosis of microalbuminuria is established if 2 of the 3 measurements are abnormal. A small amount of protein (albumin) in the urine (microalbuminuria) is an early sign of kidney damage. If microalbuminuria is present: · review diabetes control and improve if necessary · consider treatment with Angiotensin-converting enzyme (ACE) inhibitor · consider referral to a physician experienced in the care of diabetic renal disease If macroalbuminuria is present: · quantify albuminuria by measuring 24-hour urinary protein. · refer to a physician experienced in the care of diabetic renal disease. Data element attributes Collection and usage attributes Guide for use: Record the upper limit of the microalbumin normal reference range for the laboratory. Collection methods: Microalbumin is not detected by reagent strips for urinary proteins, and requires immunoassay. Measurement of microalbumin levels should be carried out by laboratories, or practices, which have been accredited to perform these tests by the National Association of Testing Authority. As urinary albumin varies with posture and exercise it is important to collect the urine under very standard conditions; short-term (2 hours) during rest, overnight (approximately 8 hours) or an early morning sample. For screening purposes an early morning urine specimen is adequate. Source and reference attributes Submitting organisation: National Diabetes Data Working Group Origin: National Diabetes Outcomes Quality Review Initiative (NDOQRIN) data dictionary Relational attributes Related metadata references: Supersedes Microalbumin - units, version 1, DE, NHDD, NHIMG, Superseded 01/03/2005.pdf (16.3 KB) Supersedes Microalbumin - upper limit of normal range, version 1, DE, NHDD, NHIMG, Superseded 01/03/2005.pdf (15.8 KB) Implementation in Data Set Specifications: Diabetes (clinical) DSS Health, Standard 21/09/2005

Data type

float

Measurement units
  • µg/min
µg/min
Microalbumin level—upper limit of normal range (milligrams per 24 hour)
Description

Laboratory standard—upper limit of normal range for microalbumin, total milligrams per 24 hour N[NN].N Obligation: Conditional Identifying and definitional attributes Short name: Microalbumin level—upper limit of normal range (milligrams per 24 hour) METeOR identifier: 270343 Registration status: Health, Standard 01/03/2005 Definition: The laboratory standard for the value of microalbumin measured in milligrams per 24 hour, that is the upper boundary of the normal reference range. Data Element Concept: Laboratory standard—upper limit of normal range for microalbumin Value domain attributes Representational attributes Representation class: Total Data type: Number Format: N[NN].N Maximum character length: 4 Supplementary values: Value Meaning 999.9 Not stated/inadequately described Unit of measure: Milligram per 24-hour period (mg/24h) Unit of measure precision: 1 Data set specification specific attributes Diabetes (clinical) DSS DSS specific information: Microalbuminuria is a strong predictor of macrovascular disease and diabetic nephropathy. Incipient diabetic nephropathy can be detected by urine testing for microalbumin. Incipient diabetic nephropathy is suspected when microalbuminuria is detected in 2 of 3 samples collected over a 6-month period in patients in whom other causes of an increased urinary albumin excretion have been excluded. Diagnosis of microalbuminuria is established if 2 of the 3 measurements are abnormal. A small amount of protein (albumin) in the urine (microalbuminuria) is an early sign of kidney damage. If microalbuminuria is present: · review diabetes control and improve if necessary · consider treatment with Angiotensin-converting enzyme (ACE) inhibitor · consider referral to a physician experienced in the care of diabetic renal disease If macroalbuminuria is present: · quantify albuminuria by measuring 24-hour urinary protein. · refer to a physician experienced in the care of diabetic renal disease. Data element attributes Collection and usage attributes Guide for use: Record the upper limit of the microalbumin normal reference range for the laboratory. Collection methods: Microalbumin is not detected by reagent strips for urinary proteins, and requires immunoassay. Measurement of microalbumin levels should be carried out by laboratories, or practices, which have been accredited to perform these tests by the National Association of Testing Authority. As urinary albumin varies with posture and exercise it is important to collect the urine under very standard conditions; short-term (2 hours) during rest, overnight (approximately 8 hours) or an early morning sample. For screening purposes an early morning urine specimen is adequate. Source and reference attributes Submitting organisation: National Diabetes Data Working Group Origin: National Diabetes Outcomes Quality Review Initiative (NDOQRIN) data dictionary. Relational attributes Related metadata references: Supersedes Microalbumin - units, version 1, DE, NHDD, NHIMG, Superseded 01/03/2005.pdf (16.3 KB) Supersedes Microalbumin - upper limit of normal range, version 1, DE, NHDD, NHIMG, Superseded 01/03/2005.pdf (15.8 KB) Implementation in Data Set Specifications: Diabetes (clinical) DSS Health, Standard 21/09/2005

Data type

float

Measurement units
  • mg/24h
mg/24h
Microalbumin level—upper limit of normal range (milligrams per litre)
Description

Laboratory standard—upper limit of normal range for microalbumin, total milligrams per litre N[NN].N Obligation: Conditional Identifying and definitional attributes Short name: Microalbumin level—upper limit of normal range (milligrams per litre) METeOR identifier: 270334 Registration status: Health, Standard 01/03/2005 Definition: The laboratory standard for the value of microalbumin measured in milligrams per litre (mg/L), that is the upper boundary of the normal reference range. Data Element Concept: Laboratory standard—upper limit of normal range for microalbumin Value domain attributes Representational attributes Representation class: Total Data type: Number Format: N[NN].N Maximum character length: 4 Supplementary values: Value Meaning 999.9 Not stated/inadequately described Unit of measure: Milligram per litre (mg/L) Unit of measure precision: 1 Data set specification specific attributes Diabetes (clinical) DSS DSS specific information: Microalbuminuria is a strong predictor of macrovascular disease and diabetic nephropathy. Incipient diabetic nephropathy can be detected by urine testing for microalbumin. Incipient diabetic nephropathy is suspected when microalbuminuria is detected in 2 of 3 samples collected over a 6-month period in patients in whom other causes of an increased urinary albumin excretion have been excluded. Diagnosis of microalbuminuria is established if 2 of the 3 measurements are abnormal. A small amount of protein (albumin) in the urine (microalbuminuria) is an early sign of kidney damage. If microalbuminuria is present: · review diabetes control and improve if necessary · consider treatment with Angiotensin-converting enzyme (ACE) inhibitor · consider referral to a physician experienced in the care of diabetic renal disease If macroalbuminuria is present: · quantify albuminuria by measuring 24-hour urinary protein. · refer to a physician experienced in the care of diabetic renal disease. Data element attributes Collection and usage attributes Guide for use: Record the upper limit of the microalbumin normal reference range for the laboratory. Collection methods: Microalbumin is not detected by reagent strips for urinary proteins, and requires immunoassay. Measurement of microalbumin levels should be carried out by laboratories, or practices, which have been accredited to perform these tests by the National Association of Testing Authority. As urinary albumin varies with posture and exercise it is important to collect the urine under very standard conditions; short-term (2 hours) during rest, overnight (approximately 8 hours) or an early morning sample. For screening purposes an early morning urine specimen is adequate. Source and reference attributes Submitting organisation: National Diabetes Data Working Group Origin: National Diabetes Outcomes Quality Review Initiative (NDOQRIN) data dictionary. Relational attributes Related metadata references: Supersedes Microalbumin - units, version 1, DE, NHDD, NHIMG, Superseded 01/03/2005.pdf (16.3 KB) Supersedes Microalbumin - upper limit of normal range, version 1, DE, NHDD, NHIMG, Superseded 01/03/2005.pdf (15.8 KB) Implementation in Data Set Specifications: Diabetes (clinical) DSS Health, Standard 21/09/2005

Data type

float

Measurement units
  • mg/L
mg/L
Glycosylated haemoglobin—upper limit of normal range (percentage)
Description

Laboratory standard—upper limit of normal range of glycosylated haemoglobin, percentage N[N].N Identifying and definitional attributes Short name: Glycosylated haemoglobin—upper limit of normal range (percentage) METeOR identifier: 270333 Registration status: Health, Standard 01/03/2005 Definition: Laboratory standard for the value of glycosylated haemoglobin (HbA1c) measured as a percentage that is the upper boundary of the normal range. Data Element Concept: Laboratory standard—upper limit of normal range of glycosylated haemoglobin Value domain attributes Representational attributes Representation class: Percentage Data type: Number Format: N[N].N Maximum character length: 3 Supplementary values: Value Meaning 99.9 Not stated/inadequately described Data set specification specific attributes Diabetes (clinical) DSS DSS specific information: HbA1c is a measurement of long-term blood glucose control and is used to assess the effectiveness of treatment. It is a convenient way to obtain an integrated assessment of antecedent glycaemia over an extended period under real life conditions and is used as a standard for assessing overall blood glucose control. The target is to achieve an HbA1c within 1% of the upper limit of normal or achieve control as near to this target as possible without producing unacceptable hypoglycaemia as recommended from the Principles of Care and Guidelines for the Clinical Management of Diabetes Mellitus. If HbA1c is 2% above the upper limit of normal, explore reasons for unsatisfactory control such as diet, intercurrent illness, appropriateness of medication, concurrent medication, stress, and exercise and review management: · review and adjust treatment · consider referral to diabetes educator · consider referral to dietitian · consider referral to endocrinologist or physician or diabetes centre. Data element attributes Collection and usage attributes Guide for use: Record the upper limit of the HbA1c normal reference range from the laboratory result. Collection methods: This value is usually notified in patient laboratory results and may vary for different laboratories. Comments: HbA1c results vary between laboratories; use the same laboratory for repeated testing. Source and reference attributes Submitting organisation: National Diabetes Data Working Group Origin: National Diabetes Outcomes Quality Review Initiative (NDOQRIN) data dictionary. Relational attributes Related metadata references: Supersedes Glycosylated Haemoglobin (HbA1c) - upper limit of normal range, version 1, DE, NHDD, NHIMG, Superseded 01/03/2005.pdf (15.9 KB) See also Person—glycosylated haemoglobin level (measured), percentage N[N].N Health, Standard 01/03/2005 Implementation in Data Set Specifications: Acute coronary syndrome (clinical) DSS 2013- Health, Standard 02/05/2013 Diabetes (clinical) DSS Health, Standard 21/09/2005

Data type

float

Measurement units
  • %
%
Patient
Description

Patient

Year of diagnosis of diabetes mellitus
Description

Patient—diagnosis date (diabetes mellitus), YYYY Identifying and definitional attributes Short name: Year of diagnosis of diabetes mellitus METeOR identifier: 269930 Registration status: Health, Standard 01/03/2005 Definition: The year a patient was first diagnosed as having diabetes Context: Public health, health care and clinical settings. Data Element Concept: Patient—diagnosis date Value domain attributes Representational attributes Representation class: Date Data type: Date/Time Format: YYYY Maximum character length: 4 Data set specification specific attributes Diabetes (clinical) DSS DSS specific information: Long-term complications of diabetes mellitus affect the eyes, kidneys, nerves, and blood vessels. Data element attributes Collection and usage attributes Guide for use: Record the year that the patient was first diagnosed as having diabetes. Collection methods: Ask the individual the year when he/ she was diagnosed with diabetes. Alternatively obtain this information from appropriate documentation, if available. Source and reference attributes Submitting organisation: National diabetes data working group Origin: National Diabetes Outcomes Quality Review Initiative (NDOQRIN) data dictionary Relational attributes Related metadata references: Supersedes Year of diagnosis of diabetes mellitus, version 1, DE, NHDD, NHIMG, Superseded 01/03/2005.pdf (14.1 KB) Implementation in Data Set Specifications: Diabetes (clinical) DSS Health, Standard 21/09/2005 Patient—initial visit since diagnosis indicator (diabetes mellitus), code N Identifying and definitional attributes Short name: Initial visit indicator—diabetes mellitus METeOR identifier: 302470 Registration status: Health, Standard 21/09/2005 Definition: Whether the visit to a health professional is an initial visit for diabetes, or other related condition, after a diagnosis of diabetes, as represented by a code. Data Element Concept: Patient—initial visit since diagnosis indicator (diabetes mellitus) Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N Maximum character length: 1 Permissible values: Value Meaning 1 Yes 2 No Supplementary values: 9 Not stated/inadequately described Collection and usage attributes Guide for use: CODE 9 Not stated/inadequately described This code is not for use in primary data collections. Data element attributes Collection and usage attributes Guide for use: CODE 1 Yes: Record if this is the initial visit of the patient for diabetes, or a related condition, after diagnosis. CODE 2 No: Record if this is not the initial visit of the patient for diabetes, or a related condition, after diagnosis. Source and reference attributes Submitting organisation: National diabetes data working group Origin: National Diabetes Outcomes Quality Review Initiative (NDOQRIN) data dictionary. Relational attributes Related metadata references: Supersedes Patient—initial visit since diagnosis status (diabetes mellitus), code N Health, Superseded 21/09/2005 Implementation in Data Set Specifications: Diabetes (clinical) DSS Health, Standard 21/09/2005

Data type

date

Year insulin started
Description

Patient—insulin start date, YYYY Identifying and definitional attributes Short name: Year insulin started METeOR identifier: 269928 Registration status: Health, Standard 01/03/2005 Definition: The year the patient started insulin injections. Context: Public health, health care and clinical settings. Data Element Concept: Patient—insulin start date Value domain attributes Representational attributes Representation class: Date Data type: Date/Time Format: YYYY Maximum character length: 4 Data set specification specific attributes Diabetes (clinical) DSS DSS specific information: This data element provides information about the duration of diabetes in individual patients. Insulin is a regulating hormone secreted into the blood in response to a rise in concentration of blood glucose or amino acids. It is a double-chain protein hormone formed from proinsulin in the beta cells of the pancreatic islets of Langerhans. Insulin promotes the storage of glucose and the uptake of amino acids, increases protein and lipid synthesis, and inhibits lipolysis and gluconeogenesis. Commercially prepared insulin is available in various types, which differ in the speed they act and in the duration of their effectiveness. Data element attributes Collection and usage attributes Guide for use: Record the year that insulin injections were started. This data element has to be completed for all patients who use insulin. It is used to cross check diabetes type assignment. Collection methods: Ask the individual the year when he/ she started to use insulin. Alternatively obtain this information from appropriate documentation, if available. Source and reference attributes Submitting organisation: National diabetes data working group Origin: National Diabetes Outcomes Quality Review Initiative (NDOQRIN) data dictionary Relational attributes Related metadata references: Supersedes Year insulin started, version 1, DE, NHDD, NHIMG, Superseded 01/03/2005.pdf (15.1 KB) Implementation in Data Set Specifications: Diabetes (clinical) DSS Health, Standard 21/09/2005

Data type

date

Person (male)
Description

Person (male)

Erectile dysfunction
Description

Person (male)—erectile dysfunction, code N Identifying and definitional attributes Short name: Erectile dysfunction METeOR identifier: 270132 Registration status: Health, Standard 01/03/2005 Definition: Whether a male individual has a history of erection failure or has received treatment to achieve erection sufficient for penetration in the last 12 months and prior, as represented by a code. Data Element Concept: Person (male)—erectile dysfunction Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N Maximum character length: 1 Permissible values: Value Meaning 1 Erectile dysfunction- developed in the last 12 months 2 Erectile dysfunction- developed prior to the last 12 months 3 No erectile dysfunction Supplementary values: 9 Not stated/inadequately described Collection and usage attributes Guide for use: Determine whether this developed within or prior to the last 12 months. Collection methods: Ask the individual if he has a history of treatment or failure to achieve or maintain erection sufficient for penetration. Data set specification specific attributes Diabetes (clinical) DSS DSS specific information: Erectile problems occur in up to 50% of men with diabetes who are over 40 years old. Erectile dysfunction may be due to psychological causes, macrovascular disease or pelvic autonomic neuropathy. An organic cause is more likely in the presence of other macro or micro vascular complications. Data element attributes Collection and usage attributes Guide for use: Record for male patients only. Source and reference attributes Submitting organisation: National Diabetes Data Working Group Origin: National Diabetes Outcomes Quality Review Initiative (NDOQRIN) data dictionary. Relational attributes Related metadata references: Supersedes Erectile dysfunction, version 1, DE, NHDD, NHIMG, Superseded 01/03/2005.pdf (15.1 KB) Implementation in Data Set Specifications: Diabetes (clinical) DSS Health, Standard 21/09/2005

Data type

text

Person
Description

Person

Blindness (diabetes complication)
Description

Person—blindness, code N Identifying and definitional attributes Short name: Blindness (diabetes complication) METeOR identifier: 270065 Registration status: Health, Standard 01/03/2005 Definition: Whether the individual has become legally blind in either or both eyes, as represented by a code. Data Element Concept: Person—blindness Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N Maximum character length: 1 Permissible values: Value Meaning 1 Blindness - ( 2 Blindness - ( 3 Blindness - ( 4 No blindness Supplementary values: 9 Not stated/inadequately described Collection and usage attributes Guide for use: CODE 3 Blindness - (< 6/60) occurred in one eye within 12 months and in the other eye prior to the last 12 months Blindness can be diagnosed in one eye within 12 months even though it has been previously diagnosed on the other eye. Collection methods: Ask the individual if he/she has been diagnosed as legally blind (< 6/60) in both or either eye. If so record whether it has occurred within or prior to the last 12 months. Alternatively determine blindness from appropriate documentation obtained from an ophthalmologist or optometrist. Data set specification specific attributes Diabetes (clinical) DSS DSS specific information: Patients with diabetes have an increased risk of developing several eye complications including retinopathy, cataract and glaucoma that lead to loss of vision. Diabetic retinopathy is a leading cause of blindness. Retinopathy is characterised by proliferation of the retina's blood vessels, which may project into the vitreous, causing vitreous haemorrhage, proliferation of fibrous tissue and retinal detachment. It is often accompanied by microaneurysms and macular oedema, which can express as blurred vision. The prevalence of retinopathy increases with increasing duration of diabetes. In the early stage, retinopathy is asymptomatic. Up to 20% of people with diabetes Type 2 have retinopathy at the time of diagnosis of diabetes. The cumulative prevalence of proliferation diabetic retinopathy and macular oedema after 20 years of type 1 diabetes is about 40%. The Diabetic Retinopathy Study Group showed that panretinal photocoagulation reduces the risk of severe loss of vision by 50%. Although diabetes retinopathy cannot totally be prevented, better control of blood sugar level slows the onset and progression of retinopathy (The Diabetes Control and Complications Trial - DCCT). Cataract and glaucoma are also associated diabetic eye problems that could lead to blindness. Regular eye checkups are important for patients suffering from diabetes mellitus. This helps to early detect abnormalities and to avoid or postpone vision-threatening complications. According to the NSW Principles of Care and Guidelines for the Clinical Management of Diabetes Mellitus, a comprehensive ophthalmological examination should be carried out: · At diagnosis and then every 1-2 years for patients whose diabetes onset was at age 30 years or more. · Within five years of diagnosis and then every 1-2 years for patients whose diabetes onset was at age less than 30 years. If retinopathy is detected, review diabetes control and improve if necessary. References: Vision Australia, No 2, 1997/8; University of Melbourne. The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) finding, DRS Report Number8. Ophthalmology. 1981; 88:583/600). Diabetes Control and Complications Trial: DCCT New England Journal of Medicine, 329(14), September 30, 1993. Data element attributes Source and reference attributes Submitting organisation: National Diabetes Data Working Group Origin: National Diabetes Outcomes Quality Review Initiative (NDOQRIN) data dictionary. Relational attributes Related metadata references: Supersedes Blindness - diabetes complication, version 1, DE, NHDD, NHIMG, Superseded 01/03/2005 .pdf (19.7 KB) Implementation in Data Set Specifications: Diabetes (clinical) DSS Health, Standard 21/09/2005

Data type

integer

Blood pressure—diastolic (measured)
Description

Person—blood pressure (diastolic) (measured), millimetres of mercury NN[N] Identifying and definitional attributes Short name: Blood pressure—diastolic (measured) METeOR identifier: 270072 Registration status: Health, Standard 01/03/2005 Definition: The person's diastolic blood pressure, measured in millimetres of mercury (mmHg). Data Element Concept: Person—blood pressure (diastolic) Value domain attributes Representational attributes Representation class: Total Data type: Number Format: NN[N] Maximum character length: 3 Supplementary values: Value Meaning 999 Not stated/inadequately described Unit of measure: Millimetre of mercury (mmHg) Data set specification specific attributes Diabetes (clinical) DSS DSS specific information: The United Kingdom Prospective Diabetes Study (1987 to 1998) showed major benefit from lowering blood pressure in preventing diabetes complications. A target for blood pressure for people who suffer from diabetes is 130/85 mm Hg or less; recommended by the Australian Diabetes Society (if proteinuria is detected it is less than 125/75 mm Hg) Australian Medicines Handbook: last modified February, 2001). Following the NSW Principles of Care and Guidelines for the Clinical Management of Diabetes Mellitus for patients who suffer from hypertension, if pharmacological intervention is required, ACE inhibitors are the preferred agents for treating hypertension in people with diabetes (unless contraindicated). High blood pressure is a major risk factor for coronary heart disease, heart failure, stroke, and renal failure with the risk increasing along with the level of blood pressure (Ashwell 1997; DHSH 1994b; Whelton 1994; Kannel 1991). Data element attributes Collection and usage attributes Guide for use: The diastolic pressure is recorded as phase V Korotkoff (disappearance of sound) however phase IV Korotkoff (muffling of sound) is used if the sound continues towards zero but does not cease. If Blood pressure - diastolic is not collected or not able to be collected, code 999. Collection methods: Measurement protocol for resting blood pressure: The diastolic blood pressure is one component of a routine blood pressure measurement (i.e. systolic/diastolic) and reflects the minimum pressure to which the arteries are exposed. · The patient should be relaxed and seated, preferably for several minutes, (at least 5 minutes). Ideally, patients should not take caffeine-containing beverages or smoke for two hours before blood pressure is measured. · Ideally, patients should not exercise within half an hour of the measurement being taken (National Nutrition Survey User's Guide). · Use a mercury sphygmomanometer. All other sphygmomanometers should be calibrated regularly against mercury sphygmomanometers to ensure accuracy. · Bladder length should be at least 80%, and width at least 40% of the circumference of the mid-upper arm. If the velcro on the cuff is not totally attached, the cuff is probably too small. · Wrap cuff snugly around upper arm, with the centre of the bladder of the cuff positioned over the brachial artery and the lower border of the cuff about 2 cm above the bend of the elbow. · Ensure cuff is at heart level, whatever the position of the patient. · Palpate the radial pulse of the arm in which the blood pressure is being measured. · Inflate cuff to the pressure at which the radial pulse disappears and note this value. Deflate cuff, wait 30 seconds, and then inflate cuff to 30 mm Hg above the pressure at which the radial pulse disappeared. · Deflate the cuff at a rate of 2-3 mm Hg/beat (2-3 mm Hg/sec) or less. · Recording the diastolic pressure use phase V Korotkoff (disappearance of sound). Use phase IV Korotkoff (muffling of sound) only if sound continues towards zero but does not cease. Wait 30 seconds before repeating the procedure in the same arm. Average the readings. · If the first two readings differ by more than 4 mmHg diastolic or if initial readings are high, take several readings after five minutes of quiet rest. Comments: The pressure head is the height difference a pressure can raise a fluid's equilibrium level above the surface subjected to pressure. (Blood pressure is usually measured as a head of Mercury, and this is the unit of measure nominated for this metadata item.) The current (2002) definition of hypertension is based on the level of blood pressure above which treatment is recommended, and this depends on the presence of other risk factors, e.g. age, diabetes etc. (NHF 1999 Guide to Management of Hypertension). Source and reference attributes Submitting organisation: Cardiovascular Data Working Group National Diabetes Data Working Group Origin: The National Heart Foundation Blood Pressure Advisory Committee's 'Guidelines for the Management of Hypertension - 1999' which are largely based on World Health Organization Recommendations. (Guidelines Subcommittee of the WHO-ISH: 1999 WHO-ISH guidelines for management of hypertension. J Hypertension 1999; 17:151-83). Australian Bureau of Statistics 1998. National Nutrition Survey User's Guide 1995. Cat. No. 4801.0. Canberra: ABS. (p. 20). National Diabetes Outcomes Quality Review Initiative (NDOQRIN) data dictionary. Reference documents: 'Guidelines for the Management of Hypertension - 1999' largely based on World Health Organization Recommendations. (Guidelines Subcommittee of the WHO) J Hypertension 1999; 17: 151-83.). Diabetes Control and Complications Trial: DCCT New England Journal of Medicine, 329(14), September 30, 1993. UKPDS 38 Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UK Prospective Diabetes Study Group. British Medical Journal (1998); 317: 703-713. Relational attributes Related metadata references: Supersedes Blood pressure - diastolic measured, version 1, DE, NHDD, NHIMG, Superseded 01/03/2005 .pdf (26.3 KB) Implementation in Data Set Specifications: Cardiovascular disease (clinical) DSS Health, Standard 01/09/2012 Diabetes (clinical) DSS Health, Standard 21/09/2005

Data type

integer

Measurement units
  • mmHg
mmHg
Blood pressure—systolic (measured)
Description

Person—blood pressure (systolic) (measured), millimetres of mercury NN[N] Identifying and definitional attributes Short name: Blood pressure—systolic (measured) METeOR identifier: 270073 Registration status: Health, Standard 01/03/2005 Definition: The person's systolic blood pressure, measured in millimetres of mercury (mmHg). Data Element Concept: Person—blood pressure (systolic) Value domain attributes Representational attributes Representation class: Total Data type: Number Format: NN[N] Maximum character length: 3 Supplementary values: Value Meaning 999 Not stated/inadequately described Unit of measure: Millimetre of mercury (mmHg) Data set specification specific attributes Diabetes (clinical) DSS DSS specific information: The United Kingdom Prospective Diabetes Study (1987 to 1998) showed major benefit from lowering blood pressure in preventing diabetes complications. A target for blood pressure for people who suffer from diabetes is 130/85 mm Hg or less; recommended by the Australian Diabetes Society (if proteinuria is detected it is less than 125/75 mm Hg) Australian Medicines Handbook: last modified February, 2001). Following the NSW Principles of Care and Guidelines for the Clinical Management of Diabetes Mellitus for patients who suffer from hypertension, if pharmacological intervention is required, ACE inhibitors are the preferred agents for treating hypertension in people with diabetes (unless contraindicated). High blood pressure is a major risk factor for coronary heart disease, heart failure, stroke, and renal failure with the risk increasing along with the level of blood pressure (Ashwell 1997; DHSH 1994b; Whelton 1994; Kannel 1991). Data element attributes Collection and usage attributes Guide for use: For recording the systolic reading, use phase I Korotkoff (the first appearance of sound). If Blood pressure - systolic is not collected or not able to be collected, code 999. Collection methods: Measurement protocol for resting blood pressure: The systolic blood pressure is one component of a routine blood pressure measurement (i.e. systolic/diastolic) and reflects the maximum pressure to which the arteries are exposed. · The patient should be relaxed and seated, preferably for several minutes, (at least 5 minutes). Ideally, patients should not take caffeine-containing beverages or smoke for two hours before blood pressure is measured. · Ideally, patients should not exercise within half an hour of the measurement being taken (National Nutrition Survey User's Guide). · Use a mercury sphygmomanometer. All other sphygmomanometers should be calibrated regularly against mercury sphygmomanometers to ensure accuracy. · Bladder length should be at least 80%, and width at least 40% of the circumference of the mid-upper arm. If the Velcro on the cuff is not totally attached, the cuff is probably too small. · Wrap cuff snugly around upper arm, with the centre of the bladder of the cuff positioned over the brachial artery and the lower border of the cuff about 2 cm above the bend of the elbow. · Ensure cuff is at heart level, whatever the position of the patient. · Palpate the radial pulse of the arm in which the blood pressure is being measured. · Inflate cuff to the pressure at which the radial pulse disappears and note this value. Deflate cuff, wait 30 seconds, and then inflate cuff to 30 mm Hg above the pressure at which the radial pulse disappeared. · Deflate the cuff at a rate of 2-3 mm Hg/beat (2-3 mm Hg/sec) or less. · For recording the systolic reading, use phase I Korotkoff (the first appearance of sound). Wait 30 seconds before repeating the procedure in the same arm. Average the readings. If the first two readings differ by more than 6 mm Hg systolic or if initial readings are high, take several readings after five minutes of quiet rest. Comments: The pressure head is the height difference a pressure can raise a fluid's equilibrium level above the surface subjected to pressure. (Blood pressure is usually measured as a head of Mercury, and this is the unit of measure nominated for this metadata item.) The current (2002) definition of hypertension is based on the level of blood pressure above which treatment is recommended, and this depends on the presence of other risk factors, e.g. age, diabetes etc. (NHF 1999 Guide to Management of Hypertension). Source and reference attributes Submitting organisation: Cardiovascular Data Working Group National Diabetes Data Working Group Origin: The National Heart Foundation Blood Pressure Advisory Committee's 'Guidelines for the Management of Hypertension - 1999' which are largely based on World Health Organization Recommendations. (Guidelines Subcommittee of the WHO-SH: 1999 WHO-ISH guidelines for management of hypertension. J Hypertension 1999; 17:151-83). Australian Bureau of Statistics 1998. National Nutrition Survey User's Guide 1995. Cat. No. 4801.0. Canberra: ABS. (p. 20). National Diabetes Outcomes Quality Review Initiative (NDOQRIN) data dictionary. Reference documents: 'Guidelines for the Management of Hypertension - 1999' largely based on World Health Organization Recommendations. (Guidelines Subcommittee of the WHO) J Hypertension 1999; 17: 151-83.). Diabetes Control and Complications Trial: DCCT New England Journal of Medicine, 329(14), September 30, 1993. UKPDS 38 Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UK Prospective Diabetes Study Group. British Medical Journal (1998); 317: 703-713. Relational attributes Related metadata references: Supersedes Blood pressure - systolic measured, version 1, DE, NHDD, NHIMG, Superseded 01/03/2005 .pdf (25.9 KB) Implementation in Data Set Specifications: Cardiovascular disease (clinical) DSS Health, Standard 01/09/2012 Diabetes (clinical) DSS Health, Standard 21/09/2005

Data type

integer

Measurement units
  • mmHg
mmHg
Cardiovascular medication (current)
Description

Person—cardiovascular medication taken (current), code N Identifying and definitional attributes Short name: Cardiovascular medication (current) METeOR identifier: 270237 Registration status: Health, Standard 01/03/2005 Definition: Whether the individual is currently taking cardiovascular medication, as represented by a code. Data Element Concept: Person—cardiovascular medication taken Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N Maximum character length: 1 Permissible values: Value Meaning 1 Angiotensin converting enzyme (ACE) inhibitors 2 Angiotensin II (A2) receptor blockers 3 Beta blockers 4 Calcium antagonists 8 None of the above Supplementary values: 9 Not stated/inadequately described Collection and usage attributes Guide for use: CODE 1 Angiotensin converting enzyme (ACE) inhibitors Use this code for ACE inhibitors (captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril and trandolapril). CODE 2 Angiotensin II (A2) receptor blockers Use this code for Angiotensin II receptor blockers (candesartan, eprosartan, irbesartan and telmisartan). CODE 3 Beta blockers Use this code for Beta blockers (atenolol, carvedilol, labetalol, metoprolol, oxprenolol, pindolol, propranolol and sotalol). CODE 4 Calcium antagonists Use this code for Calcium antagonists ( amlodipine, diltiazem, felodipine, lercanidipine, nifedipine and verapamil). CODE 8 None of the above This code is used when none of the listed medications is being taken by the person. CODE 9 Not stated/inadequately described This code should only be used in situations where it is not practicable to ask the questions. Collection methods: The person should be asked a series of questions about any current medication for a cardiovascular condition as follows: Are you currently taking any medication for a cardiovascular condition? ___Yes ___No If the person answers 'NO', then code 8 should be applied. If the person answers 'YES', then ask which one(s) (from the list of drugs in the Guide for use). Ace Inhibitors ___Yes ___No Angiotensin II receptor blockers ___Yes ___No Beta blockers ___Yes ___No Calcium antagonists ___Yes ___No The appropriate code should be recorded for each type of medication currently in use. Data set specification specific attributes Diabetes (clinical) DSS DSS specific information: A person may be taking one or more of the following medications for a cardiovascular condition. Therefore more than one code may be reported. Example 1: If a person takes one of the ACE inhibitors and a Beta blocker, the code recorded would be 13. Example 2: If a person takes one of the ACE inhibitors, an Angiotensin II receptor blocker and a Beta blocker, the code recorded would be 123. Data element attributes Collection and usage attributes Collection methods: A person may be taking one or more of the following medications for a cardiovascular condition. Therefore more than one code may be reported. Source and reference attributes Origin: National Diabetes Outcomes Quality Review Initiative (NDOQRIN) data dictionary. Australian Medicines Handbook: last modified by February 2001 Contents of Cardiovascular, Version 3, 1999 Therapeutic Guidelines Limited (05.04.2002)]. Relational attributes Related metadata references: Supersedes Cardiovascular medication - Superseded 01/03/2005, version 1, DE, NHDD, NHIMG, Superseded 01/03/2005.pdf (18.1 KB) Implementation in Data Set Specifications: Diabetes (clinical) DSS Health, Standard 21/09/2005

Data type

integer

Cataract - history
Description

Person—cataract status, code N Maximum occurences: 4 Identifying and definitional attributes Short name: Cataract - history METeOR identifier: 270252 Registration status: Health, Standard 01/03/2005 Definition: Whether the individual has a cataract present in either or both eyes or has had a cataract previously removed from either or both eyes, as represented by a code. Data Element Concept: Person—cataract status Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N Maximum character length: 1 Permissible values: Value Meaning 1 Cataract currently present or has been previously removed from the right eye 2 Cataract currently present or has been previously removed from the left eye 3 Cataract currently present or has been previously removed from both eyes 4 No cataract present or has not been previously removed from either eye Supplementary values: 9 Not stated/inadequately described Data element attributes Collection and usage attributes Collection methods: Examination of the lens of the eye through a dilated pupil (visible through the pupil by the use of an ophthalmoscope) by an ophthalmologist or optometrist, as a part of the ophthalmological assessment. Ask the individual if he/she has a cataract in either or both eyes or has had a cataract removed from either or both eyes previously. Alternatively obtain information from an ophthalmologist or optometrist or from appropriate documentation. Comments: Cataract is a clouding of the lens of the eye or its capsule sufficient to reduce vision. The formation of cataract occurs more rapidly in patients with a history of ocular trauma, uveitis, or diabetes mellitus. Cataract is an associated diabetic eye problem that could lead to blindness. Regular eye checkups are important for patients suffering from diabetes mellitus. This helps to early detect abnormalities and to avoid or postpone vision-threatening complications. A comprehensive ophthalmological examination includes: · check visual acuity with Snellen chart -correct with pinhole if indicated · examine for cataract · examine fundi with pupils dilated. Source and reference attributes Submitting organisation: National Diabetes Data Working Group Origin: National Diabetes Outcomes Quality Review Initiative (NDOQRIN) data dictionary. Relational attributes Related metadata references: Supersedes Cataract - history, version 1, DE, NHDD, NHIMG, Superseded 01/03/2005.pdf (16.4 KB) Implementation in Data Set Specifications: Diabetes (clinical) DSS Health, Standard 21/09/2005

Data type

integer

Cerebral stroke due to vascular disease (history)
Description

Person—cerebral stroke due to vascular disease (history), code N Identifying and definitional attributes Short name: Cerebral stroke due to vascular disease (history) METeOR identifier: 270355 Registration status: Health, Standard 01/03/2005 Definition: Whether the individual has had a cerebral stroke due to vascular disease, as represented by a code. Data Element Concept: Person—cerebral stroke due to vascular disease Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N Maximum character length: 1 Permissible values: Value Meaning 1 Cerebral stroke - occurred in the last 12 months 2 Cerebral stroke - occurred prior to the last 12 months 3 Cerebral stroke - occurred both in and prior to the last 12 months 4 No history of cerebral stroke due to vascular disease Supplementary values: 9 Not stated/inadequately described Data set specification specific attributes Diabetes (clinical) DSS DSS specific information: Cerebral stroke is a medical emergency condition with a high mortality rate, which is often recognised as a vascular complication of diabetes mellitus. The risk of stroke in patients with diabetes is at least twice that in non-diabetic patients according to Meigs et al. (Intern Med. 1998). Diabetes may increase actual stroke risk up to fivefold by increasing atheromatous deposits. Patients with diabetes who have a first stroke have 5-year survival rate reduced to 50% in comparison to non-diabetic stroke patients. The duration of diabetes clearly influences the severity of vascular disease. Atherosclerosis is more common and more severe earlier in the course of diabetes. In large arteries, plaque occurs from direct endothelial membrane injury, adverse balance of lipoproteins, and hyperinsulinemia (JAMA 1997). Small vessels are also affected more frequently than they are in non-diabetic stroke, resulting in an increased risk of lacunar stroke. References: Meigs J, Nathan D, Wilson P et al. Metabolic risk factors worsen continuously across the spectrum of non-diabetic glucose tolerance. Ann Intern Med. 1998; 128:524-533 Gorelick PB, Sacco RL, Smith DB, et al. Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. JAMA 1999; 281:1112-1120 Data element attributes Collection and usage attributes Collection methods: Obtain this information from appropriate documentation or from the patient. Source and reference attributes Submitting organisation: National Diabetes Data Working Group Origin: National Diabetes Outcomes Quality Review Initiative (NDOQRIN) data dictionary Relational attributes Related metadata references: Supersedes Cerebral stroke due to vascular disease - history, version 1, DE, NHDD, NHIMG, Superseded 01/03/2005.pdf (16.3 KB) Implementation in Data Set Specifications: Diabetes (clinical) DSS Health, Standard 21/09/2005

Data type

integer

Cholesterol—total (measured)
Description

Person—cholesterol level (measured), total millimoles per litre N[N].N Identifying and definitional attributes Short name: Cholesterol—total (measured) METeOR identifier: 270403 Registration status: Health, Superseded 01/10/2008 Definition: A person's total cholesterol (TC), measured in mmol/L. Data Element Concept: Person—cholesterol level Value domain attributes Representational attributes Representation class: Total Data type: Number Format: N[N].N Maximum character length: 3 Supplementary values: Value Meaning 99.9 Not stated/inadequately described. Unit of measure: Millimole per litre (mmol/L) Data set specification specific attributes Diabetes (clinical) DSS DSS specific information: The risk of coronary and other macrovascular disorders is 2-5 times higher in people with diabetes than in non-diabetic subjects and increases in parallel with the degree of dyslipidaemia. Following Principles of Care and Guidelines for the Clinical Management of Diabetes Mellitus, the targets for lipids management are: · To reduce total Cholesterols to less than 5.5 mmol/L · To reduce triglyceride levels to less than 2.0 mmol/L · To increase high density lipoprotein Cholesterols to more than or equal to 1.0 mmol/L. If pre-existing cardiovascular disease (bypass surgery or myocardial infarction), total cholesterol should be less than 4.5 mmol/L Data element attributes Collection and usage attributes Guide for use: Measurement in mmol/L to 1 decimal place. Record the absolute result of the total cholesterol measurement. When reporting, record whether or not the measurement of Cholesterol-total - measured was performed in a fasting specimen. Collection methods: When reporting, record absolute result of the most recent Cholesterol-total - measured in the last 12 months to the nearest 0.1 mmol/L. Measurement of lipid levels should be carried out by laboratories, or practices, which have been accredited to perform these tests by the National Association of Testing Authorities. · To be collected as a single venous blood sample, preferably following a 12-hour fast where only water and medications have been consumed. · Prolonged tourniquet use can artefactually increase levels by up to 20%. Comments: In settings where the monitoring of a person's health is ongoing and where a measure can change over time (such as general practice), the Service contact—service contact date, DDMMYYYY should be recorded. High blood cholesterol is a key factor in heart, stroke and vascular disease, especially coronary heart disease. Poor nutrition can be a contributing factor to heart, stroke and vascular disease as a population's level of saturated fat intake is the prime determinant of its level of blood cholesterol. Large clinical trials have shown that people at highest risk of cardiovascular events (e.g. pre-existing ischaemic heart disease) will derive the greatest benefit from lipid lowering drugs. For this group of patients, the optimum threshold plasma lipid concentration for drug treatment is still a matter of research. In May 1999 the PBS threshold total cholesterol concentration, for subsidy of drug treatment, was reduced from 5.5 to 4.0 mmol/L. (Australian Medical Handbook). Source and reference attributes Submitting organisation: Cardiovascular Data Working Group Origin: National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand, Lipid Management Guidelines - 2001, MJA 2001; 175: S57-S88 National Health Priority Areas Report: Cardiovascular Health 1998. AIHW Cat. No. PHE 9. HEALTH and AIHW, Canberra. The Royal College of Pathologists of Australasia web based Manual of Use and Interpretation of Pathology Tests Relational attributes Related metadata references: Supersedes Cholesterol-total - measured, version 1, DE, NHDD, NHIMG, Superseded 01/03/2005.pdf (21.4 KB) Has been superseded by Person—cholesterol level (measured), total millimoles per litre N[N].N Health, Standard 01/10/2008 Is used in the formation of Person—low-density lipoprotein cholesterol level (calculated), total millimoles per litre N[N].N Health, Superseded 01/10/2008 Is used in the formation of Person—low-density lipoprotein cholesterol level (calculated), total millimoles per litre N[N].N Health, Standard 01/10/2008 Implementation in Data Set Specifications: Diabetes (clinical) DSS Health, Standard 21/09/2005

Data type

float

Measurement units
  • mmol/L
mmol/L
Coronary artery disease—history of intervention or procedure
Description

Person—coronary artery disease intervention (history), code N Identifying and definitional attributes Short name: Coronary artery disease—history of intervention or procedure METeOR identifier: 270227 Registration status: Health, Standard 01/03/2005 Definition: Whether the individual has undergone a coronary artery by-pass grafting (CABG), angioplasty or stent, as represented by a code. Data Element Concept: Person—coronary artery disease intervention Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N Maximum character length: 1 Permissible values: Value Meaning 1 CABG, angioplasty or stent - undertaken in last 12 months 2 CABG, angioplasty or stent - undertaken prior to the last 12 months 3 CABG, angioplasty or stent - both within and prior to the last 12 months 4 No CABG, angioplasty or stent undertaken Supplementary values: 9 Not stated/inadequately described Collection and usage attributes Comments: CABG is known as 'bypass surgery' when a piece of vein (taken from the leg) or of an artery (taken from the chest or wrist) is used to form a connection between the aorta and the coronary artery distal to the obstructive lesion, making a bypass around the blockage. Angioplasty is an elective surgery technique of blood vessels reconstruction. Stenting is a non-surgical treatment used with balloon angioplasty or after, to treat coronary artery disease to widen a coronary artery. A stent is a small, expandable wire mesh tube that is inserted. The purpose of the stent is to help hold the newly treated artery open, reducing the risk of the artery re-closing (re-stenosis) over time. Angioplasty with stenting typically leaves less than 10% of the original blockage in the artery (Heart Center Online). These three procedures are commonly used to improve blood flow to the heart muscle when the heart's arteries are narrowed or blocked. The sooner procedures are done, the greater the chances of saving heart muscle. Data element attributes Collection and usage attributes Collection methods: Ask the individual if he/she has had a CABG, angioplasty or coronary stent. If so determine when it was undertaken within or prior to the last 12 months (or both). Source and reference attributes Submitting organisation: National Diabetes Data Working Group Origin: National Diabetes Outcomes Quality Review Initiative (NDOQRIN) data dictionary. Relational attributes Related metadata references: Supersedes Coronary artery disease - history of intervention or procedure, version 1, DE, NHDD, NHIMG, Superseded 01/03/2005.pdf (16.3 KB) Implementation in Data Set Specifications: Diabetes (clinical) DSS Health, Standard 21/09/2005

Data type

integer

Creatinine serum level (measured)
Description

Person—creatinine serum level, micromoles per litre NN[NN] Identifying and definitional attributes Short name: Creatinine serum level (measured) METeOR identifier: 270392 Registration status: Health, Superseded 01/10/2008 Definition: A person's serum creatinine level measured in micromoles per litre (µmol/L). Data Element Concept: Person—creatinine serum level Value domain attributes Representational attributes Representation class: Total Data type: String Format: NN[NN] Maximum character length: 4 Unit of measure: Micromole per litre (µmol/L) Data set specification specific attributes Diabetes (clinical) DSS DSS specific information: In settings where the monitoring of a person's health is ongoing and where a measure can change over time (such as general practice), the Service contact—service contact date, DDMMYYYY should be recorded. Record absolute result of the most recent serum creatinine measurement in the last 12 months to the nearest µmol/L (micromoles per litre). Data element attributes Collection and usage attributes Guide for use: There is no agreed standard as to which units serum creatinine should be recorded in. Note: If the measurement is obtained in mmol/L it is to be multiplied by 1000. Collection methods: Measurement of creatinine should be carried out by laboratories, or practices, which have been accredited to perform these tests by the National Association of Testing Authority. · Single venous blood test taken at the time of other screening blood tests. · Fasting not required. Comments: Serum creatinine can be used to help determine renal function. Serum creatinine by itself is an insensitive measure of renal function because it does not increase until more than 50% of renal function has been lost. Serum creatinine together with a patient's age, weight and sex can be used to calculate glomerular filtration rate (GFR), which is an indicator of renal status/ function. The calculation uses the Cockcroft-Gault formula. Creatinine is normally produced in fairly constant amounts in the muscles, as a result the breakdown of phosphocreatine. It passes into the blood and is excreted in the urine. Serum creatinine can be used to help determine renal function. The elevation in the creatinine level in the blood indicates disturbance in kidney function. GFR decreases with age, but serum creatinine remains relatively stable. When serum creatinine is measured, renal function in the elderly tends to be overestimated, and GFR should be used to assess renal function, according to the Cockcroft-Gault formula: GFR (ml/min) = (140 - age [yrs]) x body wt (kg) [x 0.85 (for women)] 814 x serum creatinine (mmol/l) To determine chronic renal impairment GFR > 90ml/min - normal GFR >60 - 90ml/min - mild renal impairment GFR >30 - 60ml/min - moderate renal impairment GFR 0 - 30 ml/min - severe renal impairment Note: The above GFR measurement should be for a period greater than 3 months. GFR may also be assessed by 24-hour creatinine clearance adjusted for body surface area. In general, patients with GFR < 30 ml/min are at high risk of progressive deterioration in renal function and should be referred to a nephrology service for specialist management of renal failure. Patients should be assessed for the complications of chronic renal impairment including anaemia, hyperparathyroidism and be referred for specialist management if required. Patients with rapidly declining renal function or clinical features to suggest that residual renal function may decline rapidly (ie. hypertensive, proteinuric (>1g/24hours), significant comorbid illness) should be considered for referral to a nephrologist well before function declines to less than 30ml/min. (Draft CARI Guidelines 2002. Australian Kidney Foundation). Patients in whom the cause of renal impairment is uncertain should be referred to a nephrologist for assessment. Source and reference attributes Submitting organisation: Cardiovascular Data Working Group National Diabetes Data Working Group Origin: Caring for Australians with Renal Impairment (CARI) Guidelines. Australian Kidney Foundation Relational attributes Related metadata references: Supersedes Creatinine serum - measured, version 1, DE, NHDD, NHIMG, Superseded 01/03/2005.pdf (19.7 KB) Has been superseded by Person—creatinine serum level, total micromoles per litre NN[NN] Health, Standard 01/10/2008 Implementation in Data Set Specifications: Diabetes (clinical) DSS Health, Standard 21/09/2005

Data type

integer

Measurement units
  • µmol/L
µmol/L
Date of birth
Description

Person—date of birth, DDMMYYYY Identifying and definitional attributes Short name: Date of birth METeOR identifier: 287007 Registration status: Housing assistance, Standard 20/06/2005 Health, Standard 04/05/2005 Early Childhood, Standard 21/05/2010 Homelessness, Standard 23/08/2010 Tasmanian Health, Final 30/06/2014 WA Health, Endorsed 19/03/2015 Independent Hospital Pricing Authority, Standard 01/11/2012 Indigenous, Endorsed 11/08/2014 National Health Performance Authority, Standard 07/11/2013 Commonwealth Department of Health, Candidate 25/05/2015 Disability, Standard 07/10/2014 Community Services (retired), Standard 25/08/2005 Definition: The date of birth of the person, expressed as DDMMYYYY. Data Element Concept: Person—date of birth Value domain attributes Representational attributes Representation class: Date Data type: Date/Time Format: DDMMYYYY Maximum character length: 8 Data element attributes Collection and usage attributes Guide for use: If date of birth is not known or cannot be obtained, provision should be made to collect or estimate age. Collected or estimated age would usually be in years for adults, and to the nearest three months (or less) for children aged less than two years. Additionally, an estimated date flag or a date accuracy indicator should be reported in conjunction with all estimated dates of birth. For data collections concerned with children's services, it is suggested that the estimated date of birth of children aged under 2 years should be reported to the nearest 3 month period, i.e. 0101, 0104, 0107, 0110 of the estimated year of birth. For example, a child who is thought to be aged 18 months in October of one year would have his/her estimated date of birth reported as 0104 of the previous year. Again, an estimated date flag or date accuracy indicator should be reported in conjunction with all estimated dates of birth. Collection methods: Information on date of birth can be collected using the one question: What is your/(the person's) date of birth? In self-reported data collections, it is recommended that the following response format is used: Date of birth: _ _ / _ _ / _ _ _ _ This enables easy conversion to the preferred representational layout (DDMMYYYY). For record identification and/or the derivation of other metadata items that require accurate date of birth information, estimated dates of birth should be identified by a date accuracy indicator to prevent inappropriate use of date of birth data. The linking of client records from diverse sources, the sharing of patient data, and data analysis for research and planning all rely heavily on the accuracy and integrity of the collected data. In order to maintain data integrity and the greatest possible accuracy an indication of the accuracy of the date collected is critical. The collection of an indicator of the accuracy of the date may be essential in confirming or refuting the positive identification of a person. For this reason it is strongly recommended that the data element Date—accuracy indicator, code AAA also be recorded at the time of record creation to flag the accuracy of the data. Comments: Privacy issues need to be taken into account in asking persons their date of birth. Wherever possible and wherever appropriate, date of birth should be used rather than age because the actual date of birth allows a more precise calculation of age. When date of birth is an estimated or default value, national health and community services collections typically use 0101 or 0107 or 3006 as the estimate or default for DDMM. It is suggested that different rules for reporting data may apply when estimating the date of birth of children aged under 2 years because of the rapid growth and development of children within this age group which means that a child's development can vary considerably over the course of a year. Thus, more specific reporting of estimated age is suggested. Source and reference attributes Origin: National Health Data Committee National Community Services Data Committee Reference documents: AS5017 Health Care Client Identification, 2002, Sydney: Standards Australia AS4846 Health Care Provider Identification, 2004, Sydney: Standards Australia Relational attributes Related metadata references: See also Date—accuracy indicator, code AAA Housing assistance, Standard 23/08/2010, Health, Standard 04/05/2005, Early Childhood, Standard 21/05/2010, Homelessness, Standard 23/08/2010, Disability, Standard 07/10/2014, Community Services (retired), Standard 30/09/2005 See also Date—estimate indicator, code N Tasmanian Health, Draft 23/07/2012, Community Services (retired), Standard 27/04/2007 Is used in the formation of Episode of admitted patient care (antenatal)—length of stay (including leave days), total N[NN] Health, Superseded 04/07/2007 Is used in the formation of Episode of admitted patient care (postnatal)—length of stay (including leave days), total N[NN] Health, Superseded 04/07/2007 Is used in the formation of Episode of admitted patient care—diagnosis related group, code (AR-DRG v 6) ANNA Health, Standard 30/06/2013, Tasmanian Health, Draft 23/07/2012, Commonwealth Department of Health, Candidate 16/07/2015 Is used in the formation of Episode of admitted patient care—diagnosis related group, code (AR-DRG v5.1) ANNA Health, Superseded 22/12/2009 Is used in the formation of Episode of admitted patient care—length of stay (including leave days) (antenatal), total N[NN] Health, Standard 04/07/2007 Is used in the formation of Episode of admitted patient care—length of stay (including leave days) (postnatal), total N[NN] Health, Standard 04/07/2007 Is used in the formation of Episode of admitted patient care—major diagnostic category, code (AR-DRG v 6) NN Health, Standard 30/06/2013, Tasmanian Health, Draft 23/07/2012, Commonwealth Department of Health, Candidate 16/07/2015 Is used in the formation of Episode of admitted patient care—major diagnostic category, code (AR-DRG v5.1) NN Health, Superseded 22/12/2009 See also Person with cancer—date of initial medical specialist consultation, DDMMYYYY Health, Standard 04/02/2015 See also Person with cancer—date of initial primary health care consultation, DDMMYYYY Health, Standard 04/02/2015 Supersedes Person—date of birth, DDMMYYYY Health, Superseded 04/05/2005, Community Services (retired), Superseded 25/08/2005 Is used in the formation of Record—linkage key, code 581 XXXXXDDMMYYYYN Housing assistance, Standard 23/08/2010, Health, Standard 07/12/2011, Early Childhood, Standard 21/05/2010, Homelessness, Standard 23/08/2010, Disability, Standard 07/10/2014, Community Services (retired), Standard 21/05/2010 Implementation in Data Set Specifications: Acute coronary syndrome (clinical) DSS 2013- Health, Standard 02/05/2013 Admitted patient care NMDS 2015-16 Health, Standard 13/11/2014 Independent Hospital Pricing Authority, Proposed 15/09/2014 Admitted patient mental health care NMDS 2015-16 Health, Standard 04/02/2015 Admitted patient palliative care NMDS 2015-16 Health, Standard 04/02/2015 Alcohol and other drug treatment services NMDS 2015- Health, Standard 13/11/2014 Audiology assessment client cluster Indigenous, Endorsed 11/08/2014 Cancer (clinical) DSS Health, Standard 14/05/2015 Cardiovascular disease (clinical) DSS Health, Standard 01/09/2012 Child protection and support services (CPSS) client cluster Community Services (retired), Standard 30/04/2008 Child protection and support services (CPSS) sibling cluster Community Services (retired), Standard 30/04/2008 Closing the Gap in the Northern Territory: Dental Services DSS, 2011 Indigenous, Endorsed 08/10/2014 Community mental health care NMDS 2015-16 Health, Standard 13/11/2014 Computer Assisted Telephone Interview demographic module DSS Health, Standard 03/12/2008 Diabetes (clinical) DSS Health, Standard 21/09/2005 Ear nose and throat services patient cluster Indigenous, Endorsed 05/09/2014 Early Childhood Education and Care: Unit Record Level NMDS 2015 Early Childhood, Standard 01/06/2015 Home purchase assistance DSS 2012-13 Housing assistance, Standard 03/07/2014 Household file cluster (Indigenous community housing) Housing assistance, Standard 01/05/2013 Indigenous, Endorsed 01/05/2013 Juvenile Justice Client file cluster Community Services (retired), Standard 14/09/2009 Medical indemnity DSS 2014- Health, Standard 21/11/2013 National Bowel Cancer Screening Program DSS 2014- Health, Standard 29/08/2014 Non-admitted patient DSS 2015-16 Health, Standard 13/11/2014 Independent Hospital Pricing Authority, Proposed 23/07/2014 Non-admitted patient emergency department care DSS 2015-16 Health, Standard 04/02/2015 Non-admitted patient emergency department care NMDS 2015-16 Health, Standard 13/11/2014 Independent Hospital Pricing Authority, Proposed 15/09/2014 Perinatal NMDS 2014- Health, Standard 07/03/2014 Person (housing assistance) cluster Housing assistance, Standard 01/05/2013 Person details data dictionary Disability, Standard 13/08/2015 Community Services (retired), Standard 06/02/2012 Person file cluster (Mainstream community housing) Housing assistance, Standard 01/05/2013 Prison clinic contact DSS Health, Standard 25/08/2011 Prison entrants DSS Health, Standard 25/08/2011 Prisoners in custody repeat medications DSS Health, Standard 25/08/2011 Private rent assistance DSS 2012-13 Housing assistance, Standard 03/07/2014 Public dental waiting times NMDS 2013- Health, Standard 09/11/2012 Radiotherapy waiting times NMDS 2015- Health, Standard 13/11/2014 Residential mental health care NMDS 2015-16 Health, Standard 13/11/2014 Statistical linkage key 581 cluster Housing assistance, Standard 23/08/2010 Health, Standard 07/12/2011 Early Childhood, Standard 21/05/2010 Homelessness, Standard 23/08/2010 Disability, Standard 07/10/2014 Community Services (retired), Standard 21/05/2010 Surveillance of healthcare associated infection: Staphylococcus aureus bacteraemia DSS Health, Standard 15/11/2012 WA Health Non-Admitted Patient Activity and Wait List Data Collection (NAPAAWL DC) 2013-14 WA Health, Endorsed 19/03/2015 WA Health Non-Admitted Patient Activity and Wait List Data Collection (NAPAAWL DC) 2014-15 WA Health, Endorsed 24/04/2015 Implementation in Indicators: Used as numerator National Health Performance Authority, Healthy Communities: Human papillomavirus (HPV) vaccination rates for girls turning 15 years in 2012 National Health Performance Authority, Standard 27/03/2014 National Health Performance Authority, Healthy Communities: Human papillomavirus (HPV) vaccination rates for girls turning 15 years in 2013 National Health Performance Authority, Standard 27/08/2015 National Health Performance Authority, Healthy Communities: Immunisation rates for children, 2012–13 National Health Performance Authority, Standard 27/03/2014 National Health Performance Authority, Healthy Communities: Number of selected potentially avoidable hospitalisations per 100,000 people, 2011–12 National Health Performance Authority, Standard 07/11/2013 National Indigenous Reform Agreement: PI 02-Mortality rate by leading causes, 2014 Indigenous, Endorsed 13/12/2013 National Indigenous Reform Agreement: PI 03-Rates of current daily smokers, 2014 Indigenous, Endorsed 13/12/2013 National Indigenous Reform Agreement: PI 06-Under five mortality rate by leading cause, 2014 Indigenous, Endorsed 13/12/2013 National Indigenous Reform Agreement: PI 10-The proportion of Indigenous children aged 4 and 5 years who are enrolled in, and attending, a preschool program in the year before full-time schooling, by remoteness, 2014 Indigenous, Endorsed 13/12/2013 Used as denominator National Health Performance Authority, Healthy Communities: Human papillomavirus (HPV) vaccination rates for girls turning 15 years in 2012 National Health Performance Authority, Standard 27/03/2014 National Health Performance Authority, Healthy Communities: Human papillomavirus (HPV) vaccination rates for girls turning 15 years in 2013 National Health Performance Authority, Standard 27/08/2015 National Health Performance Authority, Healthy Communities: Immunisation rates for children, 2012–13 National Health Performance Authority, Standard 27/03/2014 National Indigenous Reform Agreement: PI 03-Rates of current daily smokers, 2014 Indigenous, Endorsed 13/12/2013

Data type

date

Diabetes status
Description

Person—diabetes mellitus status, code NN Identifying and definitional attributes Short name: Diabetes status METeOR identifier: 270194 Registration status: Health, Standard 01/03/2005 Indigenous, Endorsed 13/03/2015 Definition: Whether a person has or is at risk of diabetes, as represented by a code. Data Element Concept: Person—diabetes mellitus status Value domain attributes Representational attributes Representation class: Code Data type: String Format: NN Maximum character length: 2 Permissible values: Value Meaning 01 Type 1 diabetes 02 Type 2 diabetes 03 Gestational diabetes mellitus (GDM) 04 Other (secondary diabetes) 05 Previous gestational diabetes mellitus (GDM) 06 Impaired fasting glucose (IFG) 07 Impaired glucose tolerance (IGT) 08 Not diagnosed with diabetes 09 Not assessed Supplementary values: 99 Not stated/inadequately described Collection and usage attributes Guide for use: Note that where there is a Gestational diabetes mellitus (GDM) or Previous GDM (i.e. permissible values 3 & 5) and a current history of Type 2 diabetes then record 'Code 2' Type 2 diabetes. This same principle applies where a history of either Impaired fasting glycaemia (IFG) or Impaired glucose tolerance (IGT) and a current history and Type 2 diabetes, then record 'Code 2' Type 2 diabetes. CODE 01 Type 1 diabetes Beta-cell destruction, usually leading to absolute insulin deficiency. Includes those cases attributed to an autoimmune process, as well as those with beta-cell destruction and who are prone to ketoacidosis for which neither an aetiology nor pathogenesis is known (idiopathic). It does not include those forms of beta-cell destruction or failure to which specific causes can be assigned (e.g. cystic fibrosis, mitochondrial defects). Some subjects with Type 1 diabetes can be identified at earlier clinical stages than 'diabetes mellitus'. CODE 02 Type 2 diabetes Type 2 includes the common major form of diabetes, which results from defect(s) in insulin secretion, almost always with a major contribution from insulin resistance. CODE 03 Gestational diabetes mellitus (GDM) GDM is a carbohydrate intolerance resulting in hyperglycaemia of variable severity with onset or first recognition during pregnancy. The definition applies irrespective of whether or not insulin is used for treatment or the condition persists after pregnancy. Diagnosis is to be based on the Australian Diabetes in Pregnancy Society (ADIPS) Guidelines. CODE 04 Other (secondary diabetes) This categorisation include less common causes of diabetes mellitus, but are those in which the underlying defect or disease process can be identified in a relatively specific manner. They include, for example, genetic defects of beta-cell function, genetic defects in insulin action, diseases of the exocrine pancreas, endocrinopathies, drug or chemical-induced, infections, uncommon forms of immune-mediated diabetes, other genetic syndromes sometimes associated with diabetes. CODE 05 Previous GDM Where the person has a history of GDM. CODE 06 Impaired fasting glycaemia (IFG) IFG or 'non-diabetic fasting hyperglycaemia' refers to fasting glucose concentrations, which are lower than those required to diagnose diabetes mellitus but higher than the normal reference range. An individual is considered to have IFG if they have a fasting plasma glucose of 6.1 or greater and less than 7.0 mmol/L if challenged with an oral glucose load, they have a fasting plasma glucose concentration of 6.1 mmol/L or greater, but less than 7.0 mmol/L, AND the 2 hour value in the Oral Glucose Tolerance Test (OGTT) is less than 7.8 mmol/L. CODE 07 Impaired glucose tolerance (IGT) IGT is categorised as a stage in the natural history of disordered carbohydrate metabolism; subjects with IGT have an increased risk of progressing to diabetes. IGT refers to a metabolic state intermediate between normal glucose homeostasis and diabetes. Those individuals with IGT manifest glucose intolerance only when challenged with an oral glucose load. IGT is diagnosed if the 2 hour value in the OGTT is greater than 7.8 mmol/L. and less than 11.1 mmol/L AND the fasting plasma glucose concentration is less than 7.0 mmol/L. CODE 08 Not diagnosed with diabetes The subject has no known diagnosis of Type 1, Type 2, GDM, Previous GDM, IFG, IGT or Other (secondary diabetes). CODE 09 Not assessed The subject has not had their diabetes status assessed. CODE 99 Not stated/inadequately described This code is for unknown or information unavailable. Collection methods: The diagnosis is derived from and must be substantiated by clinical documentation. Source and reference attributes Origin: Developed based on Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications Part 1: Diagnosis and Classifications of Diabetes Mellitus Provisional Report of a World Health Organization Consultation (Alberti & Zimmet 1998). Data set specification specific attributes Diabetes (clinical) DSS DSS specific information: Uncontrolled diabetes leads to a variety of complications, often resulting in limitation of activity, disability, illness and premature mortality. Therefore ongoing assessment is required to identify people at risk of developing complications so that early preventive strategies can be applied. Although there is no cure for diabetes, with modern treatment most people can lead a full and active life and avoid long-term complications. Aetiological classifications contained in the scientific paper 'Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications Part 1: Diagnosis and Classifications of Diabetes Mellitus Provisional Report of a WHO Consultation (Alberti & Zimmet 1998)'. Data element attributes Collection and usage attributes Collection methods: Diabetes (clinical): A type of diabetes should be recorded and coded for each episode of patient care. Source and reference attributes Submitting organisation: Cardiovascular Data Working Group National Diabetes Data Working Group Relational attributes Related metadata references: Supersedes Diabetes status, version 1, DE, NHDD, NHIMG, Superseded 01/03/2005.pdf (27.3 KB) Implementation in Data Set Specifications: Acute coronary syndrome (clinical) DSS 2013- Health, Standard 02/05/2013 Cardiovascular disease (clinical) DSS Health, Standard 01/09/2012 Diabetes (clinical) DSS Health, Standard 21/09/2005 Indigenous primary health care DSS 2015- Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Implementation in Indicators: Used as numerator Indigenous primary health care: PI05a-Number of regular clients with Type II diabetes who have had an HbA1c measurement result recorded, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI05b-Proportion of regular clients with Type II diabetes who have had an HbA1c measurement result recorded, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI06a-Number of regular clients with Type II diabetes whose HbA1c measurement result was within a specified level, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI06b-Proportion of regular clients with Type II diabetes whose HbA1c measurement result was within a specified level, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI07a-Number of regular clients with a chronic disease for whom a GP Management Plan (MBS Item 721) was claimed, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI07b-Proportion of regular clients with a chronic disease for whom a GP Management Plan (MBS Item 721) was claimed, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI08a-Number of regular clients with a chronic disease for whom a Team Care Arrangement (MBS Item 723) was claimed, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI08b-Proportion of regular clients with a chronic disease for whom a Team Care Arrangement (MBS Item 723) was claimed, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI15a-Number of regular clients with Type II diabetes or COPD who are immunised against influenza, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI15b-Proportion of regular clients with Type II diabetes or COPD who are immunised against influenza, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI18a-Number of regular clients with a selected chronic disease who have had a kidney function test, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI18b-Proportion of regular clients with a selected chronic disease who have had a kidney function test, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI19a-Number of regular clients with a selected chronic disease who have had a kidney function test with results within specified levels, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI19b-Proportion of regular clients with a selected chronic disease who have had a kidney function test with results within specified levels, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI20a-Number of regular clients who have had the necessary risk factors assessed to enable CVD assessment, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI20b-Proportion of regular clients who have had the necessary risk factors assessed to enable CVD assessment, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI23a-Number of regular clients with Type II diabetes who have had a blood pressure measurement result recorded, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI23b-Proportion of regular clients with Type II diabetes who have had a blood pressure measurement result recorded, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI24a-Number of regular clients with Type II diabetes whose blood pressure measurement result was less than or equal to 130/80 mmHg, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI24b-Proportion of regular clients with Type II diabetes whose blood pressure measurement result was less than or equal to 130/80 mmHg, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Used as denominator Indigenous primary health care: PI05b-Proportion of regular clients with Type II diabetes who have had an HbA1c measurement result recorded, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI06b-Proportion of regular clients with Type II diabetes whose HbA1c measurement result was within a specified level, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI07b-Proportion of regular clients with a chronic disease for whom a GP Management Plan (MBS Item 721) was claimed, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI08b-Proportion of regular clients with a chronic disease for whom a Team Care Arrangement (MBS Item 723) was claimed, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI15b-Proportion of regular clients with Type II diabetes or COPD who are immunised against influenza, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI18b-Proportion of regular clients with a selected chronic disease who have had a kidney function test, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI19b-Proportion of regular clients with a selected chronic disease who have had a kidney function test with results within specified levels, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI23b-Proportion of regular clients with Type II diabetes who have had a blood pressure measurement result recorded, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI24b-Proportion of regular clients with Type II diabetes whose blood pressure measurement result was less than or equal to 130/80 mmHg, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015

Data type

text

Diabetes therapy type
Description

Person—diabetes therapy type, code NN Identifying and definitional attributes Short name: Diabetes therapy type METeOR identifier: 270236 Registration status: Health, Standard 01/03/2005 Definition: The type of diabetes therapy the person is currently receiving, as represented by a code. Data Element Concept: Person—diabetes therapy type Value domain attributes Representational attributes Representation class: Code Data type: String Format: NN Maximum character length: 2 Permissible values: Value Meaning 01 Diet and exercise only 02 Oral hypoglycaemic - sulphonylurea only 03 Oral hypoglycaemic - biguanide (eg metformin) only 04 Oral hypoglycaemic - alpha-glucosidase inhibitor only 05 Oral hypoglycaemic - thiazolidinedione only 06 Oral hypoglycaemic - meglitinide only 07 Oral hypoglycaemic - combination (eg biguanide & sulphonylurea) 08 Oral hypoglycaemic - other 09 Insulin only 10 Insulin plus oral hypoglycaemic 98 Nil - not currently receiving diabetes treatment Supplementary values: 99 Not stated/inadequately described Collection and usage attributes Guide for use: CODE 01 Diet & exercise only This code includes the options of generalised prescribed diet; avoid added sugar/simple carbohydrates (CHOs); low joule diet; portion exchange diet and uses glycaemic index and a recommendation for increased exercise. CODE 98 Nil - not currently receiving diabetes treatment This code is used when there is no current diet, tablets or insulin therapy(ies). CODE 99 Not stated/inadequately described Use this code when missing information. Data set specification specific attributes Diabetes (clinical) DSS DSS specific information: The objectives and priorities of treatment must be tailored to the individual considering age, sex, weight and individual health status. An individual management plan for each patient should include the following: · establishment of targets of treatment · healthy eating plan · education in self-monitoring, · adjustment of treatment and in approaches to coping with emergencies · exercise program · risk factor reduction, e.g. smoking cessation · use of oral hypoglycaemic agents, if required · use of insulin, if required · screening for and treatment of complications of diabetes. In addition to glycaemic control, management of diabetes of either type requires close attention to other risk factors for the development of complications, and the impact of lifestyle changes on blood glucose levels should be monitored. In patients with Type 2 diabetes, an increase in physical activity is essential in management of lipids and glucose level. Increased physical activity has been recognised as perhaps the most feasible way of modifying glucose intolerance, a risk factor for developing diabetes and macrovascular disease (Guest & O'Dea 1992). Data element attributes Collection and usage attributes Collection methods: To be collected at the commencement of treatment and at each review. Comments: In settings where the monitoring of a person's health is ongoing and where management can change over time (such as general practice), the Service contact—service contact date, DDMMYYYY should be recorded. The main use of this data element is to enable categorisation of management regimes against best practice for diabetes. Source and reference attributes Submitting organisation: National Diabetes Data Working Group Cardiovascular Data Working Group Reference documents: Berkow R, editor. The Merck Manual. 16th ed. Rahway (New Jersey, USA): Merck Research Laboratories; 1992. Relational attributes Related metadata references: Supersedes Diabetes therapy type, version 1, DE, NHDD, NHIMG, Superseded 01/03/2005.pdf (19.1 KB) See also Female—type of diabetes mellitus therapy during pregnancy, code N Health, Standard 07/03/2014 Implementation in Data Set Specifications: Acute coronary syndrome (clinical) DSS 2013- Health, Standard 02/05/2013 Cardiovascular disease (clinical) DSS Health, Standard 01/09/2012 Diabetes (clinical) DSS Health, Standard 21/09/2005

Data type

text

Dyslipidaemia treatment indicator
Description

Person—dyslipidaemia treatment with anti-lipid medication indicator (current), code N Identifying and definitional attributes Short name: Dyslipidaemia treatment indicator METeOR identifier: 302440 Registration status: Health, Standard 21/09/2005 Definition: Whether a person is being currently treated for dyslipidaemia using anti-lipid medication, as represented by a code. Data Element Concept: Person—dyslipidaemia treatment with anti-lipid medication indicator Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N Maximum character length: 1 Permissible values: Value Meaning 1 Yes 2 No Supplementary values: 9 Not stated/inadequately described Collection and usage attributes Guide for use: CODE 9 Not stated/inadequately described This code is not for use in primary data collections. Data set specification specific attributes Diabetes (clinical) DSS DSS specific information: Dyslipidaemia is associated with many health problems including diabetes and hypertension. It is often related to overweight and obesity. Usually caused by inappropriate diet and sedentary lifestyle, dyslipidaemia has been reaching epidemic proportions. Active lifestyle and low calorie diets are the best way of prevention, however sometimes for the treatment of dyslipidaemia the use of pharmacotherapy is required. Abnormal levels of blood lipids are associated with increased risk of developing CHD especially in diabetic patients. The risk of coronary and other macrovascular disorders is 2-5 times higher in people with diabetes than in non-diabetic subjects and increases in parallel with the degree of dyslipidaemia. Diabetes mellitus greatly modifies the significance of lipoprotein levels, particularly when associated with smoking, hypertension and family history of CVD. Poor metabolic control of diabetes seems to have impact on abnormal lipoprotein level. Primary dyslipidaemia, due to genetic and environmental (especially dietary) factors, is diagnosed if secondary causes have been excluded (hypothyroidism, nephrotic syndrome, cholestasis, anorexia nervosa, diabetes mellitus Type 2, renal impairment). Data element attributes Collection and usage attributes Guide for use: CODE 1 Yes: Record if a person is being treated for dyslipidaemia using anti-lipid medication. CODE 2 No: Record if a person is not being treated for dyslipidaemia using anti-lipid medication. Collection methods: Ask the individual if he/she is currently treated with anti-lipid medication. Alternatively obtain the relevant information from appropriate documentation. Source and reference attributes Submitting organisation: National diabetes data working group Origin: National Diabetes Outcomes Quality Review Initiative (NDOQRIN) data dictionary. Relational attributes Related metadata references: Supersedes Person—dyslipidaemia treatment status (anti-lipid medication), code N Health, Superseded 21/09/2005 Implementation in Data Set Specifications: Acute coronary syndrome (clinical) DSS 2013- Health, Standard 02/05/2013 Diabetes (clinical) DSS Health, Standard 21/09/2005

Data type

integer

Renal disease—end-stage (diabetes complication)
Description

Person—end-stage renal disease status (diabetes complication), code N Identifying and definitional attributes Short name: Renal disease—end-stage (diabetes complication) METeOR identifier: 270373 Registration status: Health, Standard 01/03/2005 Definition: Whether an individual has end-stage renal disease as a complication of diabetes, and has required dialysis or has undergone a kidney transplant, as represented by a code. Data Element Concept: Person—end-stage renal disease status Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N Maximum character length: 1 Permissible values: Value Meaning 1 End-stage renal disease - developed in the last 12 months 2 End-stage renal disease - developed prior to the last 12 months 3 No end-stage of renal disease Supplementary values: 9 Not stated/inadequately described Data set specification specific attributes Diabetes (clinical) DSS DSS specific information: To determine chronic renal impairment: - Glomerular filtration rate (GFR) GFR > 90 ml/min normal GFR > 60 - 90 ml/min: mild renal impairment GFR > 30 - 60 ml/min: moderate renal impairment GFR 0- 30 ml/min: severe renal impairment For greater than 3 months. In general, patients with GFR Patients should be assessed for the complications of chronic renal impairment including anaemia, hyperparathyroidism and be referred for specialist management if required. Patients with rapidly declining renal function or clinical features to suggest that residual renal function may decline rapidly (i.e. hypertensive, proteinuric (>1 g/24 hours), significant co-morbid illness) should be considered for referral to a nephrologist well before function declines to less than 30 ml/min. (Draft CARI Guidelines 2002. Australian Kidney Foundation). Patients in whom the cause of renal impairment is uncertain should be referred to a nephrologist for assessment. End-stage renal disease is a recognised complication of Type 1 and Type 2 diabetes mellitus. Diabetes is the commonest cause for renal dialysis in Australia. The term end-stage renal disease has become synonymous with the late stages of chronic renal failure. Diabetic nephropathy may be effectively prevented and treated by controlling glycemia and administering angiotensin-converting enzyme (ACE) inhibitors. J Am Soc Nephrol 2002 Jun; 13(6): 1615-1625]. Data element attributes Collection and usage attributes Collection methods: Ask the individual if he/she has required dialysis or has undergone a kidney (renal) transplant (due to diabetic nephropathy). Alternatively obtain the relevant information from appropriate documentation. Source and reference attributes Submitting organisation: National Diabetes Data Working Group Origin: National Diabetes Outcomes Quality Review Initiative (NDOQRIN) data dictionary. Relational attributes Related metadata references: Supersedes Renal disease - end stage, diabetes complication, version 1, DE, NHDD, NHIMG, Superseded 01/03/2005.pdf (17.9 KB) Implementation in Data Set Specifications: Diabetes (clinical) DSS Health, Standard 21/09/2005

Data type

integer

Foot deformity
Description

Person—foot deformity indicator, code N Identifying and definitional attributes Short name: Foot deformity METeOR identifier: 302449 Registration status: Health, Standard 21/09/2005 Definition: Whether a deformity is present on either foot, as represented by a code. Data Element Concept: Person—foot deformity indicator Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N Maximum character length: 1 Permissible values: Value Meaning 1 Yes 2 No Supplementary values: 9 Not stated/inadequately described Collection and usage attributes Guide for use: CODE 9 Not stated/inadequately described This code is not for use in primary data collections. Data set specification specific attributes Diabetes (clinical) DSS DSS specific information: Foot deformities are frequently the result of diabetic motor neuropathy and diabetic foot disease is the most common cause of hospitalisation in people with diabetes. Diabetic foot complications are common in the elderly, and amputation rates increase with age: by threefold in those aged 45 - 74 years and sevenfold over 75 years. In people with diabetes, amputations are 15 times more common than in people without diabetes and 50% of all amputations occur in people with diabetes (Epidemiology of the diabetic foot; Report of the Diabetic Foot and Amputation Group). All patients with diabetes mellitus should be instructed about proper foot care in an attempt to prevent ulcers. Feet should be kept clean and dry at all times. Patients with neuropathy should not walk barefoot, even in the home. Properly fitted shoes are essential. Specialised foot clinics appear to decrease further episodes of foot ulceration and decrease hospital admissions for amputations. Principles of Care and Guidelines for the Clinical Management of Diabetes Mellitus recommendations include: · feet should be examined every 6 months or at every visit if high risk foot or active foot problem. · refer to specialists experienced in the care of the diabetic foot if infection or ulceration is present. · ensure that patients with 'high-risk foot' or an active foot problem receive appropriate care from specialists and podiatrists expert in the treatment of diabetic foot problems. · to identify the 'high-risk foot' as indicated by a past history of foot problems, especially ulceration, and/or the presence of Peripheral neuropathy · assessment outcome, peripheral vascular disease, or foot deformity or history of previous ulceration. Data element attributes Collection and usage attributes Guide for use: CODE 1 Yes: Record if a foot deformity is present on either foot. CODE 2 No: Record if no foot deformity is present on either foot. Common deformities include claw toes, pes cavus, hallux valgus, hallux rigidus, hammer toe, Charcot foot and nail deformity. Collection methods: Both feet to be examined for the presence of foot deformity. Comments: Foot deformities are associated with high mechanical pressure on the overlying skin that lead to ulceration in the absence of protective pain sensation and when shoes are unsuitable. Limited joint mobility is often present, with displaced plantar fat pad and more prominent metatarsal heads. Source and reference attributes Submitting organisation: National diabetes data working group Origin: National Diabetes Outcomes Quality Review Initiative (NDOQRIN) data dictionary Reference documents: Lesley V Campbell, Antony R Graham, Rosalind M Kidd, Hugh F Molloy, Sharon R O'Rourke and Stephen Colagiuri: The Lower Limb in People With Diabetes; Content 1997/98 Australian Diabetes Society. Edmonds M, Boulton A, Buckenham T, et al. Report of the Diabetic Foot and Amputation Group. Diabet Med 1996; 13: S27 - 42. Reiber GE. Epidemiology of the diabetic foot. In: Levin ME, O'Neal LW, Bowker JH, editors. The diabetic foot. 5th ed. St Louis: Mosby Year Book, 1993; 1 - 5. Most RS, Sinnock P. The epidemiology of lower limb extremity amputations in diabetic individuals. Diabetes Care 1983; 6: 87 - 91. Therapeutic Guidelines Limited (05.04.2002) Management plan for diabetes. Relational attributes Related metadata references: Supersedes Person—foot deformity status, code N Health, Superseded 21/09/2005 Implementation in Data Set Specifications: Diabetes (clinical) DSS Health, Standard 21/09/2005

Data type

integer

Foot lesion (active)
Description

Person—foot lesion indicator (active), code N Identifying and definitional attributes Short name: Foot lesion (active) METeOR identifier: 302437 Registration status: Health, Standard 21/09/2005 Definition: Whether an individual has an active foot lesion, other than an ulcer, on either foot, as represented by a code. Data Element Concept: Person—foot lesion indicator Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N Maximum character length: 1 Permissible values: Value Meaning 1 Yes 2 No Supplementary values: 9 Not stated/inadequately described Collection and usage attributes Guide for use: CODE 9 Not stated/inadequately described This code is not for use in primary data collections. Data set specification specific attributes Diabetes (clinical) DSS DSS specific information: Early detection and appropriate management of the 'high risk foot' and active foot problems can reduce morbidity, hospitalisation and amputation in people with diabetes. Data element attributes Collection and usage attributes Guide for use: CODE 1 Yes: Record if current active foot lesion other than ulceration is present on either foot. CODE 2 No: Record if no current active foot lesion other than ulceration is present on either foot. The following entities would be included: fissures, infections, inter-digital maceration, corns, calluses and nail dystrophy. Collection methods: Assess whether the individual has an active foot lesion on either foot. Source and reference attributes Submitting organisation: National Diabetes Data Working Group Origin: National Diabetes Outcomes Quality Review Initiative (NDOQRIN) data dictionary. Relational attributes Related metadata references: Supersedes Person—foot lesion status (active), code N Health, Superseded 21/09/2005 Implementation in Data Set Specifications: Diabetes (clinical) DSS Health, Standard 21/09/2005

Data type

integer

Foot ulcer (current)
Description

Person—foot ulcer indicator (current), code N Identifying and definitional attributes Short name: Foot ulcer (current) METeOR identifier: 302445 Registration status: Health, Standard 21/09/2005 Definition: Whether an individual has a current foot ulcer on either foot, as represented by a code. Data Element Concept: Person—foot ulcer indicator Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N Maximum character length: 1 Permissible values: Value Meaning 1 Yes 2 No Supplementary values: 9 Not stated/inadequately described Collection and usage attributes Guide for use: CODE 9 Not stated/inadequately described This code is not for use in primary data collections. Data set specification specific attributes Diabetes (clinical) DSS DSS specific information: The development of ulcers of the feet and lower extremities is a special problem in the diabetic patient, and appears to be due primarily to abnormal pressure distribution secondary to diabetic neuropathy. Diabetic foot ulceration is a serious problem and the lack of pain does not mean that the ulcer can be ignored or neglected. The absence of pain is very common in people with diabetes due to peripheral neuropathy. All patients with diabetes mellitus should be instructed about proper foot care in an attempt to prevent ulcers. Feet should be kept clean and dry at all times. Patients with neuropathy should not walk barefoot, even in the home. Properly fitted shoes are essential. Early detection and appropriate management of the 'high-risk foot' and current foot ulceration can reduce morbidity, hospitalisation and amputation in people with diabetes. Data element attributes Collection and usage attributes Guide for use: CODE 1 Yes: Record if a foot ulcer is currently present on either foot. CODE 2 No: Record if a foot ulcer is not currently present on either foot. Collection methods: Access whether the individual has a current foot ulcer on either foot. Assessment · ask the patient about previous or current foot problems, neuropathic symptoms, rest pain and intermittent claudication; · inspect the feet (whole foot, nails, between the toes) to identify active foot problems and the 'high-risk foot'; · assess footwear; · check peripheral pulses; · examine for neuropathy by testing reflexes and sensation preferably using tuning fork, 10 g monofilament and/or biothesiometer. Comments: Foot ulcer is usually situated on the edge of the foot or toes because blood supply is the poorest at these sites. In a purely vascular ulcer, nerve function is normal and sensation is intact, hence vascular ulcers are usually painful. Foot ulcers require urgent care from an interdisciplinary team, which may include a general practitioner, podiatrist, endocrinologist physician, nurse or surgeon. Source and reference attributes Submitting organisation: National diabetes data working group Origin: National Diabetes Outcomes Quality Review Initiative (NDOQRIN) data dictionary. Reference documents: The Diabetic Foot Vol 3 No 4. Principles of Care and Guidelines for the Clinical Management of Diabetes Mellitus. Relational attributes Related metadata references: Supersedes Person—foot ulcer status (current), code N Health, Superseded 21/09/2005 Implementation in Data Set Specifications: Diabetes (clinical) DSS Health, Standard 21/09/2005

Data type

integer

Foot ulcer (history)
Description

Person—foot ulcer indicator (history), code N Identifying and definitional attributes Short name: Foot ulcer (history) METeOR identifier: 302819 Registration status: Health, Standard 21/09/2005 Definition: Whether person has a previous history of ulceration on either foot, as represented by a code. Data Element Concept: Person—foot ulcer indicator Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N Maximum character length: 1 Permissible values: Value Meaning 1 Yes 2 No Supplementary values: 9 Not stated/inadequately described Collection and usage attributes Guide for use: CODE 9 Not stated/inadequately described This code is not for use in primary data collections. Data set specification specific attributes Diabetes (clinical) DSS DSS specific information: Past history of foot ulceration, peripheral neuropathy and foot deformities have been associated with increased risk of foot ulceration and lower limb amputation for patients who suffer from diabetes. The aim is to identify the 'high-risk foot' as indicated by a past history of foot problems, especially ulceration. Following the Principles of Care and Guidelines for the Clinical Management of Diabetes Mellitus, individuals with a 'high-risk foot' or a significant active foot problem should be examined every six months or at every visit. Assessment: · ask patient about previous foot problems, neuropathic symptoms, rest pain and intermittent claudication · inspect the feet (whole foot, nails, between the toes) to identify active foot problems and the 'high-risk foot' · assess footwear · check peripheral pulses · examine for neuropathy by testing reflexes and sensation preferably using tuning fork, 10 g monofilament and/or biothesiometer. Data element attributes Collection and usage attributes Guide for use: CODE 1 Yes: Record if person has a previous history of ulceration on either foot. CODE 2 No: Record if person has no previous history of ulceration on either foot. Collection methods: Ask the individual if he/she a previous history of foot ulceration. Alternatively obtain this information from appropriate documentation. Source and reference attributes Submitting organisation: National diabetes data working group Origin: National Diabetes Outcomes Quality Review Initiative (NDOQRIN) data dictionary Relational attributes Related metadata references: Supersedes Person—foot ulcer history status, code N Health, Superseded 21/09/2005 Implementation in Data Set Specifications: Diabetes (clinical) DSS Health, Standard 21/09/2005

Data type

integer

Glycosylated haemoglobin level (measured)
Description

Person—glycosylated haemoglobin level (measured), percentage N[N].N Identifying and definitional attributes Short name: Glycosylated haemoglobin level (measured) METeOR identifier: 270325 Registration status: Health, Standard 01/03/2005 Definition: A person's glycosylated haemoglobin (HbA1c) level, measured as percentage. Data Element Concept: Person—glycosylated haemoglobin level Value domain attributes Representational attributes Representation class: Percentage Data type: Number Format: N[N].N Maximum character length: 3 Supplementary values: Value Meaning 99.9 Not stated/inadequately described Data set specification specific attributes Diabetes (clinical) DSS DSS specific information: The HbA1c along with regular blood glucose monitoring is the best way to see the overall picture of blood glucose levels. HbA1c is a measurement of long-term blood glucose control and is used to assess the effectiveness of treatment. The level of HbA1c is proportional to the level of glucose in the blood over a period of approximately two months, because glucose attaches to the haemoglobin (red blood cells) and remains there for the life of the red blood cell, approximately 120 days. The HbA1c gives an average of the blood glucose level over the past 6-8 weeks and therefore HbA1c is accepted as an indicator of the mean daily blood glucose concentration over the preceding two months. HbA1c is formed by the non-enzymatic glycation of the N-terminus of the B- chain of haemoglobin Ao. It is a convenient way to obtain an integrated assessment of antecedent glycaemia over an extended period under real life conditions used as a standard for assessing overall blood glucose control. Research studies in the United States have found that for every 1% reduction in results of HbA1c blood tests, the risk of developing micro vascular diabetic complications (eye, kidney, and nerve disease) is reduced by 40 percent. The maintenance of good glycaemic control (in diabetes Type 1 and Type 2), significantly reduces progression of diabetes-related complications such as retinopathy, nephropathy and neuropathy, as indicated in the Diabetes Control and Complications Trial (DCCT 1993) and United Kingdom Prospective Diabetes Study (UKPDS 1997). The target proposed by the Australian Diabetes Society for glycosylated haemoglobin (HbA1c)is 7.0% or less and a doctor may order this test about every 3 - 6 months. Data element attributes Collection and usage attributes Guide for use: HbA1c results vary between laboratories; use the same laboratory for repeated testing. When reporting, record absolute result of the most recent HbA1c level in the last 12 months. Record the absolute result of the test (%). Collection methods: Test is performed in accredited laboratories: · A single blood sample is sufficient and no preparation of the patient is required. · Measure HbA1c ideally using High Performance Liquid Chromatography (HPLC). Source and reference attributes Submitting organisation: National diabetes data working group Origin: National Diabetes Outcomes Quality Review Initiative (NDOQRIN) data dictionary. Reference documents: Koening, R. J. Peterson, CM and Kilo, C et al. Hemoglobin A1c as an indicator of the degree of glucose intolerance in diabetes. Diabetes 259 (1976): 230-232. Nathan, D.M., Singer, D.E, Hurxthal, K, and Goodson, J.D. The clinical information value of the glycosylated hemoglobin assay. N. Eng. J. Med. 310 (1984): 341-346. Relational attributes Related metadata references: Supersedes Glycosylated Haemoglobin (HbA1c) - measured, version 1, DE, NHDD, NHIMG, Superseded 01/03/2005.pdf (18.0 KB) See also Laboratory standard—upper limit of normal range of glycosylated haemoglobin, percentage N[N].N Health, Standard 01/03/2005 Implementation in Data Set Specifications: Acute coronary syndrome (clinical) DSS 2013- Health, Standard 02/05/2013 Diabetes (clinical) DSS Health, Standard 21/09/2005

Data type

float

Measurement units
  • %
%
Health professionals attended (diabetes mellitus)
Description

Person—health professionals attended for diabetes mellitus (last 12 months), code N Identifying and definitional attributes Short name: Health professionals attended (diabetes mellitus) METeOR identifier: 270287 Registration status: Health, Standard 01/03/2005 Definition: The health professionals that a person has attended in the last 12 months in relation to issues arising from diabetes mellitus, as represented by a code. Data Element Concept: Person—health professionals attended for diabetes mellitus Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N Maximum character length: 1 Permissible values: Value Meaning 1 Diabetes educator 2 Dietician 3 Ophthalmologist 4 Optometrist 5 Podiatrist 8 None of the above Supplementary values: 9 Not stated/inadequately described Data set specification specific attributes Diabetes (clinical) DSS DSS specific information: Management of diabetes requires a team approach, comprising selected health professionals, to provide services specific to the individual with diabetes. All patients with diabetes require diet therapy in conjunction with exercise and/or medication to achieve optimal control of blood glucose, body weight and blood lipids. In insulin treated diabetics, diet management aims to restrict variations in the timing, size or composition of meals that could result in hypoglycaemia or postprandial hyperglycaemia. Based on the Healthy Eating Pyramid, meals should be low in saturated fat, and rich in high-fibre carbohydrates with low glycaemic index (GI). Saturated fats have to be replaced with monounsaturated and polyunsaturated fats. According to the Principles of Care and Guidelines for the Clinical Management of Diabetes Mellitus, a comprehensive ophthalmological examination should be carried out: · At diagnosis and then every 1-2 years for patients whose diabetes onset was at age 30 years or more · Within five years of diagnosis and then every 1-2 years for patients whose diabetes onset was at age less than 30 years. Principles of Care and Guidelines for the Clinical Management of Diabetes Mellitus recommendations include: · Foot examination to be performed every 6 months or at every visit if high risk foot or active foot problem · Refer to specialists experienced in the care of the diabetic foot if infection or ulceration is present · To identify the 'high risk foot' as indicated by a past history of foot problems, especially ulceration, and/or the presence of peripheral neuropathy, peripheral vascular disease, or foot deformity and history of previous ulceration · Ensure that patients with 'high risk foot' or an active foot problem receive appropriate care from specialists and podiatrists expert in the treatment of diabetic foot problems. Data element attributes Collection and usage attributes Guide for use: Record a code sequentially for each health professional attended. A person may have attended several health professionals in the last 12 months; therefore more than one code can be recorded sequentially. Example 1: If a person has attended a diabetes educator and a podiatrist in the last twelve months, the code recorded would be 15. Example 2: If all have been seen, the code recorded would be 12345. If the person answers 'NO' to all the health professionals specified, code 8 should be applied. CODE 9 should only be used in situations where it is not practicable to ask the questions. Collection methods: The person should be asked about each type of health professional in successive questions, as follows: Have you attended any of the following health professionals in relation to diabetes mellitus in the last 12 months? Diabetes educator ___Yes ___ No Dietician ___Yes ___ No Ophthalmologist ___Yes ___ No Optometrist ___Yes ___ No Podiatrist ___Yes ___ No The appropriate code should be recorded for each health professional attended. Comments: The health professional occupations are assigned the following codes at the occupation level of the Australian Standard Classification of Occupations, Second Edition, Australian Bureau of Statistics, 1997, Catalogue No. 1220.0 Diabetes educator 2512-13 Dietician 2393-11 Ophthalmologist 2312-19 Optometrist 2384-11 Podiatrist 2388-11 Source and reference attributes Submitting organisation: National Diabetes Data Working Group Origin: National Diabetes Outcomes Quality Review Initiative (NDOQRIN) data dictionary. Relational attributes Related metadata references: Supersedes Health professionals attended - diabetes mellitus, version 1, DE, NHDD, NHIMG, Superseded 01/03/2005.pdf (19.8 KB) Implementation in Data Set Specifications: Diabetes (clinical) DSS Health, Standard 21/09/2005

Data type

integer

Height (measured)
Description

Person—height (measured), total centimetres NN[N].N Identifying and definitional attributes Short name: Height (measured) METeOR identifier: 270361 Registration status: Health, Standard 01/03/2005 Definition: The height of a person measured in centimetres. Context: Public health and health care Data Element Concept: Person—height Value domain attributes Representational attributes Representation class: Total Data type: Number Format: NN[N].N Maximum character length: 4 Supplementary values: Value Meaning 999.9 Not measured Unit of measure: Centimetre (cm) Data set specification specific attributes Diabetes (clinical) DSS DSS specific information: Disease, nutritional, genetic and environmental factors all exert an influence on the height of an individual, hence this variable, together with its related variable weight, is of unique value in health surveillance. It enables the calculation of body mass index which requires the measurement of height and weight (body mass) for adults as well as sex and date of birth for children and adolescents. Stature is a major indicator of general body size and of bone length and of nutritional and health status of the individual and the community at large. It is important in screening for disease or malnutrition, and in the interpretation of weight (Lohman et al. 1988). Shortness is known to be a predictor of all-cause mortality, coronary heart disease mortality in middle-aged men, and of less favourable gestational outcomes in women (Marmot et al. 1984, Kramer 1988). Data element attributes Collection and usage attributes Guide for use: In order to ensure consistency in measurement, the measurement protocol described under Collection methods should be used. Measurements of height should be assessed in relation to children and adolescents' age and pubertal status. Collection methods: The measurement protocol described below are those recommended by the International Society for the Advancement of Kinanthropometry as described by Norton et al. (1996), and the World Health Organization (WHO Expert Committee 1995), which was adapted from Lohman et al. (1988). Measurement protocol: Height measurements can be based on recumbent length or standing height. In general, length measurements are recommended for children under 2 years of age and height measurements for others. The measurement of height requires a vertical metric rule, a horizontal headboard, and a non-compressible flat even surface on which the subject stands. The equipment may be fixed or portable, and should be described and reported. The graduations on the metric rule should be at 0.1 cm intervals, and the metric rule should have the capacity to measure up to at least 210 cm. Measurement intervals and labels should be clearly readable under all conditions of use of the instrument. Apparatus that allows height to be measured while the subject stands on a platform scale is not recommended. Adults and children who can stand: The subject should be measured without shoes (i.e. is barefoot or wears thin socks) and wears little clothing so that the positioning of the body can be seen. Anything that may affect or interfere with the measurement should be noted on the data collection form (e.g. hairstyles and accessories, or physical problems). The subject stands with weight distributed evenly on both feet, heels together, and the head positioned so that the line of vision is at right angles to the body. The correct position for the head is in the Frankfort horizontal plan (Norton et al. 1996). The arms hang freely by the sides. The head, back, buttocks and heels are positioned vertically so that the buttocks and the heels are in contact with the vertical board. To obtain a consistent measure, the subject is asked to inhale deeply and stretch to their fullest height. The measurer applies gentle upward pressure through the mastoid processes to maintain a fully erect position when the measurement is taken. Ensure that the head remains positioned so that the line of vision is at right angles to the body, and the heels remain in contact with the base board. The movable headboard is brought onto the top of the head with sufficient pressure to compress the hair. The measurement is recorded to the nearest 0.1 cm. Take a repeat measurement. If the two measurements disagree by more than 0.5 cm, then take a third measurement. All raw measurements should be recorded on the data collection form. If practical, it is preferable to enter the raw data into the database as this enables intra-observer and, where relevant, inter-observer errors to be assessed. The subject's measured height is subsequently calculated as the mean of the two observations, or the mean of the two closest measurements if a third is taken, and recorded on the form. If only a mean value is entered into the database then the data collection forms should be retained. It may be necessary to round the mean value to the nearest 0.1 cm. If so, rounding should be to the nearest even digit to reduce systematic over reporting (Armitage & Berry 1994). For example, a mean value of 172.25 cm would be rounded to 172.2 cm, while a mean value of 172.35 cm would be rounded to 172.4 cm. Infants: For the measurement of supine length of children up to and including 2 years of age, two observers are required. One observer positions the head correctly while the other ensures the remaining position is correct and brings the measuring board in contact with the feet. The subject lies in a supine position on a recumbent length table or measuring board. The crown of the head must touch the stationary, vertical headboard. The subject's head is held with the line of vision aligned perpendicular to the plane of the measuring surface. The shoulders and buttocks must be flat against the table top, with the shoulders and hips aligned at right angles to the long axis of the body. The legs must be extended at the hips and knees and lie flat against the table top and the arms rest against the sides of the trunk. The measurer must ensure that the legs remain flat on the table and must shift the movable board against the heels. In infants care has to be taken to extend the legs gently. In some older children two observers may also be required. In general, length or height is measured and reported to the nearest 0.1 cm. For any child, the length measurement is approximately 0.5 - 1.5 cm greater than the height measurement. It is therefore recommended that when a length measurement is applied to a height-based reference for children over 24 months of age (or over 85 cm if age is not known), 1.0 cm be subtracted before the length measurement is compared with the reference. It is also recommended that as a matter of procedure and data recording accuracy, the date be recorded when the change is made from supine to standing height measure. Validation and quality control measures: All equipment, whether fixed or portable should be checked prior to each measurement session to ensure that both the headboard and floor (or footboard) are at 90 degrees to the vertical rule. With some types of portable anthropometer it is necessary to check the correct alignment of the headboard, during each measurement, by means of a spirit level. Within- and, if relevant, between-observer variability should be reported. They can be assessed by the same (within-) or different (between-) observers repeating the measurement of height, on the same subjects, under standard conditions after a short time interval. The standard deviation of replicate measurements (technical error of measurement (Pederson & Gore 1996)) between observers should not exceed 5 mm and be less than 5 mm within observers. Extreme values at the lower and upper end of the distribution of measured height should be checked both during data collection and after data entry. Individuals should not be excluded on the basis of true biological difference. Last digit preference, and preference or avoidance of certain values, should be analysed in the total sample and (if relevant) by observer, survey site and over time if the survey period is long. Comments: This metadata item applies to persons of all ages. It is recommended for use in population surveys and health care settings. It is recommended that in population surveys, sociodemographic data including ethnicity should be collected, as well as other risk factors including physiological status (e.g. pregnancy), physical activity, smoking and alcohol consumption. Summary statistics may need to be adjusted for these variables. Metadata items currently exist for sex, date of birth, country of birth, Indigenous status and smoking. Metadata items are being developed for physical activity. Presentation of data: Means, 95% confidence intervals, medians and centiles should be reported to one decimal place. Where the sample permits, population estimates should be presented by sex and 5-year age groups. However 5-year age groups are not generally suitable for children and adolescents. Estimates based on sample surveys may need to take into account sampling weights. For consistency with conventional practice, and for current comparability with international data sets, recommended centiles are 5, 10, 15, 25, 50, 75, 85, 90 and 95. To estimate the 5th and 95th centiles, a sample size of at least 200 is recommended for each group for which the centiles are being specified. For some reporting purposes, it may be desirable to present height data in categories. It is recommended that 5 cm groupings are used for this purpose. Height data should not be rounded before categorisation. The following categories may be appropriate for describing the heights of Australian men, women, children and adolescents although the range will depend on the population: Height 70 cm = Height 75 cm = Height ... in 5 cm categories 185 cm = Height Height => 190 cm Relational attributes Related metadata references: Is used in the formation of Adult—body mass index (measured), ratio NN[N].N[N] Health, Standard 01/03/2005 Is used in the formation of Adult—body mass index (self-reported), ratio NN[N].N[N] Health, Standard 01/03/2005, National Health Performance Authority, Standard 24/10/2013 Is used in the formation of Child—body mass index (measured), ratio NN[N].N[N] Health, Standard 01/03/2005 Is used in the formation of Child—body mass index (self-reported), ratio NN[N].N[N] Health, Standard 01/03/2005 Supersedes Height - measured, version 2, DE, NHDD, NHIMG, Superseded 01/03/2005.pdf (28.7 KB) Implementation in Data Set Specifications: Acute coronary syndrome (clinical) DSS 2013- Health, Standard 02/05/2013 Cardiovascular disease (clinical) DSS Health, Standard 01/09/2012 Diabetes (clinical) DSS Health, Standard 21/09/2005 Perinatal DSS 2015-16 Health, Standard 13/11/2014

Data type

float

Measurement units
  • cm
cm
Cholesterol—HDL (measured)
Description

Person—high-density lipoprotein cholesterol level (measured), total millimoles per litre [N].NN Identifying and definitional attributes Short name: Cholesterol—HDL (measured) METeOR identifier: 270401 Registration status: Health, Standard 01/03/2005 Definition: A person's high-density lipoprotein cholesterol (HDL-C), measured in mmol/L. Data Element Concept: Person—high-density lipoprotein cholesterol level Value domain attributes Representational attributes Representation class: Total Data type: Number Format: [N].NN Maximum character length: 3 Supplementary values: Value Meaning 9.99 Not measured/inadequately described Unit of measure: Millimole per litre (mmol/L) Data set specification specific attributes Diabetes (clinical) DSS DSS specific information: Lowered HDL-Cholesterol, with increased serum triglyceride and increased low-density lipoprotein cholesterol are important risk factors for vascular disease in type 2 diabetes. In the New South Wales Principles of Care and Guidelines for the Clinical Management of Diabetes Mellitus, recommendations are that HDL, total cholesterol, triglycerides are to be measured: · every 1-2 years (if normal) · every 3-6 months (if abnormal or on treatment) and the target is: · to increase HDL Cholesterol to more than or equal to 1.0 mmol/L · to reduce total Cholesterol to less than 5.5 mmol/L · to reduce triglyceride levels to less than 2.0 mmol/L. If pre-existing cardiovascular disease (bypass surgery or myocardial infarction) total cholesterol should be less than 4.5 mmol/L. A level below 1.0 mmol/L increases risk approximately 2-fold (Gordon et al. 1989; Assmann et al, 1998), (Draft NHF Lipid Guidelines Paper 2001). It has been concluded from prospective population studies that for every 0.025 mmol/L increase in HDL-C, the coronary risk is reduced by 2-5%. In settings such as general practice where the monitoring of a person's health is ongoing and where a measure can change over time, the date of assessment should be recorded. References: National Heart Foundation of Australia - Lipid Management Guidelines 2001. Data element attributes Collection and usage attributes Guide for use: When reporting, record whether or not the measurement of High-density Lipoprotein Cholesterol (HDL-C) was performed in a fasting specimen. In settings where the monitoring of a person's health is ongoing and where a measure can change over time (such as general practice), the date of assessment should be recorded. Collection methods: When reporting, record absolute result of the most recent HDL-Cholesterol measurement in the last 12 months to the nearest 0.01 mmol/L. Measurement of lipid levels should be carried out by laboratories, or practices, which have been accredited to perform these tests by the National Association of Testing Authorities. · To be collected as a single venous blood sample, preferably following a 12-hour fast where only water and medications have been consumed. · Prolonged tourniquet use can artefactually increase levels by up to 20%. Source and reference attributes Submitting organisation: Cardiovascular Data Working Group National Diabetes Data Working Group Origin: National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand, Lipid Management Guidelines - 2001, MJA 2001; 175: S57-S88. Relational attributes Related metadata references: Supersedes Cholesterol-HDL - measured, version 1, DE, NHDD, NHIMG, Superseded 01/03/2005.pdf (22.0 KB) Is used in the formation of Person—low-density lipoprotein cholesterol level (calculated), total millimoles per litre N[N].N Health, Superseded 01/10/2008 Is used in the formation of Person—low-density lipoprotein cholesterol level (calculated), total millimoles per litre N[N].N Health, Standard 01/10/2008 Implementation in Data Set Specifications: Acute coronary syndrome (clinical) DSS 2013- Health, Standard 02/05/2013 Cardiovascular disease (clinical) DSS Health, Standard 01/09/2012 Diabetes (clinical) DSS Health, Standard 21/09/2005

Data type

float

Measurement units
  • mmol/L
mmol/L
Hypertension - treatment
Description

Person—hypertension treatment with antihypertensive medication indicator (current), code N Identifying and definitional attributes Short name: Hypertension - treatment METeOR identifier: 302442 Registration status: Health, Standard 21/09/2005 Definition: Whether a person is currently being treated for hypertension (high blood pressure) using antihypertensive medication, as represented by a code. Data Element Concept: Person—hypertension treatment with antihypertensive medication indicator Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N Maximum character length: 1 Permissible values: Value Meaning 1 Yes 2 No Supplementary values: 9 Not stated/inadequately described Collection and usage attributes Guide for use: CODE 9 Not stated/inadequately described This code is not for use in primary data collections. Data set specification specific attributes Diabetes (clinical) DSS DSS specific information: Hypertension is probably the most important public health problem in developed countries. It is common, asymptomatic, readily detectable, usually easily treatable, and often leads to lethal complications if left untreated. Elevated blood pressure (Hypertension) is a recognised risk for microvascular and macro vascular complications of diabetes (coronary, cerebral and peripheral). Hypertension is elevated arterial blood pressure above the normal range (130 to 139/85 to 89 mm Hg) and values above these are defined as hypertension. Lower levels of target blood pressure should be aimed for in specific groups, e.g. in diabetics aim for blood pressure less than 135/80 mm Hg. Many diabetics fail to control high blood pressure. Among all the diabetics with high blood pressure, 29% were unaware that they had high blood pressure and only slightly more than half were receiving hypertensive medications as treatment. Numbers of studies have shown that good management of blood pressure is at least as important as good control of blood glucose and the reduction of cholesterol in preventing the complications of diabetes. Antihypertensives - Australian Medicines Handbook: February, 2001. Tight blood control in diabetes usually requires combination therapy as stated by (Australian Diabetes society) Therapeutic Guidelines Limited (05.04.2002). People taking antihypertensives are also encouraged to make healthy lifestyle changes, such as quit smoking, lose weight and have regular physical activity. The level of blood pressure should generally be established on at least two to four occasions prior to initiating antihypertensive medication. Systematic reviews of studies that have reported outcomes in patients with diabetes and hypertension indicate that combination therapy is frequently required and may be more beneficial than monotherapy. In the past multi-drug therapy to control hypertension has not been advocated much, but according to the special report published in the American Journal of Kidney Diseases, if ACE inhibitor therapy alone doesn't achieve good blood pressure control, multi-drug therapy should be implemented. (Heart Center Online) Data element attributes Collection and usage attributes Guide for use: CODE 1 Yes Record if a person is currently being treated for hypertension using antihypertensive medication. CODE 2 No Record if a person is not currently being treated for hypertension using antihypertensive medication. Collection methods: Ask the individual if he/she is currently treated with anti-hypertensive medications. Alternatively obtain the relevant information from appropriate documentation. Source and reference attributes Submitting organisation: National diabetes data working group Origin: National Diabetes Outcomes Quality Review Initiative (NDOQRIN) data dictionary. Reference documents: Pahor M, Psaty BM, Furberg CD. Treatment of hypertensive patients with diabetes. Lancet 1998; 351:689-90. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group [erratum appears in Br Med J 1999; 318:29]. Br Med J 1998; 317:703-13. Grossman E, Messerli FH, Goldbourt U, Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996; 276:1886-92. Hypertension in diabetes [Australian Prescriber Feb 2002]. American Journal of Preventive Medicine 2002;21. Relational attributes Related metadata references: Supersedes Person—hypertension treatment status (antihypertensive medication), code N Health, Superseded 21/09/2005 Implementation in Data Set Specifications: Acute coronary syndrome (clinical) DSS 2013- Health, Standard 02/05/2013 Diabetes (clinical) DSS Health, Standard 21/09/2005

Data type

integer

Indigenous status
Description

Person—Indigenous status, code N Identifying and definitional attributes Short name: Indigenous status METeOR identifier: 291036 Registration status: Housing assistance, Standard 15/04/2010 Health, Standard 04/05/2005 Early Childhood, Standard 21/05/2010 Homelessness, Standard 23/08/2010 Tasmanian Health, Final 30/06/2014 WA Health, Endorsed 04/03/2014 Independent Hospital Pricing Authority, Standard 01/11/2012 Indigenous, Endorsed 11/09/2012 Commonwealth Department of Health, Candidate 16/07/2015 Disability, Standard 07/10/2014 Community Services (retired), Standard 25/08/2005 Definition: Whether a person identifies as being of Aboriginal or Torres Strait Islander origin, as represented by a code. This is in accord with the first two of three components of the Commonwealth definition. Data Element Concept: Person—Indigenous status Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N Maximum character length: 1 Permissible values: Value Meaning 1 Aboriginal but not Torres Strait Islander origin 2 Torres Strait Islander but not Aboriginal origin 3 Both Aboriginal and Torres Strait Islander origin 4 Neither Aboriginal nor Torres Strait Islander origin Supplementary values: 9 Not stated/inadequately described Collection and usage attributes Guide for use: This metadata item is based on the Australian Bureau of Statistics (ABS) standard for Indigenous status. For detailed advice on its use and application please refer to the ABS Website as indicated in the Reference documents. The classification for Indigenous status has a hierarchical structure comprising two levels. There are four categories at the detailed level of the classification which are grouped into two categories at the broad level. There is one supplementary category for 'not stated' responses. The classification is as follows: Indigenous: · Aboriginal but not Torres Strait Islander origin. · Torres Strait Islander but not Aboriginal origin. · Both Aboriginal and Torres Strait Islander origin. Non-Indigenous: · Neither Aboriginal nor Torres Strait Islander origin. Not stated/ inadequately described: This category is not to be available as a valid answer to the questions but is intended for use: · Primarily when importing data from other data collections that do not contain mappable data. · Where an answer was refused. · Where the question was not able to be asked prior to completion of assistance because the client was unable to communicate or a person who knows the client was not available. Only in the last two situations may the tick boxes on the questionnaire be left blank. Data element attributes Collection and usage attributes Collection methods: The standard question for Indigenous Status is as follows: [Are you] [Is the person] [Is (name)] of Aboriginal or Torres Strait Islander origin? (For persons of both Aboriginal and Torres Strait Islander origin, mark both 'Yes' boxes.) No.................................................... Yes, Aboriginal............................... Yes, Torres Strait Islander............ This question is recommended for self-enumerated or interview-based collections. It can also be used in circumstances where a close relative, friend, or another member of the household is answering on behalf of the subject. It is strongly recommended that this question be asked directly wherever possible. When someone is not present, the person answering for them should be in a position to do so, i.e. this person must know well the person about whom the question is being asked and feel confident to provide accurate information about them. This question must always be asked regardless of data collectors' perceptions based on appearance or other factors. The Indigenous status question allows for more than one response. The procedure for coding multiple responses is as follows: If the respondent marks 'No' and either 'Aboriginal' or 'Torres Strait Islander', then the response should be coded to either Aboriginal or Torres Strait Islander as indicated (i.e. disregard the 'No' response). If the respondent marks both the 'Aboriginal' and 'Torres Strait Islander' boxes, then their response should be coded to 'Both Aboriginal and Torres Strait Islander Origin'. If the respondent marks all three boxes ('No', 'Aboriginal' and 'Torres Strait Islander'), then the response should be coded to 'Both Aboriginal and Torres Strait Islander Origin' (i.e. disregard the 'No' response). This approach may be problematical in some data collections, for example when data are collected by interview or using screen based data capture systems. An additional response category Yes, both Aboriginal and Torres Strait Islander... may be included if this better suits the data collection practices of the agency or establishment concerned. Comments: The following definition, commonly known as 'The Commonwealth Definition', was given in a High Court judgement in the case of Commonwealth v Tasmania (1983) 46 ALR 625. 'An Aboriginal or Torres Strait Islander is a person of Aboriginal or Torres Strait Islander descent who identifies as an Aboriginal or Torres Strait Islander and is accepted as such by the community in which he or she lives'. There are three components to the Commonwealth definition: · descent; · self-identification; and · community acceptance. In practice, it is not feasible to collect information on the community acceptance part of this definition in general purpose statistical and administrative collections and therefore standard questions on Indigenous status relate to descent and self-identification only. Source and reference attributes Origin: National Health Data Committee National Community Services Data Committee Reference documents: Australian Bureau of Statistics 1999. Standards for Social, Labour and Demographic Variables. Cultural Diversity Variables, Canberra. Viewed 3 August 2005. Relational attributes Related metadata references: See also Person—Indigenous status, code AAA WA Health, Endorsed 19/03/2015 Supersedes Person—Indigenous status, code N Health, Superseded 04/05/2005, Community Services (retired), Superseded 25/08/2005 Has been superseded by Person—Indigenous status, code N Health, Standardisation pending 05/03/2015 See also Service provider organisation—number of Indigenous children attending a preschool program, total number N[NNNN] Early Childhood, Superseded 28/05/2014, Indigenous, Endorsed 11/09/2012 See also Service provider organisation—number of Indigenous children attending an early childhood education program, total number N[NNNN] Early Childhood, Superseded 01/06/2015 See also Service provider organisation—number of Indigenous children attending an early childhood education program, total number N[NNNN] Early Childhood, Standard 01/06/2015 See also Service provider organisation—number of Indigenous children enrolled in a preschool program, total N[NNNN] Early Childhood, Superseded 28/05/2014, Indigenous, Endorsed 08/04/2013 See also Service provider organisation—number of Indigenous children enrolled in a preschool program, total N[NNNN] Early Childhood, Superseded 08/04/2013, Indigenous, Archived 08/04/2013 See also Service provider organisation—number of Indigenous children enrolled in an early childhood education program, total N[NNNN] Early Childhood, Standard 01/06/2015 See also Service provider organisation—number of Indigenous children enrolled in an early childhood education program, total N[NNNN] Early Childhood, Superseded 01/06/2015 Implementation in Data Set Specifications: Aboriginal and Torres Strait Islander primary health-care services client numbers cluster Indigenous, Endorsed 16/09/2014 Aboriginal and Torres Strait Islander primary health-care services episodes of care cluster Indigenous, Endorsed 16/09/2014 Aboriginal and Torres Strait Islander primary health-care services paid full-time equivalent positions cluster Indigenous, Endorsed 16/09/2014 Aboriginal and Torres Strait Islander primary health-care services unpaid full-time equivalent positions cluster Indigenous, Endorsed 16/09/2014 Aboriginal and Torres Strait Islander standalone substance use services client numbers cluster Indigenous, Endorsed 16/09/2014 Aboriginal and Torres Strait Islander standalone substance use services non-residential/follow-up/aftercare client numbers cluster Indigenous, Endorsed 16/09/2014 Aboriginal and Torres Strait Islander standalone substance use services non-residential/follow-up/aftercare episodes of care cluster Indigenous, Endorsed 16/09/2014 Aboriginal and Torres Strait Islander standalone substance use services paid full-time equivalent positions cluster Indigenous, Endorsed 16/09/2014 Aboriginal and Torres Strait Islander standalone substance use services residential treatment/rehabilitation client numbers cluster Indigenous, Endorsed 16/09/2014 Aboriginal and Torres Strait Islander standalone substance use services residential/rehabilitation episodes of care cluster Indigenous, Endorsed 16/09/2014 Aboriginal and Torres Strait Islander standalone substance use services sobering up/residential respite/short-term care client numbers cluster Indigenous, Endorsed 16/09/2014 Aboriginal and Torres Strait Islander standalone substance use services sobering-up/residential respite/short term care episodes of care cluster Indigenous, Endorsed 16/09/2014 Aboriginal and Torres Strait Islander standalone substance use services unpaid full-time equivalent positions cluster Indigenous, Endorsed 16/09/2014 Acute coronary syndrome (clinical) DSS 2013- Health, Standard 02/05/2013 Admitted patient care NMDS 2015-16 Health, Standard 13/11/2014 Independent Hospital Pricing Authority, Proposed 15/09/2014 Admitted patient mental health care NMDS 2015-16 Health, Standard 04/02/2015 Admitted patient palliative care NMDS 2015-16 Health, Standard 04/02/2015 Adoptions DSS 2011-13 Community Services (retired), Standard 20/05/2013 Alcohol and other drug treatment services NMDS 2015- Health, Standard 13/11/2014 Bringing Them Home/Link Up Counselling Program client contacts cluster Indigenous, Endorsed 16/09/2014 Bringing them Home/Link Up Counselling Program client numbers cluster Indigenous, Endorsed 16/09/2014 Bringing them Home/Link Up Counsellors cluster Indigenous, Endorsed 16/09/2014 Cancer (clinical) DSS Health, Standard 14/05/2015 Cardiovascular disease (clinical) DSS Health, Standard 01/09/2012 Child protection and support services (CPSS) client cluster Community Services (retired), Standard 30/04/2008 Community mental health care NMDS 2015-16 Health, Standard 13/11/2014 Computer Assisted Telephone Interview demographic module DSS Health, Standard 03/12/2008 Cultural and language diversity cluster Disability, Standard 13/08/2015 Community Services (retired), Standard 10/04/2013 Diabetes (clinical) DSS Health, Standard 21/09/2005 Disability services client details cluster Disability, Standard 13/08/2015 Community Services (retired), Standard 10/04/2013 Disability Services NMDS 2012-14 Community Services (retired), Standard 13/03/2013 Disability Services NMDS 2014-15 Disability, Standard 07/10/2014 Community Services (retired), Proposed 23/04/2014 Early Childhood Education and Care: Aggregate NMDS 2015 Early Childhood, Standard 01/06/2015 Early Childhood Education and Care: Unit Record Level NMDS 2015 Early Childhood, Standard 01/06/2015 Elective surgery waiting times (census data) NMDS 2015- Health, Standard 12/06/2015 Elective surgery waiting times (removals data) NMDS 2015- Health, Standard 12/06/2015 Estimated resident population (ERP) cluster (early childhood education and care) Early Childhood, Standard 21/05/2010 Indigenous primary health care DSS 2015- Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Juvenile Justice Client file cluster Community Services (retired), Standard 14/09/2009 Medical indemnity DSS 2014- Health, Standard 21/11/2013 National Bowel Cancer Screening Program DSS 2014- Health, Standard 29/08/2014 Non-admitted patient DSS 2015-16 Health, Standard 13/11/2014 Independent Hospital Pricing Authority, Proposed 23/07/2014 Non-admitted patient emergency department care DSS 2015-16 Health, Standard 04/02/2015 Non-admitted patient emergency department care NMDS 2015-16 Health, Standard 13/11/2014 Independent Hospital Pricing Authority, Proposed 15/09/2014 Perinatal NMDS 2014- Health, Standard 07/03/2014 Person (housing assistance) cluster Housing assistance, Standard 01/05/2013 Prison clinic contact DSS Health, Standard 25/08/2011 Prison entrants DSS Health, Standard 25/08/2011 Prisoners in custody repeat medications DSS Health, Standard 25/08/2011 Public dental waiting times NMDS 2013- Health, Standard 09/11/2012 Radiotherapy waiting times NMDS 2015- Health, Standard 13/11/2014 Registered chiropractic labour force DSS Health, Standard 10/12/2009 Registered dental and allied dental health professional labour force DSS Health, Standard 10/12/2009 Registered medical professional labour force DSS Health, Standard 10/12/2009 Registered midwifery labour force DSS Health, Standard 10/12/2009 Registered nursing professional labour force DSS Health, Standard 10/12/2009 Registered optometry labour force DSS Health, Standard 10/12/2009 Registered osteopathy labour force DSS Health, Standard 10/12/2009 Registered pharmacy labour force DSS Health, Standard 10/12/2009 Registered physiotherapy labour force DSS Health, Standard 10/12/2009 Registered podiatry labour force DSS Health, Standard 10/12/2009 Registered psychology labour force DSS Health, Standard 10/12/2009 Residential mental health care NMDS 2015-16 Health, Standard 13/11/2014 Specialist Homelessness Services NMDS 2014-15 Housing assistance, Standard 30/06/2014 Homelessness, Standard 30/06/2014 Surveillance of healthcare associated infection: Staphylococcus aureus bacteraemia DSS Health, Standard 15/11/2012 WA Abortion Notification System WA Health, Endorsed 04/03/2014 Implementation in Indicators: Used as numerator Indigenous primary health care: PI01a-Number of Indigenous babies born within the previous 12 months whose birth weight has been recorded, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI01b-Proportion of Indigenous babies born within the previous 12 months whose birth weight has been recorded, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI02a-Number of Indigenous babies born within the previous 12 months whose birth weight results were low, normal or high, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI02b-Proportion of Indigenous babies born within the previous 12 months whose birth weight results were low, normal or high, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI03a-Number of regular clients for whom an MBS Health Assessment for Aboriginal and Torres Strait Islander People (MBS Item 715) was claimed, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI03b-Proportion of regular clients for whom an MBS Health Assessment for Aboriginal and Torres Strait Islander People (MBS Item 715) was claimed, 20155 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI04a-Number of Indigenous children who are fully immunised, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI04b-Proportion of Indigenous children who are fully immunised, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI05a-Number of regular clients with Type II diabetes who have had an HbA1c measurement result recorded, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI05b-Proportion of regular clients with Type II diabetes who have had an HbA1c measurement result recorded, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI06a-Number of regular clients with Type II diabetes whose HbA1c measurement result was within a specified level, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI06b-Proportion of regular clients with Type II diabetes whose HbA1c measurement result was within a specified level, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI07a-Number of regular clients with a chronic disease for whom a GP Management Plan (MBS Item 721) was claimed, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI07b-Proportion of regular clients with a chronic disease for whom a GP Management Plan (MBS Item 721) was claimed, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI08a-Number of regular clients with a chronic disease for whom a Team Care Arrangement (MBS Item 723) was claimed, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI08b-Proportion of regular clients with a chronic disease for whom a Team Care Arrangement (MBS Item 723) was claimed, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI09a-Number of regular clients whose smoking status has been recorded, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI09b-Proportion of regular clients whose smoking status has been recorded, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI10a-Number of regular clients with a smoking status result, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI10b-Proportion of regular clients with a smoking status result, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI11a-Number of regular clients who gave birth within the previous 12 months with a smoking status of 'current smoker', 'ex-smoker' or 'never smoked', 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI11b-Proportion of regular clients who gave birth within the previous 12 months with a smoking status of 'current smoker', 'ex-smoker' or 'never smoked', 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI12a-Number of regular clients who are classified as overweight or obese, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI12b-Proportion of regular clients who are classified as overweight or obese, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI13a-Number of regular clients who had their first antenatal care visit within specified periods, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI13b-Proportion of regular clients who had their first antenatal care visit within specified periods, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI14a-Number of regular clients aged 50 years and over who are immunised against influenza, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI14b-Proportion of regular clients aged 50 years and over who are immunised against influenza, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI15a-Number of regular clients with Type II diabetes or COPD who are immunised against influenza, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI15b-Proportion of regular clients with Type II diabetes or COPD who are immunised against influenza, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI16a-Number of regular clients whose alcohol consumption status has been recorded, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI16b-Proportion of regular clients whose alcohol consumption status has been recorded, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI17a-Number of regular clients who had an AUDIT-C with result within specified levels, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI17b-Proportion of regular clients who had an AUDIT-C with result within specified levels, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI18a-Number of regular clients with a selected chronic disease who have had a kidney function test, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI18b-Proportion of regular clients with a selected chronic disease who have had a kidney function test, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI19a-Number of regular clients with a selected chronic disease who have had a kidney function test with results within specified levels, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI19b-Proportion of regular clients with a selected chronic disease who have had a kidney function test with results within specified levels, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI20a-Number of regular clients who have had the necessary risk factors assessed to enable CVD assessment, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI20b-Proportion of regular clients who have had the necessary risk factors assessed to enable CVD assessment, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI21a-Number of regular clients aged 35 to 74 years who have had an absolute cardiovascular disease risk assessment with results within specified levels, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI21b-Proportion of regular clients aged 35 to 74 years who have had an absolute cardiovascular disease risk assessment with results within specified levels, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI22a-Number of regular clients who have had a cervical screening, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI22b-Proportion of regular clients who have had a cervical screening, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI23a-Number of regular clients with Type II diabetes who have had a blood pressure measurement result recorded, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI23b-Proportion of regular clients with Type II diabetes who have had a blood pressure measurement result recorded, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI24a-Number of regular clients with Type II diabetes whose blood pressure measurement result was less than or equal to 130/80 mmHg, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI24b-Proportion of regular clients with Type II diabetes whose blood pressure measurement result was less than or equal to 130/80 mmHg, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 National Disability Agreement: f(1)-Number of Indigenous people with disability receiving disability services as a proportion of the Indigenous potential population requiring services, 2012 Indigenous, Endorsed 11/09/2012 Community Services (retired), Superseded 23/05/2013 National Disability Agreement: f(2)-Number of Indigenous people with disability receiving disability services as a proportion of the Indigenous potential population requiring services, 2012 Indigenous, Endorsed 11/09/2012 Community Services (retired), Superseded 23/05/2013 National Disability Agreement: f(3)-Number of non-Indigenous persons and Indigenous persons who separated from permanent residential aged care to return home/family, 2013 Disability, Standard 13/08/2015 Community Services (retired), Standard 23/05/2013 National Healthcare Agreement: PI 09-Incidence of heart attacks (acute coronary events), 2015 Health, Standard 14/01/2015 National Healthcare Agreement: PI 64a-Indigenous Australians in the health workforce, 2012 Health, Retired 25/06/2013 Indigenous, Endorsed 11/09/2012 National Healthcare Agreement: PI 64b-Indigenous Australians in the health workforce, 2012 Health, Retired 25/06/2013 Indigenous, Endorsed 11/09/2012 National Indigenous Reform Agreement: PI 10-The proportion of Indigenous children aged 4 and 5 years who are enrolled in, and attending, a preschool program in the year before full-time schooling, by remoteness, 2014 Indigenous, Endorsed 13/12/2013 Used as denominator Indigenous primary health care: PI01b-Proportion of Indigenous babies born within the previous 12 months whose birth weight has been recorded, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI02b-Proportion of Indigenous babies born within the previous 12 months whose birth weight results were low, normal or high, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI03b-Proportion of regular clients for whom an MBS Health Assessment for Aboriginal and Torres Strait Islander People (MBS Item 715) was claimed, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI04b-Proportion of Indigenous children who are fully immunised, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI05b-Proportion of regular clients with Type II diabetes who have had an HbA1c measurement result recorded, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI06b-Proportion of regular clients with Type II diabetes whose HbA1c measurement result was within a specified level, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI07b-Proportion of regular clients with a chronic disease for whom a GP Management Plan (MBS Item 721) was claimed, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI09b-Proportion of regular clients whose smoking status has been recorded, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI10b-Proportion of regular clients with a smoking status result, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI11b-Proportion of regular clients who gave birth within the previous 12 months with a smoking status of 'current smoker', 'ex-smoker' or 'never smoked', 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI12b-Proportion of regular clients who are classified as overweight or obese, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI13b-Proportion of regular clients who had their first antenatal care visit within specified periods, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI14b-Proportion of regular clients aged 50 years and over who are immunised against influenza, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI15b-Proportion of regular clients with Type II diabetes or COPD who are immunised against influenza, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI16b-Proportion of regular clients whose alcohol consumption status has been recorded, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI17b-Proportion of regular clients who had an AUDIT-C with result within specified levels, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI18b-Proportion of regular clients with a selected chronic disease who have had a kidney function test, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI19b-Proportion of regular clients with a selected chronic disease who have had a kidney function test with results within specified levels, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI20b-Proportion of regular clients who have had the necessary risk factors assessed to enable CVD assessment, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI21b-Proportion of regular clients aged 35 to 74 years who have had an absolute cardiovascular disease risk assessment with results within specified levels, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI22b-Proportion of regular clients who have had a cervical screening, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI23b-Proportion of regular clients with Type II diabetes who have had a blood pressure measurement result recorded, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI24b-Proportion of regular clients with Type II diabetes whose blood pressure measurement result was less than or equal to 130/80 mmHg, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 National Disability Agreement: d(1)-Proportion of the potential population who used State/Territory delivered disability support services, 2013 Disability, Standard 13/08/2015 Community Services (retired), Standard 23/05/2013 National Disability Agreement: d(2)-Proportion of people with a disability with an employment restriction who used Disability Employment Services (Open Employment), 2013 Disability, Standard 13/08/2015 Community Services (retired), Standard 23/05/2013 National Disability Agreement: d(3)-Proportion of the potential population who used Australian Disability Enterprises (Supported Employment), 2013 Disability, Standard 13/08/2015 Community Services (retired), Standard 23/05/2013 National Disability Agreement: f(1)-Number of Indigenous people with disability receiving disability services as a proportion of the Indigenous potential population requiring services, 2012 Indigenous, Endorsed 11/09/2012 Community Services (retired), Superseded 23/05/2013 National Disability Agreement: f(1)-Rate of non-Indigenous persons and Indigenous persons admitted to permanent residential aged care, 2013 Disability, Standard 13/08/2015 Community Services (retired), Standard 23/05/2013 National Disability Agreement: f(2)-Number of Indigenous people with disability receiving disability services as a proportion of the Indigenous potential population requiring services, 2012 Indigenous, Endorsed 11/09/2012 Community Services (retired), Superseded 23/05/2013 -

Data type

integer

Lower limb amputation due to vascular disease
Description

Person—lower limb amputation due to vascular disease, code N Identifying and definitional attributes Short name: Lower limb amputation due to vascular disease METeOR identifier: 270162 Registration status: Health, Standard 01/03/2005 Definition: Whether a person has undergone an amputation of toe, forefoot or leg (above or below knee), due to vascular disease, as represented by a code. Data Element Concept: Person—lower limb amputation due to vascular disease Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N Maximum character length: 1 Permissible values: Value Meaning 1 Lower limb amputation - occurred in the last 12 months 2 Lower limb amputation - occurred prior to the last 12 months 3 Lower limb amputation - occurred both in and prior to the last 12 months 4 No history of lower limb amputation due to vascular disease Supplementary values: 9 Not stated/inadequately described Collection and usage attributes Collection methods: Ask the individual if he/she has had an amputated toe or forefoot or leg (above or below knee), not due to trauma or causes other than vascular disease. If so determine when it was undertaken; within or prior to the last 12 months (or both). Alternatively obtain this information from appropriate documentation. Data set specification specific attributes Diabetes (clinical) DSS DSS specific information: In people with diabetes, amputations are 15 times more common than in people without diabetes, and 50% of all amputations occur in people with diabetes (The Lower Limb in People With Diabetes; 1997/98 Australian Diabetes Society). Diabetic foot disease is the most common cause of hospitalisation in people with diabetes. Diabetic foot complications are common in the elderly, and amputation rates increase with age: by threefold in those aged 45 - 74 years and sevenfold in population aged over 75 years. As stated by Duffy and authors the rate of lower extremity amputations can be reduced by 50% by the institution of monofilament testing in a preventive care program. Data element attributes Source and reference attributes Submitting organisation: National Diabetes Data Working Group Origin: National Diabetes Outcomes Quality Review Initiative (NDOQRIN) data dictionary. Reference documents: Duffy MD, John C and Patout MD, Charles A. 1990. Management of the Insensitive Foot in Diabetes: Lessons from Hansen's Disease. Military Medicine, 155:575-579. Edmonds M, Boulton A, Buckenham T et al. Report of the Diabetic Foot and Amputation Group. Diabet Med 1996; 13: S27-42. Sharon R O'Rourke and Stephen Colagiuri: The Lower Limb in People With Diabetes; Content 1997/98 Australian Diabetes Society. Colagiuri S, Colagiuri R, Ward J. National Diabetes Strategy and Implementation Plan. Canberra: Diabetes Australia, 1998. Relational attributes Related metadata references: Supersedes Lower limb amputation due to vascular disease, version 1, DE, NHDD, NHIMG, Superseded 01/03/2005.pdf (17.6 KB) Implementation in Data Set Specifications: Diabetes (clinical) DSS Health, Standard 21/09/2005

Data type

integer

Microalbumin level—albumin/creatinine ratio (measured)
Description

Person—microalbumin level (measured), albumin/creatinine ratio N[NN].N Obligation: Conditional Identifying and definitional attributes Short name: Microalbumin level—albumin/creatinine ratio (measured) METeOR identifier: 270339 Registration status: Health, Standard 01/03/2005 Definition: A person's microalbumin level, measured as an albumin/creatinine ratio. Data Element Concept: Person—microalbumin level Value domain attributes Representational attributes Representation class: Ratio Data type: Number Format: N[NN].N Maximum character length: 4 Supplementary values: Value Meaning 999.9 Not stated/inadequately described Unit of measure: Milligram per millimole (mg/mmol) Unit of measure precision: 1 Data set specification specific attributes Diabetes (clinical) DSS DSS specific information: A small amount of protein (albumin) in the urine (microalbuminuria) is an early sign of kidney damage. Microalbuminuria is a strong predictor of macrovascular disease and diabetic nephropathy. Incipient diabetic nephropathy can be detected by urine testing for microalbumin. Incipient diabetic nephropathy is suspected when microalbuminuria is detected in two of three samples collected over a six-month period in patients in whom other causes of an increased urinary album excretion have been excluded. Diagnosis of microalbuminuria is established if 2 of the 3 measurements are abnormal. According to the Principles of Care and Guidelines for the Clinical Management of Diabetes Mellitus a test for microalbuminuria is to be performed: · at diagnosis and then every 12 months for patients with Type 2 diabetes, · 5 years post diagnosis and then every 12 months for patients with Type 1 diabetes, · if microalbuminuria is present, perform up to two additional measurements in the next 6 weeks. Data element attributes Collection and usage attributes Collection methods: Measurement of microalbumin levels should be carried out by laboratories, or practices, which have been accredited to perform these tests by the National Association of Testing Authority. Microalbumin is not detected by reagent strips for urinary proteins, and requires immunoassay. As urinary albumin varies with posture and exercise it is important to collect the urine under very standard conditions; short-term (2 hours) during rest, overnight (approximately 8 hours) or an early morning sample. For screening purposes an early morning urine specimen is adequate, and if the albumin/creatinine ratio is found to be greater than 3.5 mg/mmol then a timed overnight sample should be obtained for estimation of the albumin excretion rate. Test for albuminuria by measuring microalbumin in timed or first morning urine sample. The results considered elevated are · spot urine 30 to 300 mg/L; or · timed urine (24 hour collection) 20 to 200 µg/min. Source and reference attributes Submitting organisation: National Diabetes Data Working Group Origin: National Diabetes Outcomes Quality Review Initiative (NDOQRIN) data dictionary Relational attributes Related metadata references: See also Laboratory standard—upper limit of normal range for microalbumin, albumin/creatinine ratio N[NN].N Health, Standard 01/03/2005 Supersedes Microalbumin - units, version 1, DE, NHDD, NHIMG, Superseded 01/03/2005.pdf (16.3 KB) Supersedes Microalbumin/protein - measured, version 1, DE, NHDD, NHIMG, Superseded 01/03/2005.pdf (16.5 KB) Implementation in Data Set Specifications: Diabetes (clinical) DSS Health, Standard 21/09/2005

Data type

float

Measurement units
  • mg/mmol
mg/mmol
Microalbumin level—micrograms per minute (measured)
Description

Person—microalbumin level (measured), total micrograms per minute N[NNN].N Obligation: Conditional Identifying and definitional attributes Short name: Microalbumin level—micrograms per minute (measured) METeOR identifier: 270336 Registration status: Health, Standard 01/03/2005 Definition: A person's microalbumin level measured in microgram per minute (µg/min). Data Element Concept: Person—microalbumin level Value domain attributes Representational attributes Representation class: Total Data type: Number Format: N[NNN].N Maximum character length: 5 Supplementary values: Value Meaning 9999.9 Not stated/inadequately described Unit of measure: Microgram per minute (µg/min) Unit of measure precision: 1 Data set specification specific attributes Diabetes (clinical) DSS DSS specific information: A small amount of protein (albumin) in the urine (microalbuminuria) is an early sign of kidney damage. Microalbuminuria is a strong predictor of macrovascular disease and diabetic nephropathy. Incipient diabetic nephropathy can be detected by urine testing for microalbumin. Incipient diabetic nephropathy is suspected when microalbuminuria is detected in two of three samples collected over a six-month period in patients in whom other causes of an increased urinary album excretion have been excluded. Diagnosis of microalbuminuria is established if 2 of the 3 measurements are abnormal. According to the Principles of Care and Guidelines for the Clinical Management of Diabetes Mellitus a test for microalbuminuria is to be performed: · at diagnosis and then every 12 months for patients with Type 2 diabetes, · 5 years post diagnosis and then every 12 months for patients with Type 1 diabetes, · if microalbuminuria is present, perform up to two additional measurements in the next 6 weeks. Data element attributes Collection and usage attributes Collection methods: Measurement of microalbumin levels should be carried out by laboratories, or practices, which have been accredited to perform these tests by the National Association of Testing Authority. Microalbumin is not detected by reagent strips for urinary proteins, and requires immunoassay. As urinary albumin varies with posture and exercise it is important to collect the urine under very standard conditions; short-term (2 hours) during rest, overnight (approximately 8 hours) or an early morning sample. For screening purposes an early morning urine specimen is adequate. Test for albuminuria by measuring microalbumin in timed or first morning urine sample. The results considered elevated are · spot urine 30 to 300mg/L; or · timed urine (24 hr collection) 20 to 200 µg/min. Source and reference attributes Submitting organisation: National Diabetes Data Working Group Origin: National Diabetes Outcomes Quality Review Initiative (NDOQRIN) data dictionary Relational attributes Related metadata references: See also Laboratory standard—upper limit of normal range for microalbumin, total micrograms per minute N[NN].N Health, Standard 01/03/2005 Supersedes Microalbumin - units, version 1, DE, NHDD, NHIMG, Superseded 01/03/2005.pdf (16.3 KB) Supersedes Microalbumin/protein - measured, version 1, DE, NHDD, NHIMG, Superseded 01/03/2005.pdf (16.5 KB) Implementation in Data Set Specifications: Diabetes (clinical) DSS Health, Standard 21/09/2005

Data type

float

Measurement units
  • µg/min
µg/min
Microalbumin level—milligrams per 24 hour (measured)
Description

Person—microalbumin level (measured), total milligrams per 24 hour N[NNN].N Obligation: Conditional Identifying and definitional attributes Short name: Microalbumin level—milligrams per 24 hour (measured) METeOR identifier: 270337 Registration status: Health, Standard 01/03/2005 Definition: A person's microalbumin level measured in milligrams per 24 hours. Data Element Concept: Person—microalbumin level Value domain attributes Representational attributes Representation class: Total Data type: Number Format: N[NNN].N Maximum character length: 5 Supplementary values: Value Meaning 9999.9 Not stated/inadequately described Unit of measure: Milligram per 24-hour period (mg/24h) Unit of measure precision: 1 Data set specification specific attributes Diabetes (clinical) DSS DSS specific information: A small amount of protein (albumin) in the urine (microalbuminuria) is an early sign of kidney damage. Microalbuminuria is a strong predictor of macrovascular disease and diabetic nephropathy. Incipient diabetic nephropathy can be detected by urine testing for microalbumin. Incipient diabetic nephropathy is suspected when microalbuminuria is detected in two of three samples collected over a six-month period in patients in whom other causes of an increased urinary album excretion have been excluded. Diagnosis of microalbuminuria is established if 2 of the 3 measurements are abnormal. According to the Principles of Care and Guidelines for the Clinical Management of Diabetes Mellitus a test for microalbuminuria is to be performed: · at diagnosis and then every 12 months for patients with Type 2 diabetes, · 5 years post diagnosis and then every 12 months for patients with Type 1 diabetes, · if microalbuminuria is present, perform up to two additional measurements in the next 6 weeks. Data element attributes Collection and usage attributes Collection methods: Measurement of microalbumin levels should be carried out by laboratories, or practices, which have been accredited to perform these tests by the National Association of Testing Authority. Microalbumin is not detected by reagent strips for urinary proteins, and requires immunoassay. As urinary albumin varies with posture and exercise it is important to collect the urine under very standard conditions; short-term (2 hours) during rest, overnight (approximately 8 hours) or an early morning sample. For screening purposes an early morning urine specimen is adequate. Test for albuminuria by measuring microalbumin in timed or first morning urine sample. The results considered elevated are · spot urine 30 to 300mg/L; or · timed urine (24 hr collection) 20 to 200 ug/min. Source and reference attributes Submitting organisation: National Diabetes Data Working Group Origin: National Diabetes Outcomes Quality Review Initiative (NDOQRIN) data dictionary Relational attributes Related metadata references: See also Laboratory standard—upper limit of normal range for microalbumin, total milligrams per 24 hour N[NN].N Health, Standard 01/03/2005 Supersedes Microalbumin - units, version 1, DE, NHDD, NHIMG, Superseded 01/03/2005.pdf (16.3 KB) Supersedes Microalbumin/protein - measured, version 1, DE, NHDD, NHIMG, Superseded 01/03/2005.pdf (16.5 KB) Implementation in Data Set Specifications: Diabetes (clinical) DSS Health, Standard 21/09/2005

Data type

float

Measurement units
  • mg/24h
mg/24h
Microalbumin level—milligrams per litre (measured)
Description

Person—microalbumin level (measured), total milligrams per litre N[NNN].N Obligation: Conditional Identifying and definitional attributes Short name: Microalbumin level—milligrams per litre (measured) METeOR identifier: 270335 Registration status: Health, Standard 01/03/2005 Definition: A person's microalbumin level measured in milligrams per litre (mg/L). Data Element Concept: Person—microalbumin level Value domain attributes Representational attributes Representation class: Total Data type: Number Format: N[NNN].N Maximum character length: 5 Supplementary values: Value Meaning 9999.9 Not stated/inadequately described Unit of measure: Milligram per litre (mg/L) Unit of measure precision: 1 Data set specification specific attributes Diabetes (clinical) DSS DSS specific information: A small amount of protein (albumin) in the urine (microalbuminuria) is an early sign of kidney damage. Microalbuminuria is a strong predictor of macrovascular disease and diabetic nephropathy. Incipient diabetic nephropathy can be detected by urine testing for microalbumin. Incipient diabetic nephropathy is suspected when microalbuminuria is detected in two of three samples collected over a six-month period in patients in whom other causes of an increased urinary album excretion have been excluded. Diagnosis of microalbuminuria is established if 2 of the 3 measurements are abnormal. According to the Principles of Care and Guidelines for the Clinical Management of Diabetes Mellitus a test for microalbuminuria is to be performed: · at diagnosis and then every 12 months for patients with Type 2 diabetes, · 5 years post diagnosis and then every 12 months for patients with Type 1 diabetes, · if microalbuminuria is present, perform up to two additional measurements in the next 6 weeks. Data element attributes Collection and usage attributes Collection methods: Measurement of microalbumin levels should be carried out by laboratories, or practices, which have been accredited to perform these tests by the National Association of Testing Authority. Microalbumin is not detected by reagent strips for urinary proteins, and requires immunoassay. As urinary albumin varies with posture and exercise it is important to collect the urine under very standard conditions; short-term (2 hours) during rest, overnight (approximately 8 hours) or an early morning sample. For screening purposes an early morning urine specimen is adequate. Test for albuminuria by measuring microalbumin in timed or first morning urine sample. The results considered elevated are: · spot urine 30 to 300mg/L; or · timed urine (24 hr collection) 20 to 200 ug/min. Source and reference attributes Submitting organisation: National Diabetes Data Working Group Origin: National Diabetes Outcomes Quality Review Initiative (NDOQRIN) data dictionary Relational attributes Related metadata references: See also Laboratory standard—upper limit of normal range for microalbumin, total milligrams per litre N[NN].N Health, Standard 01/03/2005 Supersedes Microalbumin - units, version 1, DE, NHDD, NHIMG, Superseded 01/03/2005.pdf (16.3 KB) Supersedes Microalbumin/protein - measured, version 1, DE, NHDD, NHIMG, Superseded 01/03/2005.pdf (16.5 KB) Implementation in Data Set Specifications: Diabetes (clinical) DSS Health, Standard 21/09/2005

Data type

float

Measurement units
  • mg/L
mg/L
Myocardial infarction (history)
Description

Person—myocardial infarction (history), code N Identifying and definitional attributes Short name: Myocardial infarction (history) METeOR identifier: 270285 Registration status: Health, Standard 01/03/2005 Definition: Whether the individual has had a myocardial infarction, as represented by a code. Data Element Concept: Person—myocardial infarction Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N Maximum character length: 1 Permissible values: Value Meaning 1 Myocardial infarction - occurred in the last 12 months 2 Myocardial infarction - occurred prior to the last 12 months 3 Myocardial infarction - occurred both in and prior to the last 12 months 4 No history of myocardial infarction Supplementary values: 9 Not stated/inadequately described Data element attributes Collection and usage attributes Collection methods: Ask the individual if he/she has had a myocardial infarction. If so determine whether it was within or prior to the last 12 months (or both).Record if evidenced by ECG changes or plasma enzyme changes. Alternatively obtain this information from appropriate documentation. Source and reference attributes Submitting organisation: National diabetes data working group Origin: National Diabetes Outcomes Quality Review Initiative (NDOQRIN) data dictionary. Reference documents: Long-term Results From the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) Study Circulation. 1999;99: 2626-2632. Relational attributes Related metadata references: Supersedes Myocardial infarction - history, version 1, DE, NHDD, NHIMG, Superseded 01/03/2005.pdf (16.7 KB) Implementation in Data Set Specifications: Diabetes (clinical) DSS Health, Standard 21/09/2005

Data type

integer

Ophthalmological assessment—outcome (left retina)
Description

Person—ophthalmological assessment outcome (left retina) (last 12 months), code N Identifying and definitional attributes Short name: Ophthalmological assessment—outcome (left retina) METeOR identifier: 270472 Registration status: Health, Standard 01/03/2005 Definition: The result of an ophthalmological assessment for the left retina during the last 12 months, as represented by a code. Data Element Concept: Person—ophthalmological assessment outcome Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N Maximum character length: 1 Permissible values: Value Meaning 1 Normal 2 Diabetes abnormality 3 Non-diabetes abnormality 4 Not visualised Supplementary values: 9 Not stated/inadequately described Data set specification specific attributes Diabetes (clinical) DSS DSS specific information: Patients with diabetes have increased risk of developing several eye complications including retinopathy, cataract and glaucoma that lead to loss of vision. Many diabetes eye related problems are asymptomatic and require appropriate eye assessment to be detected. Regular eye checkup is important for patients suffering from diabetes mellitus. This helps to early detect abnormalities and to avoid or postpone complications and prevent blindness in people with diabetes. According to Principles of Care and Guidelines for the Clinical Management of Diabetes Mellitus a comprehensive ophthalmological examination should be carried out: · at diagnosis and then every 1-2 years for patients whose diabetes onset was at age 30 years or more, · within five years of diagnosis and then every 1-2 years for patients whose diabetes onset was at age less than 30 years. Assessment by an ophthalmologist is essential: · at initial examination if the corrected visual acuity is less than 6/6 in either eye; · at subsequent examinations if declining visual acuity is detected · if any retinal abnormality is detected; · if clear view of retina is not obtained. References: Vision Australia, No 2, 1997/8; University of Melbourne. Diabetes Control and Complications Trial: DCCT New England Journal of Medicine, 329(14), September 30, 1993. US National Eye Institute. Data element attributes Collection and usage attributes Guide for use: This is a repeating record of both eyes. 1st field - Right retina 2nd field - Left retina Record the result of the fundus examination for each eye as: Normal/ Diabetes abnormality/ Non-diabetes abnormality/ or Not visualised. Example: · code 12 for right retina Normal and left retina Diabetes abnormality · code 32 for right retina Non-diabetes abnormality and left retina Diabetes abnormality Only the result of an assessment carried out in the last 12 months should be recorded. Collection methods: Ophthalmological assessment should be performed by an ophthalmologist or a suitably trained clinician. A comprehensive ophthalmological examination includes: · Checking visual acuity with Snellen chart - correct with pinhole if indicated; · Examination for cataract; · Examination of fundi with pupils dilated. Source and reference attributes Submitting organisation: National Diabetes Data Working Group Origin: National Diabetes Outcomes Quality Review Initiative (NDOQRIN) data dictionary. Relational attributes Related metadata references: Supersedes Ophthalmological assessment - outcome, version 1, DE, NHDD, NHIMG, Superseded 01/03/2005.pdf (18.5 KB) See also Person—ophthalmological assessment outcome (right retina) (last 12 months), code N Health, Standard 01/03/2005 Implementation in Data Set Specifications: Diabetes (clinical) DSS Health, Standard 21/09/2005

Data type

integer

Ophthalmoscopy performed indicator
Description

Person—ophthalmoscopy performed indicator (last 12 months), code N Identifying and definitional attributes Short name: Ophthalmoscopy performed indicator METeOR identifier: 302821 Registration status: Health, Standard 21/09/2005 Definition: Whether or not an examination of the fundus of the eye by an ophthalmologist or optometrist, as a part of the ophthalmological assessment, has been undertaken in the last 12 months, as represented by a code. Data Element Concept: Person—ophthalmoscopy performed indicator Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N Maximum character length: 1 Permissible values: Value Meaning 1 Yes 2 No Supplementary values: 9 Not stated/inadequately described Collection and usage attributes Guide for use: CODE 9 Not stated/inadequately described This code is not for use in primary data collections. Data set specification specific attributes Diabetes (clinical) DSS DSS specific information: Patients with diabetes have an increased risk of developing several eye complications including retinopathy, cataract and glaucoma that lead to loss of vision. Eye examinations should be commenced at the time diabetes is diagnosed. If no retinopathy is present, repeat the eye examination at least every 2 years. Once retinopathy is identified more frequent observation is required. Diabetic retinopathy is a leading cause of blindness. Retinopathy is characterised by proliferation of the retina's blood vessels, which may project into the vitreous, causing vitreous haemorrhage, proliferation of fibrous tissue and retinal detachment. It is often accompanied by microaneurysms and macular oedema, which can express as a blurred vision. The prevalence of retinopathy increases with increasing duration of diabetes. In the early stage, retinopathy is asymptomatic, however up to 20% of people with diabetes Type 2 have retinopathy at the time of diagnosis of diabetes. Cataract and glaucoma are also associated diabetic eye problems that could lead to blindness. Regular eye checkups are important for patients suffering from diabetes mellitus. This helps to detect and treat abnormalities early and to avoid or postpone vision-threatening complications. References: Vision Australia, No. 2 - 1997/8; University of Melbourne. Diabetes: complications: Therapeutic Guidelines Limited (05.04.2002). Data element attributes Collection and usage attributes Guide for use: CODE 1 Yes: Record if a fundus examination of eye has occurred. CODE 2 No: Record if a fundus examination of eye has not occurred. Collection methods: Ask the individual if he/she has undertaken an eye check, including examination of fundi with pupils dilated. Pupil dilatation and an adequate magnified view of the fundus is essential, using either detailed direct or indirect ophthalmoscopy or fundus camera. This will usually necessitate referral to an ophthalmologist. Source and reference attributes Submitting organisation: National diabetes data working group Origin: National Diabetes Outcomes Quality Review Initiative (NDOQRIN) data dictionary. Relational attributes Related metadata references: Supersedes Person—ophthalmoscopy performed status (previous 12 months), code N Health, Superseded 21/09/2005 Implementation in Data Set Specifications: Diabetes (clinical) DSS Health, Standard 21/09/2005

Data type

integer

Peripheral neuropathy (status)
Description

Person—peripheral neuropathy indicator, code N Identifying and definitional attributes Short name: Peripheral neuropathy (status) METeOR identifier: 302457 Registration status: Health, Standard 21/09/2005 Definition: Whether peripheral neuropathy is present, as represented by a code. Data Element Concept: Person—peripheral neuropathy indicator Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N Maximum character length: 1 Permissible values: Value Meaning 1 Yes 2 No Supplementary values: 9 Not stated/inadequately described Collection and usage attributes Guide for use: CODE 9 Not stated/inadequately described This code is not for use in primary data collections. Data set specification specific attributes Diabetes (clinical) DSS DSS specific information: The most important aspect of grading diabetic neuropathy from a foot ulceration point of view is to assess the degree of loss of sensation in the feet. Diabetic neuropathy tends to occur in the setting of long-standing hyperglycaemia. Peripheral neuropathy, which affects about 30% of people with either type 1 or type 2 diabetes, is the major predisposing disorder for diabetic foot disease. Peripheral neuropathy in feet results in loss of sensation and autonomic dysfunction. Neuropathy can occur either alone (neuropathic feet) or in combination with peripheral vascular disease causing ischaemia (neuro-ischaemic feet). Purely ischaemic feet are unusual, but are managed in the same way as neuro-ischaemic feet (see Australian Diabetes Society - Position Statement - The Lower Limb in People With Diabetes). As stated by Duffy and others, the rate of lower extremity amputations can be reduced by 50% by the institution of monofilament testing in a preventive care program. Diabetes polyneuropathy is frequently asymptomatic but may be associated with numbness, tingling and paraesthesia in the extremities, and less often with hyperesthesias. The most common form is a distal, symmetric, predominantly sensory polyneuropathy, which begins and is usually most marked in the feet and legs. If symptomatic neuropathy is present consult with endocrinologist or physician specialising in diabetes care since options are available for the relief of symptoms. Peripheral nerve function should be checked at least yearly in the patient with diabetes. Data element attributes Collection and usage attributes Guide for use: CODE 1 Yes: Record if peripheral neuropathy is present in the person. CODE 2 No: Record if peripheral neuropathy is not present in the person. Record whether or not peripheral neuropathy is present determined by clinical judgement following assessment using pinprick and vibration (using perhaps a Biothesiometer) or Monofilament. Collection methods: Examine for neuropathy by testing reflexes and sensation preferably using tuning fork (standard vibration fork 128 hz), pinprick, 10g monofilament and/or biothesiometer. The preferred assessment methods are monofilament and biothesiometer. These two non-invasive tests provide more objective and repeatable results than testing sensation with pinprick or a tuning fork, which are very difficult to standardise. 1 The 'Touch-Test' Sensory Evaluation (Semmens-Weinstein Monofilaments) application guidelines: · Occlude the patient's vision by using a shield or by having the patient look away or close his or her eyes. · Instruct the patient to respond when a stimulus is felt by saying 'touch' or 'yes'. · Prepare to administer the stimulus to the foot (dorsal or plantar surface). · Press the filament of the Touch · Test at a 90 degree angle against the skin until it bows. Hold in place for approximately 1.5 seconds and then remove. To assure the validity of the sensory test findings: · The patient must not be able to view the administration of the stimuli so that false indications are avoided. · The nylon filament must be applied at a 90 degree angle against the skin until it bows for approximately 1.5 second before removing. · If the patient does not feel the filament, then protective pain sensation has been lost. 2 Testing vibration sensation with a biothesiometer - application guidelines: · The biothesiometer has readings from 0 to 50 volts. It can be made to vibrate at increasing intensity by turning a dial. · A probe is applied to part of the foot, usually on the big toe. · The person being tested indicates as soon as he/she can feel the vibration and the reading on the dial at that point is recorded. The reading is low in young normal individuals (i.e. they are very sensitive to vibration). In older individuals, the biothesiometer reading becomes progressively higher. From experience, it is known that the risk of developing a neuropathic ulcer is much higher if a person has a biothesiometer reading greater than 30-40 volts. Source and reference attributes Submitting organisation: National Diabetes Data Working Group Origin: National Diabetes Outcomes Quality Review Initiative (NDOQRIN) data dictionary Reference documents: 1997 North Coast Medical, INC. San Jose, CA 95125; 800 821 - 9319 Duffy MD, John C and Patout MD, Charles A. 1990. 'Management of the Insensitive Foot in Diabetes: Lessons from Hansen's Disease'. Military Medicine, 155:575-579 Bell- Krotovski OTR, FAOT, FAOTA, Judith and Elizabeth Tomancik LOTR. 1987.The Repeatability of testing with Semmens-Weinstein Monofilaments. 'The Journal of Hand Surgery,' 12A: 155 - 161 Edmonds M, Boulton A, Buckenham T, et al. Report of the Diabetic Foot and Amputation Group. Diabet Med 1996; 13: S27 - 42 Foot Examination -an interactive guide; Aust Prescr 2002; 25:8 - 10 Relational attributes Related metadata references: Supersedes Person—peripheral neuropathy status, code N Health, Superseded 21/09/2005 Implementation in Data Set Specifications: Diabetes (clinical) DSS Health, Standard 21/09/2005

Data type

integer

Peripheral vascular disease in feet (status)
Description

Person—peripheral vascular disease indicator (foot), code N Identifying and definitional attributes Short name: Peripheral vascular disease in feet (status) METeOR identifier: 302459 Registration status: Health, Standard 21/09/2005 Definition: Whether peripheral vascular disease is present in either foot, as represented by a code. Data Element Concept: Person—peripheral vascular disease indicator (foot) Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N Maximum character length: 1 Permissible values: Value Meaning 1 Yes 2 No Supplementary values: 9 Not stated/inadequately described Collection and usage attributes Guide for use: CODE 9 Not stated/inadequately described This code is not for use in primary data collections. Data set specification specific attributes Diabetes (clinical) DSS DSS specific information: Peripheral vascular disease is the leading cause of occlusion of blood vessels of the extremities with increasing prevalence in individuals with hypertension, hypercholesterolemia and diabetes mellitus, and in cigarette smokers. Peripheral vascular disease is estimated to occur 11 times more frequently and develop about 10 years earlier in people with diabetes. Presence of symptomatic peripheral vascular disease requires an interdisciplinary approach including a vascular surgeon, an endocrinologist or physician specialising in diabetes care. References: Foot Examination - an interactive guide; Australian Prescriber Data element attributes Collection and usage attributes Guide for use: CODE 1 Yes: Record if peripheral vascular disease is present in either foot. CODE 2 No: Record if peripheral vascular disease is not present in either foot. Collection methods: If it is mild, peripheral vascular disease can be completely without symptoms. However, compromised blood supply in the long term could cause claudication (pain in the calf after walking for a distance or up an incline or stairs), rest pain or vascular ulceration. Physical examination is necessary to assess the peripheral vascular circulation. Purplish colour and cold temperature of feet are indications to suspect that the circulation may be impaired. Palpate pulses: The simplest method to estimate blood flow and to detect ischaemia to the lower extremities is palpation of the foot pulses (posterior tibial and dorsalis pedis arteries) in both feet. Note whether pulses are present or absent. If pulses in the foot can be clearly felt, the risk of foot ulceration due to vascular disease is small. Test capillary return: A helpful confirmation sign of arterial insufficiency is pallor of the involved feet after 1 - 2 min of elevation if venous filling time is delayed beyond the normal limit of 15 sec. Doppler probe: If pulses cannot be palpated, apply a small hand-held Doppler, placed over the dorsalis pedis or posterior tibial arteries to detect pulses, quantify the vascular supply and listen to the quality of the signal. When the foot pulses are very weak or not palpable, the risk assessment could be completed by measuring the ankle brachial index (ankle pressure/ brachial pressure). Normal ankle brachial index is 0.9 - 1.2. An ankle brachial index less than 0.6 indicates compromised peripheral circulation. Source and reference attributes Submitting organisation: National Diabetes Data Working Group Origin: National Diabetes Outcomes Quality Review Initiative (NDOQRIN) data dictionary. Relational attributes Related metadata references: Supersedes Person—peripheral vascular disease status (foot), code N Health, Superseded 21/09/2005 Implementation in Data Set Specifications: Diabetes (clinical) DSS Health, Standard 21/09/2005

Data type

integer

Referred to ophthalmologist (diabetes mellitus)
Description

Person—referral to ophthalmologist indicator (last 12 months), code N Identifying and definitional attributes Short name: Referred to ophthalmologist (diabetes mellitus) METeOR identifier: 302823 Registration status: Health, Standard 21/09/2005 Definition: Whether the individual was referred to an ophthalmologist within the last 12 months, as represented by a code. Data Element Concept: Person—referral to ophthalmologist indicator Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N Maximum character length: 1 Permissible values: Value Meaning 1 Yes 2 No Supplementary values: 9 Not stated/inadequately described Collection and usage attributes Guide for use: CODE 9 Not stated/inadequately described This code is not for use in primary data collections. Data set specification specific attributes Diabetes (clinical) DSS DSS specific information: Patients with diabetes have increased risk of developing several eye complications including retinopathy, cataract and glaucoma that may lead to loss of vision. Regular eye checkup is important for patients suffering from diabetes mellitus. This helps to detect abnormalities early and to avoid or postpone complications. Data element attributes Collection and usage attributes Guide for use: CODE 1 Yes: Record if the individual was referred to an ophthalmologist during the last 12 months. CODE 2 No: Record if the individual was not referred to an ophthalmologist during the last 12 months. Collection methods: Ask the individual if he/she was referred to an ophthalmologist during the last 12 months. Alternatively, obtain this information from appropriate documentation. Source and reference attributes Submitting organisation: National diabetes data working group Origin: National Diabetes Outcomes Quality Review Initiative (NDOQRIN) data dictionary Reference documents: Diabetes Control and Complications Trial: DCCT New England Journal of Medicine, 329(14), September 30, 1993. Relational attributes Related metadata references: Supersedes Health service event—referral to ophthalmologist status (last 12 months), code N Health, Superseded 21/09/2005 Implementation in Data Set Specifications: Diabetes (clinical) DSS Health, Standard 21/09/2005

Data type

integer

Tobacco smoking status (diabetes mellitus)
Description

Person—regular tobacco smoking indicator (last 3 months), code N Identifying and definitional attributes Short name: Tobacco smoking status (diabetes mellitus) METeOR identifier: 302467 Registration status: Health, Standard 21/09/2005 Definition: Whether an individual has been a regular smoker (daily or weekly) of any tobacco material over the previous 3 months, as represented by a code. Data Element Concept: Person—regular tobacco smoking indicator Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N Maximum character length: 1 Permissible values: Value Meaning 1 Yes 2 No Supplementary values: 9 Not stated/inadequately described Collection and usage attributes Guide for use: CODE 9 Not stated/inadequately described This code is not for use in primary data collections. Data set specification specific attributes Diabetes (clinical) DSS DSS specific information: For people with diabetes smoking is one of the most powerful treatable risk factors. Associated with hypertension, diabetes and hypercholesterolemia, smoking is a definite health hazard for coronary heart disease. Data element attributes Collection and usage attributes Guide for use: CODE 1 Yes: Record if the person has smoked daily or weekly over the previous 3 months. CODE 2 No: Record if the person has not smoked daily or weekly over the previous 3 months or has been an irregular smoker. Collection methods: Ask the individual if he/she has regularly smoked (daily or weekly) any tobacco material over the past 3 months. Source and reference attributes Submitting organisation: National diabetes data working group Origin: National Diabetes Outcomes Quality Review Initiative (NDOQRIN) data dictionary. Relational attributes Related metadata references: Supersedes Person—tobacco smoking status (previous three months), code N Health, Superseded 21/09/2005 Implementation in Data Set Specifications: Diabetes (clinical) DSS Health, Standard 21/09/2005

Data type

integer

Hypoglycaemia - severe
Description

Person—severe hypoglycaemia indicator, code N Identifying and definitional attributes Short name: Hypoglycaemia - severe METeOR identifier: 302825 Registration status: Health, Standard 21/09/2005 Definition: Whether a person has had severe hypoglycaemia, as represented by a code. Data Element Concept: Person—severe hypoglycaemia indicator Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N Maximum character length: 1 Permissible values: Value Meaning 1 Yes 2 No Supplementary values: 9 Not stated/inadequately described Collection and usage attributes Guide for use: CODE 9 Not stated/inadequately described This code is not for use in primary data collections. Data set specification specific attributes Diabetes (clinical) DSS DSS specific information: Most hypoglycaemic reactions, however, do not cause long term problems, but the risks of permanent injury to the brain are greater in children under the age of 5 years, the elderly with associated cerebrovascular disease and patients with other medical conditions such as cirrhosis and coeliac disease. The serious consequences of hypoglycaemia relate to its effects on the brain. Rarely hypoglycaemia may cause death. It is important to know how to recognise and react when someone is unconscious from hypoglycaemia. These people should be placed on their side and the airway checked so that breathing is unhampered and nothing should be given by mouth as food may enter the breathing passages. Treatment needs to be given by injection - either glucagon (a hormone which raises the blood glucose by mobilising liver stores) or glucose itself. Glucagon should be given by injection (usually intramuscular) at a dose of 0.5 units (or mg) in children under the age of 5 years and 1.0 units (mg) for all older age groups. All diabetic patients at risk of developing hypoglycaemia should have glucagon at home. Their families need to be shown how to administer it in times of severe hypoglycaemia. Data element attributes Collection and usage attributes Guide for use: CODE 1 Yes: Record if the person has a history of severe hypoglycaemia. CODE 2 No: Record if the person has no history of severe hypoglycaemia. Collection methods: Ask the individual if he/she has had a severe hypoglycaemia requiring assistance. Alternatively obtain the relevant information from appropriate documentation. Comments: The medications used in the treatment of diabetes may cause the blood glucose value to fall below the normal range and this is called hypoglycaemia. Source and reference attributes Submitting organisation: National diabetes data working group Origin: National Diabetes Outcomes Quality Review Initiative (NDOQRIN) data dictionary. Reference documents: Definition corresponds with the Diabetes Control and Complications Trial (DCCT): DCCT New England Journal of Medicine, 329(14), September 30, 1993. Report of the Health Care Committee Expert Panel on Diabetes; Commonwealth of Australia 1991; ISBN 0644143207. Relational attributes Related metadata references: Supersedes Person—severe hypoglycaemia history, status code N Health, Superseded 21/09/2005 Implementation in Data Set Specifications: Diabetes (clinical) DSS Health, Standard 21/09/2005

Data type

integer

Sex
Description

Person—sex, code N Identifying and definitional attributes Short name: Sex METeOR identifier: 287316 Registration status: Housing assistance, Standard 10/02/2006 Health, Standard 04/05/2005 Early Childhood, Standard 21/05/2010 Homelessness, Standard 23/08/2010 WA Health, Draft 23/08/2012 Independent Hospital Pricing Authority, Standard 01/11/2012 Indigenous, Endorsed 11/08/2014 National Health Performance Authority, Standard 07/11/2013 Commonwealth Department of Health, Candidate 16/07/2015 Disability, Standard 07/10/2014 Community Services (retired), Standard 25/08/2005 Definition: The biological distinction between male and female, as represented by a code. Data Element Concept: Person—sex Value domain attributes Representational attributes Representation class: Code Data type: Number Format: N Maximum character length: 1 Permissible values: Value Meaning 1 Male 2 Female 3 Intersex or indeterminate Supplementary values: 9 Not stated/inadequately described Collection and usage attributes Guide for use: Diagnosis and procedure codes should be checked against the national ICD-10-AM sex edits, unless the person is undergoing, or has undergone a sex change or has a genetic condition resulting in a conflict between sex and ICD-10-AM code. CODE 3 Intersex or indeterminate Intersex or indeterminate, refers to a person, who because of a genetic condition, was born with reproductive organs or sex chromosomes that are not exclusively male or female or whose sex has not yet been determined for whatever reason. Intersex or indeterminate, should be confirmed if reported for people aged 90 days or greater. Comments: The definition for Intersex in Guide for use is sourced from the ACT Legislation (Gay, Lesbian and Transgender) Amendment Act 2003. Source and reference attributes Origin: Australian Capital Territory 2003. Legislation (Gay, Lesbian and Transgender) Amendment Act 2003 Reference documents: Legislation (Gay, Lesbian and Transgender) Amendment Act 2003. See http://www.legislation.act.gov.au/a/2003-14/20030328-4969/pdf/2003-14.pdf. Data element attributes Collection and usage attributes Collection methods: Operationally, sex is the distinction between male and female, as reported by a person or as determined by an interviewer. When collecting data on sex by personal interview, asking the sex of the respondent is usually unnecessary and may be inappropriate, or even offensive. It is usually a simple matter to infer the sex of the respondent through observation, or from other cues such as the relationship of the person(s) accompanying the respondent, or first name. The interviewer may ask whether persons not present at the interview are male or female. A person's sex may change during their lifetime as a result of procedures known alternatively as sex change, gender reassignment, transsexual surgery, transgender reassignment or sexual reassignment. Throughout this process, which may be over a considerable period of time, the person's sex could be recorded as either Male or Female. In data collections that use the ICD-10-AM classification, where sex change is the reason for admission, diagnoses should include the appropriate ICD-10-AM code(s) that clearly identify that the person is undergoing such a process. This code(s) would also be applicable after the person has completed such a process, if they have a procedure involving an organ(s) specific to their previous sex (e.g. where the patient has prostate or ovarian cancer). CODE 3 Intersex or indeterminate Is normally used for babies for whom sex has not been determined for whatever reason. Should not generally be used on data collection forms completed by the respondent. Should only be used if the person or respondent volunteers that the person is intersex or where it otherwise becomes clear during the collection process that the individual is neither male nor female. CODE 9 Not stated/inadequately described Is not to be used on primary collection forms. It is primarily for use in administrative collections when transferring data from data sets where the item has not been collected. Source and reference attributes Origin: Australian Institute of Health and Welfare (AIHW) National Mortality Database 1997/98 AIHW 2001 National Diabetes Register, Statistical Profile, December 2000 (Diabetes Series No. 2.) Reference documents: Australian Bureau of Statistics AS4846 Health Care Provider Identification, 2004, Sydney: Standards Australia AS5017 Health Care Client Identification, 2002, Sydney: Standards Australia In AS4846 and AS5017 alternative codes are presented. Refer to the current standard for more details. Relational attributes Related metadata references: Is used in the formation of Episode of admitted patient care—diagnosis related group, code (AR-DRG v 6) ANNA Health, Standard 30/06/2013, Tasmanian Health, Draft 23/07/2012, Commonwealth Department of Health, Candidate 16/07/2015 Is used in the formation of Episode of admitted patient care—diagnosis related group, code (AR-DRG v5.1) ANNA Health, Superseded 22/12/2009 Is used in the formation of Episode of admitted patient care—major diagnostic category, code (AR-DRG v 6) NN Health, Standard 30/06/2013, Tasmanian Health, Draft 23/07/2012, Commonwealth Department of Health, Candidate 16/07/2015 Is used in the formation of Episode of admitted patient care—major diagnostic category, code (AR-DRG v5.1) NN Health, Superseded 22/12/2009 See also Person—gender, code N Housing assistance, Proposed 28/06/2013, Health, Proposed 28/06/2013, Early Childhood, Proposed 28/06/2013, Homelessness, Proposed 28/06/2013, Indigenous, Endorsed 05/09/2014, Community Services (retired), Candidate 02/09/2013 Supersedes Person—sex (housing assistance), code N Housing assistance, Superseded 10/02/2006 See also Person—sex, code A WA Health, Endorsed 19/03/2015 Supersedes Person—sex, code N Health, Superseded 04/05/2005, Community Services (retired), Superseded 31/08/2005 Is used in the formation of Record—linkage key, code 581 XXXXXDDMMYYYYN Housing assistance, Standard 23/08/2010, Health, Standard 07/12/2011, Early Childhood, Standard 21/05/2010, Homelessness, Standard 23/08/2010, Disability, Standard 07/10/2014, Community Services (retired), Standard 21/05/2010 Implementation in Data Set Specifications: Aboriginal and Torres Strait Islander primary health-care services episodes of care cluster Indigenous, Endorsed 16/09/2014 Aboriginal and Torres Strait Islander primary health-care services individual client contacts cluster Indigenous, Endorsed 16/09/2014 Aboriginal and Torres Strait Islander standalone substance use services client numbers cluster Indigenous, Endorsed 16/09/2014 Aboriginal and Torres Strait Islander standalone substance use services non-residential/follow-up/aftercare client numbers cluster Indigenous, Endorsed 16/09/2014 Aboriginal and Torres Strait Islander standalone substance use services non-residential/follow-up/aftercare episodes of care cluster Indigenous, Endorsed 16/09/2014 Aboriginal and Torres Strait Islander standalone substance use services residential treatment/rehabilitation client numbers cluster Indigenous, Endorsed 16/09/2014 Aboriginal and Torres Strait Islander standalone substance use services residential treatment/rehabilitation length of stay cluster Indigenous, Endorsed 16/09/2014 Aboriginal and Torres Strait Islander standalone substance use services residential/rehabilitation episodes of care cluster Indigenous, Endorsed 16/09/2014 Aboriginal and Torres Strait Islander standalone substance use services sobering up/residential respite/short-term care client numbers cluster Indigenous, Endorsed 16/09/2014 Aboriginal and Torres Strait Islander standalone substance use services sobering-up/residential respite/short term care episodes of care cluster Indigenous, Endorsed 16/09/2014 Acute coronary syndrome (clinical) DSS 2013- Health, Standard 02/05/2013 Admitted patient care NMDS 2015-16 Health, Standard 13/11/2014 Independent Hospital Pricing Authority, Proposed 15/09/2014 Admitted patient mental health care NMDS 2015-16 Health, Standard 04/02/2015 Admitted patient palliative care NMDS 2015-16 Health, Standard 04/02/2015 Adoptions DSS 2011-13 Community Services (retired), Standard 20/05/2013 Alcohol and other drug treatment services NMDS 2015- Health, Standard 13/11/2014 Audiology assessment client cluster Indigenous, Endorsed 11/08/2014 Bringing Them Home/Link Up Counselling Program client contacts cluster Indigenous, Endorsed 16/09/2014 Bringing them Home/Link Up Counselling Program client numbers cluster Indigenous, Endorsed 16/09/2014 Cancer (clinical) DSS Health, Standard 14/05/2015 Cardiovascular disease (clinical) DSS Health, Standard 01/09/2012 Child protection and support services (CPSS) client cluster Community Services (retired), Standard 30/04/2008 Child protection and support services (CPSS) sibling cluster Community Services (retired), Standard 30/04/2008 Closing the Gap in the Northern Territory: Dental Services DSS, 2011 Indigenous, Endorsed 08/10/2014 Community mental health care NMDS 2015-16 Health, Standard 13/11/2014 Computer Assisted Telephone Interview demographic module DSS Health, Standard 03/12/2008 Diabetes (clinical) DSS Health, Standard 21/09/2005 Early Childhood Education and Care: Unit Record Level NMDS 2015 Early Childhood, Standard 01/06/2015 Household file cluster (Indigenous community housing) Housing assistance, Standard 01/05/2013 Indigenous, Endorsed 01/05/2013 Indigenous primary health care DSS 2015- Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Juvenile Justice Client file cluster Community Services (retired), Standard 14/09/2009 Medical indemnity DSS 2014- Health, Standard 21/11/2013 National Bowel Cancer Screening Program DSS 2014- Health, Standard 29/08/2014 Non-admitted patient DSS 2015-16 Health, Standard 13/11/2014 Independent Hospital Pricing Authority, Proposed 23/07/2014 Non-admitted patient emergency department care DSS 2015-16 Health, Standard 04/02/2015 Non-admitted patient emergency department care NMDS 2015-16 Health, Standard 13/11/2014 Independent Hospital Pricing Authority, Proposed 15/09/2014 Perinatal NMDS 2014- Health, Standard 07/03/2014 Person (housing assistance) cluster Housing assistance, Standard 01/05/2013 Person details data dictionary Disability, Standard 13/08/2015 Community Services (retired), Standard 06/02/2012 Person file cluster (Mainstream community housing) Housing assistance, Standard 01/05/2013 Prison clinic contact DSS Health, Standard 25/08/2011 Prison entrants DSS Health, Standard 25/08/2011 Prisoners in custody repeat medications DSS Health, Standard 25/08/2011 Private rent assistance DSS 2012-13 Housing assistance, Standard 03/07/2014 Public dental waiting times NMDS 2013- Health, Standard 09/11/2012 Radiotherapy waiting times NMDS 2015- Health, Standard 13/11/2014 Registered chiropractic labour force DSS Health, Standard 10/12/2009 Registered dental and allied dental health professional labour force DSS Health, Standard 10/12/2009 Registered medical professional labour force DSS Health, Standard 10/12/2009 Registered midwifery labour force DSS Health, Standard 10/12/2009 Registered nursing professional labour force DSS Health, Standard 10/12/2009 Registered optometry labour force DSS Health, Standard 10/12/2009 Registered osteopathy labour force DSS Health, Standard 10/12/2009 Registered pharmacy labour force DSS Health, Standard 10/12/2009 Registered physiotherapy labour force DSS Health, Standard 10/12/2009 Registered podiatry labour force DSS Health, Standard 10/12/2009 Registered psychology labour force DSS Health, Standard 10/12/2009 Residential mental health care NMDS 2015-16 Health, Standard 13/11/2014 Sex of prison entrants cluster Health, Standard 25/08/2011 Statistical linkage key 581 cluster Housing assistance, Standard 23/08/2010 Health, Standard 07/12/2011 Early Childhood, Standard 21/05/2010 Homelessness, Standard 23/08/2010 Disability, Standard 07/10/2014 Community Services (retired), Standard 21/05/2010 Surveillance of healthcare associated infection: Staphylococcus aureus bacteraemia DSS Health, Standard 15/11/2012 Implementation in Indicators: Used as numerator Indigenous primary health care: PI19a-Number of regular clients with a selected chronic disease who have had a kidney function test with results within specified levels, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI19b-Proportion of regular clients with a selected chronic disease who have had a kidney function test with results within specified levels, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI20a-Number of regular clients who have had the necessary risk factors assessed to enable CVD assessment, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI20b-Proportion of regular clients who have had the necessary risk factors assessed to enable CVD assessment, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI22a-Number of regular clients who have had a cervical screening, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI22b-Proportion of regular clients who have had a cervical screening, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 National Health Performance Authority, Healthy Communities: Human papillomavirus (HPV) vaccination rates for girls turning 15 years in 2012 National Health Performance Authority, Standard 27/03/2014 National Health Performance Authority, Healthy Communities: Human papillomavirus (HPV) vaccination rates for girls turning 15 years in 2013 National Health Performance Authority, Standard 27/08/2015 National Healthcare Agreement: PI 24-Survival of people diagnosed with notifiable cancers, 2015 Health, Standard 14/01/2015 Used as denominator Indigenous primary health care: PI13b-Proportion of regular clients who had their first antenatal care visit within specified periods, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI19b-Proportion of regular clients with a selected chronic disease who have had a kidney function test with results within specified levels, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI20b-Proportion of regular clients who have had the necessary risk factors assessed to enable CVD assessment, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 Indigenous primary health care: PI22b-Proportion of regular clients who have had a cervical screening, 2015 Health, Standard 13/03/2015 Indigenous, Endorsed 13/03/2015 National Disability Agreement: d(1)-Proportion of the potential population who used State/Territory delivered disability support services, 2013 Disability, Standard 13/08/2015 Community Services (retired), Standard 23/05/2013 National Disability Agreement: d(2)-Proportion of people with a disability with an employment restriction who used Disability Employment Services (Open Employment), 2013 Disability, Standard 13/08/2015 Community Services (retired), Standard 23/05/2013 National Disability Agreemennt: d(3)-Proportion of the potential population who used Australian Disability Enterprises (Supported Employment), 2013 Disability, Standard 13/08/2015 Community Services (retired), Standard 23/05/2013 National Disability Agreement: f(1)-Number of Indigenous people with disability receiving disability services as a proportion of the Indigenous potential population requiring services, 2012 Indigenous, Endorsed 11/09/2012 Community Services (retired), Superseded 23/05/2013 National Disability Agreement: f(1)-Rate of non-Indigenous persons and Indigenous persons admitted to permanent residential aged care, 2013 Disability, Standard 13/08/2015 Community Services (retired), Standard 23/05/2013 National Disability Agreement: f(2)-Number of Indigenous people with disability receiving disability services as a proportion of the Indigenous potential population requiring services, 2012 Indigenous, Endorsed 11/09/2012 Community Services (retired), Superseded 23/05/2013 National Health Performance Authority, Healthy Communities: Human papillomavirus (HPV) vaccination rates for girls turning 15 years in 2012 National Health Performance Authority, Standard 27/03/2014 National Health Performance Authority, Healthy Communities: Human papillomavirus (HPV) vaccination rates for girls turning 15 years in 2013 National Health Performance Authority, Standard 27/08/2015 National Healthcare Agreement: PI 02-Incidence of selected cancers, 2015 Health, Standard 14/01/2015 National Healthcare Agreement: PI 24-Survival of people diagnosed with notifiable cancers, 2015 Health, Standard 14/01/2015

Data type

integer

Triglyceride level (measured)
Description

Person—triglyceride level (measured), total millimoles per litre N[N].N Identifying and definitional attributes Short name: Triglyceride level (measured) METeOR identifier: 270229 Registration status: Health, Superseded 01/10/2008 Definition: A person's triglyceride level measured in millimoles per litre. Data Element Concept: Person—triglyceride level Value domain attributes Representational attributes Representation class: Total Data type: Number Format: N[N].N Maximum character length: 3 Supplementary values: Value Meaning 99.9 Not stated/inadequately described. Unit of measure: Millimole per litre (mmol/L) Data set specification specific attributes Diabetes (clinical) DSS DSS specific information: Following Principles of Care and Guidelines for the Clinical Management of Diabetes Mellitus, the targets for lipids management are: · to reduce total cholesterol to less than 5.5 mmol/L · to reduce triglyceride level to less than 2.0 mmol/L · to increase HDL-C to more than or equal to 1.0 mmol/L. Alterations in fat transport, often resulting in hyper-triglyceridaemia, are well-recognised concomitants of diabetes mellitus. Elevated plasma triglyceride levels are present in about one third of diabetic patients. It seems that triglycerides are related to the critical role of insulin in the production and removal from plasma of triglyceride-rich lipoproteins. Lifestyle modifications, including weight loss and reduction of excess alcohol intake, are particularly effective for reducing triglyceride and increasing HDL-C. Data element attributes Collection and usage attributes Guide for use: Record the absolute result of the total triglyceride measurement. Collection methods: Measurement of lipid levels should be carried out by laboratories, or practices, which have been accredited to perform these tests by the National Association of Testing Authorities. · To be collected as a single venous blood sample, preferably following a 12-hour fast where only water and medications have been consumed. Note that to calculate the low-density lipoprotein - cholesterol (LDL-C) from the Friedwald Equation (Friedwald et al, 1972): · a fasting level of plasma triglyceride and knowledge of the levels of plasma total cholesterol and high-density lipoprotein - cholesterol (HDL-C) is required, · the Friedwald equation becomes unreliable when the plasma triglyceride exceeds 4.5 mmol/L, and · that while levels are reliable for the first 24 hours after the onset of acute coronary syndromes, they may be unreliable for the subsequent 6 weeks after an event. Source and reference attributes Submitting organisation: Cardiovascular Data Working Group Relational attributes Related metadata references: Is used in the formation of Person—low-density lipoprotein cholesterol level (calculated), total millimoles per litre N[N].N Health, Superseded 01/10/2008 Is used in the formation of Person—low-density lipoprotein cholesterol level (calculated), total millimoles per litre N[N].N Health, Standard 01/10/2008 Has been superseded by Person—triglyceride level (measured), total millimoles per litre N[N].N Health, Standard 01/10/2008 Supersedes Triglycerides - measured, version 1, DE, NHDD, NHIMG, Superseded 01/03/2005.pdf (21.1 KB) Implementation in Data Set Specifications: Diabetes (clinical) DSS Health, Standard 21/09/2005

Data type

float

Measurement units
  • mmol/L
mmol/L
Visual acuity (left eye)
Description

Person—visual acuity (left eye), code NN Identifying and definitional attributes Short name: Visual acuity (left eye) METeOR identifier: 269963 Registration status: Health, Standard 01/03/2005 Definition: A person's left eye visual acuity, as represented by a code. Data Element Concept: Person—visual acuity Value domain attributes Representational attributes Representation class: Code Data type: String Format: NN Maximum character length: 2 Permissible values: Value Meaning 01 6/5 02 6/6 03 6/9 04 6/12 05 6/18 06 6/24 07 6/36 08 6/60 09 CF (count fingers) 10 HM (hand movement) 11 PL (perceive light) 12 BL (blind) 13 6/7.5 Supplementary values: 99 Not stated/inadequately described Data set specification specific attributes Diabetes (clinical) DSS DSS specific information: Patients with diabetes have an increased risk of developing several eye complications including retinopathy, cataract and glaucoma that can lead to loss of vision. Regular eye checkups are important for patients suffering from diabetes mellitus. This helps to detect and treat abnormalities early and to avoid or postpone vision-threatening complications. Assessment by an ophthalmologist is essential: · at initial examination if the corrected visual acuity is less than 6/6 in either eye · if at subsequent examinations declining visual acuity is detected · if any retinal abnormality is detected · if clear view of retina is not obtained. Data element attributes Collection and usage attributes Guide for use: Record actual result for both right and left eyes: · 1st field: Right eye · 2nd field: Left eye. Test wearing distance glasses if prescribed. Use pinhole if vision less than 6/6. Collection methods: One of the most often utilised tests for visual acuity uses the Snellen chart. · At a distance of 6 metres all subjects should be able to read the 6/6 line with each eye using the proper refractive correction. · Both eyes are to be opened and then cover one eye with the ocular occluder. · The observer has to read out the smallest line of letters that he/she can see from the chart. · This is to be repeated with the other eye. Eye examination should be performed by an ophthalmologist or a suitably trained clinician: · within five years of diagnosis and then every 1-2 years for patients whose diabetes onset was at age under 30 years · at diagnosis and then every 1-2 years for patients whose diabetes onset was at age 30 years or more. Source and reference attributes Origin: National Diabetes Outcomes Quality Review Initiative (NDOQRIN) data dictionary Reference documents: Vision Australia, No 2, 1997/8; University of Melbourne World Health Organization US National Library of Medicine Diabetes Control and Complications Trial: DCCT New England Journal of Medicine, 329(14), September 30, 1993 Principles of Care and Guidelines for the Clinical Management of Diabetes Mellitus Relational attributes Related metadata references: See also Person—visual acuity (right eye), code NN Health, Standard 01/03/2005 Supersedes Visual acuity, version 1, DE, NHDD, NHIMG, Superseded 01/03/2005.pdf (19.3 KB) Implementation in Data Set Specifications: Diabetes (clinical) DSS Health, Standard 21/09/2005

Data type

text

Weight in kilograms (measured)
Description

Person—weight (measured), total kilograms N[NN].N Identifying and definitional attributes Short name: Weight in kilograms (measured) Synonymous names: Infant weight, neonate, stillborn METeOR identifier: 270208 Registration status: Health, Standard 01/03/2005 Definition: The weight (body mass) of a person measured in kilograms. Data Element Concept: Person—weight Value domain attributes Representational attributes Representation class: Total Data type: Number Format: N[NN].N Maximum character length: 4 Supplementary values: Value Meaning 999.9 Not collected Unit of measure: Kilogram (Kg) Unit of measure precision: 1 Collection and usage attributes Guide for use: A continuous variable measured to the nearest 0.1 kg. CODE 999.9 Not collected Use this code if measured weight is not collected. Data set specification specific attributes Diabetes (clinical) DSS DSS specific information: Following Principles of Care and Guidelines for the Clinical Management of Diabetes Mellitus, body mass index (BMI) should be below 27 kg/m 2 for men and women. For adults who suffer from diabetes, the recommendation is to measure weight and calculate BMI on the initial visit and then measure weight every 3 months. If the patient is on a weight reduction program, weight is to be measured more frequently. Strong evidence exists that weight loss reduces blood pressure in both overweight hypertensive and non-hypertensive individuals; reduces serum triglycerides and increases high-density lipoprotein (HDL)-cholesterol; and generally produces some reduction in total serum cholesterol and low-density lipoprotein (LDL)-cholesterol. The risk of developing diabetes rises continuously with increasing obesity (DHAC & AIHW 1999:13). An increased central distribution of body fat (when fatness is concentrated in the abdomen) also appears to be associated more often with Type 2 diabetes (Bishop et al. 1998:430-1). Weight loss reduces blood glucose levels in overweight and obese persons with and without diabetes; and weight loss also reduces blood glucose levels and HbA1c in some patients with type 2 diabetes. Although there have been no prospective trials to show changes in mortality with weight loss in obese patients, reductions in risk factors would suggest that development of type 2 diabetes and CVD would be reduced with weight loss. Weight is an overall measure of body size that does not distinguish between fat and muscle. Weight is an indicator of nutritional and health status. Low pre-pregnancy weight is an indicator of poorer gestational outcome in women (Kramer 1988). Low weight is also associated with osteoporosis. In general, change in weight in adults is of interest because it is an indicator of changing health status, and in children as it indicates changing health status and growth and development. Self-reported or parentally-reported weight for children and adolescents should be used cautiously if at all. It enables the calculation of body mass index (BMI) which requires the measurement of height and weight for adults as well as sex and date of birth for children and adolescents. Data element attributes Collection and usage attributes Guide for use: In order to ensure consistency in measurement, the measurement protocol described under Collection methods should be used. Collection methods: The collection of anthropometric measurements, particularly in those who are overweight or obese or who are concerned about their weight, should be performed with great sensitivity and without drawing attention to an individual's weight. The measurement protocol described below is that recommended by the WHO Expert Committee (1995). Measurement protocol: Equipment used should be described and reported. Scales should have a resolution of at least 0.1kg and should have the capacity to weigh up to at least 200 kg. Measurement intervals and labels should be clearly readable under all conditions of use of the instrument. Scales should be capable of being calibrated across the entire range of measurements. Precision error should be no more than 0.1kg. Scales should be calibrated on each day of use. Manufacturers' guidelines should be followed with regard to the transportation of the scales. Adults and children who can stand: The subject stands over the centre of the weighing instrument, with the body weight evenly distributed between both feet. Heavy jewellery should be removed and pockets emptied. Light indoor clothing can be worn, excluding shoes, belts, and sweater. Any variations from light indoor clothing (e.g. heavy clothing, such as kaftans or coats worn because of cultural practices) should be noted on the data collection form. Adjustments for non-standard clothing (i.e. other than light indoor clothing) should only be made in the data checking/cleaning stage prior to data analysis. If the subject has had one or more limbs amputated, record this on the data collection form and weigh them as they are. If they are wearing an artificial limb, record this on the data collection form but do not ask them to remove it. Similarly, if they are not wearing the limb, record this but do not ask them to put it on. The measurement is recorded to the nearest 0.1 kg. If the scales do not have a digital readout, take a repeat measurement. If the two measurements disagree by more than 0.5 kg, then take a third measurement. All raw measurements should be recorded on the data collection form. If practical, it is preferable to enter the raw data into the database as this enables intra-observer and, where relevant, inter-observer errors to be assessed. The subject's measured weight is subsequently calculated as the mean of the two observations, or the mean of the two closest measurements if a third is taken, and recorded on the form. If only a mean value is entered into the database then the data collection forms should be retained. It may be necessary to round the mean value to the nearest 0.1 kg. If so, rounding should be to the nearest even digit to reduce systematic over reporting (Armitage and Berry 1994). For example, a mean value of 72.25 kg would be rounded to 72.2 kg, while a mean value of 72.35 kg would be rounded to 72.4 kg. Infants: Birth weight and gender should be recorded with gestational age. During infancy a levelled pan scale with a bean and movable weights or digital scales capable of measuring to two decimal places of a kilogram are acceptable. Birth weight should be determined within 12 hours of birth. The infant, with or without a nappy or diaper is placed on the scales so that the weight is distributed equally about the centre of the pan. When the infant is lying or suspended quietly, weight is recorded to the nearest 10 grams. If the nappy or diaper is worn, its weight is subtracted from the observed weight i.e. reference data for infants are based on nude weights. Validation and quality control measures: If practical, equipment should be checked daily using one or more objects of known weight in the range to be measured. It is recommended that the scale be calibrated at the extremes and in the mid range of the expected weight of the population being studied. Within- and, if relevant, between-observer variability should be reported. They can be assessed by the same (within -) or different (between-) observers repeating the measurement of weight, on the same subjects, under standard conditions after a short time interval. The standard deviation of replicate measurements (technical error of measurement) between observers should not exceed 0.5 kg and be less than 0.5 kg within observers. Extreme values at the lower and upper end of the distribution of measured height should be checked both during data collection and after data entry. Individuals should not be excluded on the basis of true biological difference. Last digit preference, and preference or avoidance of certain values, should be analysed in the total sample and (if relevant) by observer, survey site and over time if the survey period is long. Comments: This metadata item applies to persons of all ages. It is recommended for use in population surveys and health care settings. It is recommended that in population surveys, sociodemographic data including ethnicity should be collected, as well as other risk factors including physiological status (e.g. pregnancy), physical activity, smoking and alcohol consumption. Summary statistics may need to be adjusted for these variables. Metadata items currently exist for sex, date of birth, country of birth, Indigenous status and smoking. Metadata items are being developed for physical activity. Presentation of data: Means and 95% confidence intervals, medians and centiles should be reported to one decimal place. Where the sample permits, population estimates should be presented by sex and 5-year age groups. However 5-year age groups are not generally suitable for children and adolescents. Estimates based on sample surveys may need to take into account sampling weights. For consistency with conventional practice, and for current comparability with international data sets, recommended centiles are 5, 10, 15, 25, 50, 75, 85, 90 and 95. To estimate the 5th and 95th centiles, a sample size of at least 200 is recommended for each group for which the centiles are being specified. For some reporting purposes, it may be desirable to present weight data in categories. It is recommended that 5 kg groupings are used for this purpose. Weight data should not be rounded before categorisation. The following categories may be appropriate for describing the weights of Australian men, women, children and adolescents, although the range will depend on the population. Weight 10 kg = Weight 15 kg = Weight ... in 5 kg categories 135 kg = Weight Weight => 140 kg Source and reference attributes Submitting organisation: World Health Organization The consortium to develop standard methods for the collection and collation of anthropometric data in children as part of the National Food and Nutrition Monitoring and Surveillance Project, funded by the Commonwealth Department of Health and Ageing Reference documents: Clinical Guidelines on the Identification, Evaluation and Treatment of Overweight and Obesity in Adults (US National Heart, Lung and Blood Institute (NHLBI) in cooperation with the National Institute of Diabetes and Digestive and Kidney Diseases). Chronic Diseases and Associated Risk Factors in Australia 2001 (AIHW). Relational attributes Related metadata references: Is used in the formation of Adult—body mass index (measured), ratio NN[N].N[N] Health, Standard 01/03/2005 Is used in the formation of Adult—body mass index (self-reported), ratio NN[N].N[N] Health, Standard 01/03/2005, National Health Performance Authority, Standard 24/10/2013 Is used in the formation of Child—body mass index (measured), ratio NN[N].N[N] Health, Standard 01/03/2005 Is used in the formation of Child—body mass index (self-reported), ratio NN[N].N[N] Health, Standard 01/03/2005 Supersedes Weight - measured, version 2, DE, NHDD, NHIMG, Superseded 01/03/2005.pdf (29.3 KB) Implementation in Data Set Specifications: Acute coronary syndrome (clinical) DSS 2013- Health, Standard 02/05/2013 Cardiovascular disease (clinical) DSS Health, Standard 01/09/2012 Diabetes (clinical) DSS Health, Standard 21/09/2005 Perinatal DSS 2015-16 Health, Standard 13/11/2014

Data type

float

Measurement units
  • Kg
Kg
Service contact
Description

Service contact

Service contact date
Description

Service contact—service contact date, DDMMYYYY Identifying and definitional attributes Short name: Service contact date METeOR identifier: 270122 Registration status: Health, Standard 01/03/2005 Indigenous, Draft 18/10/2012 National Health Performance Authority, Standard 09/08/2013 Definition: The date of service contact between a health service provider and patient/client. Data Element Concept: Service contact—service contact date Value domain attributes Representational attributes Representation class: Date Data type: Date/Time Format: DDMMYYYY Maximum character length: 8 Data element attributes Collection and usage attributes Guide for use: Requires services to record the date of each service contact, including the same date where multiple visits are made on one day (except where the visits may be regarded as a continuation of the one service contact). Where an individual patient/client participates in a group activity, a service contact date is recorded if the person's participation in the group activity results in a dated entry being made in the patient's/client's record. Collection methods: For collection from community based (ambulatory and non-residential) agencies. Relational attributes Related metadata references: Is used in the formation of Person—number of service contact dates, total N[NN] Health, Standard 01/03/2005 Supersedes Service contact date, version 1, DE, NHDD, NHIMG, Superseded 01/03/2005.pdf (15.1 KB) Implementation in Data Set Specifications: Cardiovascular disease (clinical) DSS Health, Standard 01/09/2012 Diabetes (clinical) DSS Health, Standard 21/09/2005 Implementation in Indicators: Used as numerator National Health Performance Authority, Healthy Communities: Immunisation rates for children, 2012–13 National Health Performance Authority, Standard 27/03/2014 Used as denominator National Health Performance Authority, Healthy Communities: Immunisation rates for children, 2012–13 National Health Performance Authority, Standard 27/03/2014

Data type

date

Similar models

Diabetes (clinical) DSS Metadata Online Registry (METeOR)

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Female
Item
Pregnancy—current status
integer
Code List
Pregnancy—current status
CL Item
Yes (1)
CL Item
No (2)
CL Item
Not stated/inadequately described (9)
Item Group
Health service event
Item
Fasting status
integer
Code List
Fasting status
CL Item
Yes (1)
CL Item
No (2)
CL Item
Not stated/inadequately described (9)
Item Group
Laboratory standard
Upper limit of normal range for microalbumin, albumin/creatinine ratio
Item
Microalbumin level—upper limit of normal range (albumin/creatinine ratio)
float
Upper limit of normal range for microalbumin (total micrograms per minute)
Item
Microalbumin level—upper limit of normal range (micrograms per minute)
float
Upper limit of normal range for microalbumin (total milligrams per 24 hour)
Item
Microalbumin level—upper limit of normal range (milligrams per 24 hour)
float
Upper limit of normal range for microalbumin (total milligrams per litre)
Item
Microalbumin level—upper limit of normal range (milligrams per litre)
float
Upper limit of normal range of glycosylated haemoglobin (percentage)
Item
Glycosylated haemoglobin—upper limit of normal range (percentage)
float
Item Group
Patient
Diagnosis date (diabetes mellitus)
Item
Year of diagnosis of diabetes mellitus
date
Insulin start date
Item
Year insulin started
date
Item Group
Person (male)
Item
Erectile dysfunction
text
Code List
Erectile dysfunction
CL Item
Erectile dysfunction- developed in the last 12 months (1)
CL Item
Erectile dysfunction- developed prior to the last 12 months (2)
CL Item
No erectile dysfunction (3)
CL Item
Not stated/inadequately described (9)
Item Group
Person
Item
Blindness (diabetes complication)
integer
Code List
Blindness (diabetes complication)
CL Item
Blindness  (1)
CL Item
Blindness  (2)
CL Item
Blindness (3)
CL Item
No blindness (4)
CL Item
Not stated/inadequately described (9)
Blood pressure—diastolic (measured)
Item
Blood pressure—diastolic (measured)
integer
Blood pressure—systolic (measured)
Item
Blood pressure—systolic (measured)
integer
Item
Cardiovascular medication (current)
integer
Code List
Cardiovascular medication (current)
CL Item
Angiotensin converting enzyme (ACE) inhibitors (1)
CL Item
Angiotensin II (A2) receptor blockers (2)
CL Item
Beta blockers (3)
CL Item
Calcium antagonists (4)
CL Item
None of the above (8)
CL Item
Not stated/inadequately described (9)
Item
Cataract - history
integer
Code List
Cataract - history
CL Item
Cataract currently present or has been previously removed from the right eye (1)
CL Item
Cataract currently present or has been previously removed from the left eye (2)
CL Item
Cataract currently present or has been previously removed from both eyes (3)
CL Item
No cataract present or has not been previously removed from either eye (4)
CL Item
Not stated/inadequately described (9)
Item
Cerebral stroke due to vascular disease (history)
integer
Code List
Cerebral stroke due to vascular disease (history)
CL Item
Cerebral stroke - occurred in the last 12 months (1)
CL Item
Cerebral stroke - occurred prior to the last 12 months (2)
CL Item
Cerebral stroke - occurred both in and prior to the last 12 months (3)
CL Item
No history of cerebral stroke due to vascular disease (4)
CL Item
Not stated/inadequately described (9)
Cholesterol level (measured)
Item
Cholesterol—total (measured)
float
Item
Coronary artery disease—history of intervention or procedure
integer
Code List
Coronary artery disease—history of intervention or procedure
CL Item
CABG, angioplasty or stent - undertaken in last 12 months (1)
CL Item
CABG, angioplasty or stent - undertaken prior to the last 12 months (2)
CL Item
CABG, angioplasty or stent - both within and prior to the last 12 months (3)
CL Item
No CABG, angioplasty or stent undertaken (4)
CL Item
Not stated/inadequately described (9)
Creatinine serum level
Item
Creatinine serum level (measured)
integer
Date of birth
Item
Date of birth
date
Item
Diabetes status
text
Code List
Diabetes status
CL Item
Type 1 diabetes (01)
CL Item
Type 2 diabetes (02)
CL Item
Gestational diabetes mellitus (GDM) (03)
CL Item
Other (secondary diabetes) (04)
CL Item
Previous gestational diabetes mellitus (GDM) (05)
CL Item
Impaired fasting glucose (IFG) (06)
CL Item
Impaired glucose tolerance (IGT) (07)
CL Item
Not diagnosed with diabetes (08)
CL Item
Not assessed (09)
CL Item
Not stated/inadequately described (99)
Item
Diabetes therapy type
text
Code List
Diabetes therapy type
CL Item
Diet and exercise only (01)
CL Item
Oral hypoglycaemic - sulphonylurea only (02)
CL Item
Oral hypoglycaemic - biguanide (eg metformin) only (03)
CL Item
Oral hypoglycaemic - alpha-glucosidase inhibitor only (04)
CL Item
Oral hypoglycaemic - thiazolidinedione only (05)
CL Item
Oral hypoglycaemic - meglitinide only (06)
CL Item
Oral hypoglycaemic - combination (eg biguanide & sulphonylurea) (07)
CL Item
Oral hypoglycaemic - other (08)
CL Item
Insulin only  (09)
CL Item
Insulin plus oral hypoglycaemic (10)
CL Item
Nil - not currently receiving diabetes treatment (98)
CL Item
Not stated/inadequately described (99)
CL Item
Yes (1)
CL Item
No (2)
CL Item
Not stated/inadequately described (9)
Item
Renal disease—end-stage (diabetes complication)
integer
Code List
Renal disease—end-stage (diabetes complication)
CL Item
End-stage renal disease - developed in the last 12 months (1)
CL Item
End-stage renal disease - developed prior to the last 12 months (2)
CL Item
No end-stage of renal disease (3)
CL Item
Not stated/inadequately described (9)
Item
Foot deformity
integer
Code List
Foot deformity
CL Item
Yes (1)
CL Item
No (2)
CL Item
Not stated/inadequately described (9)
Item
Foot lesion (active)
integer
Code List
Foot lesion (active)
CL Item
Yes (1)
CL Item
No (2)
CL Item
Not stated/inadequately described (9)
Item
Foot ulcer (current)
integer
Code List
Foot ulcer (current)
CL Item
Yes (1)
CL Item
No (2)
CL Item
Not stated/inadequately described (9)
Item
Foot ulcer (history)
integer
Code List
Foot ulcer (history)
CL Item
Yes (1)
CL Item
No (2)
CL Item
Not stated/inadequately described (9)
Glycosylated haemoglobin level (measured)
Item
Glycosylated haemoglobin level (measured)
float
Item
Health professionals attended (diabetes mellitus)
integer
Code List
Health professionals attended (diabetes mellitus)
CL Item
Diabetes educator (1)
CL Item
Dietician (2)
CL Item
Ophthalmologist (3)
CL Item
Optometrist (4)
CL Item
Podiatrist (5)
CL Item
None of the above (8)
CL Item
Not stated/inadequately described (9)
Height (measured)
Item
Height (measured)
float
High-density lipoprotein cholesterol level (measured)
Item
Cholesterol—HDL (measured)
float
CL Item
Yes (1)
CL Item
No (2)
CL Item
Not stated/inadequately described (9)
Item
Indigenous status
integer
Code List
Indigenous status
CL Item
Aboriginal but not Torres Strait Islander origin (1)
CL Item
Torres Strait Islander but not Aboriginal origin (2)
CL Item
Both Aboriginal and Torres Strait Islander origin (3)
CL Item
Neither Aboriginal nor Torres Strait Islander origin (4)
CL Item
Not stated/inadequately described (9)
Item
Lower limb amputation due to vascular disease
integer
Code List
Lower limb amputation due to vascular disease
CL Item
Lower limb amputation - occurred in the last 12 months (1)
CL Item
Lower limb amputation - occurred prior to the last 12 months (2)
CL Item
Lower limb amputation - occurred both in and prior to the last 12 months (3)
CL Item
No history of lower limb amputation due to vascular disease (4)
CL Item
Not stated/inadequately described (9)
Microalbumin level (measured), albumin/creatinine ratio
Item
Microalbumin level—albumin/creatinine ratio (measured)
float
Microalbumin level (measured), total micrograms per minute
Item
Microalbumin level—micrograms per minute (measured)
float
Microalbumin level (measured), total milligrams per 24 hour
Item
Microalbumin level—milligrams per 24 hour (measured)
float
Microalbumin level (measured), total milligrams per litre
Item
Microalbumin level—milligrams per litre (measured)
float
Item
Myocardial infarction (history)
integer
Code List
Myocardial infarction (history)
CL Item
Myocardial infarction - occurred in the last 12 months (1)
CL Item
Myocardial infarction - occurred prior to the last 12 months (2)
CL Item
Myocardial infarction - occurred both in and prior to the last 12 months (3)
CL Item
No history of myocardial infarction (4)
CL Item
Not stated/inadequately described (9)
Item
Ophthalmological assessment—outcome (left retina)
integer
Code List
Ophthalmological assessment—outcome (left retina)
CL Item
Normal (1)
CL Item
Diabetes abnormality (2)
CL Item
Non-diabetes abnormality (3)
CL Item
Not visualised (4)
CL Item
Not stated/inadequately described (9)
Item
Ophthalmoscopy performed indicator
integer
Code List
Ophthalmoscopy performed indicator
CL Item
Yes (1)
CL Item
No (2)
CL Item
Not stated/inadequately described (9)
Item
Peripheral neuropathy (status)
integer
Code List
Peripheral neuropathy (status)
CL Item
Yes (1)
CL Item
No (2)
CL Item
Not stated/inadequately described (9)
Item
Peripheral vascular disease in feet (status)
integer
Code List
Peripheral vascular disease in feet (status)
CL Item
Yes (1)
CL Item
No (2)
CL Item
Not stated/inadequately described (9)
Item
Referred to ophthalmologist (diabetes mellitus)
integer
Code List
Referred to ophthalmologist (diabetes mellitus)
CL Item
Yes (1)
CL Item
No (2)
CL Item
Not stated/inadequately described (9)
Item
Tobacco smoking status (diabetes mellitus)
integer
Code List
Tobacco smoking status (diabetes mellitus)
CL Item
Yes (1)
CL Item
No (2)
CL Item
Not stated/inadequately described (9)
Item
Hypoglycaemia - severe
integer
Code List
Hypoglycaemia - severe
CL Item
Yes (1)
CL Item
No (2)
CL Item
Not stated/inadequately described (9)
Item
Sex
integer
Code List
Sex
CL Item
Male (1)
CL Item
Female (2)
CL Item
Intersex or indeterminate (3)
CL Item
Not stated/inadequately described (9)
Triglyceride level (measured)
Item
Triglyceride level (measured)
float
Item
Visual acuity (left eye)
text
Code List
Visual acuity (left eye)
CL Item
6/5 (01)
CL Item
6/6 (02)
CL Item
6/9 (03)
CL Item
6/12 (04)
CL Item
6/18 (05)
CL Item
6/24 (06)
CL Item
6/36 (07)
CL Item
6/60 (08)
CL Item
CF (count fingers) (09)
CL Item
HM (hand movement) (10)
CL Item
PL (perceive light) (11)
CL Item
BL (blind) (12)
CL Item
6/7.5 (13)
CL Item
Not stated/inadequately described (99)
Weight (measured)
Item
Weight in kilograms (measured)
float
Item Group
Service contact
Service contact date
Item
Service contact date
date